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“If we knew what it was we were doing, it would not be called 
research, would it?”  
Albert Einstein 
  
 
 
Abstract 
Platinum-based drugs are an important group of alkylating-like agents which are used in cancer 
chemotherapy treatment. Cisplatin and oxaliplatin in particular are still commonly used today and 
are the focus of this thesis. As with most chemotherapy drugs, the efficacy of these drugs are 
limited by toxicity as well as tumour resistance, and therefore by increasing our understanding of 
these areas it is hoped to one day achieve personalised chemotherapy. 
The use of ICP-MS in the study of bio-sciences is still relatively new, however it has the ability to 
provide robust, fast and accurate methods for the quantification of platinum in biological 
samples. The research presented here utilised mass spectrometry in the study of the formation of 
Pt-DNA adducts in the clinical samples, the binding of oxaliplatin to short peptides and the effect 
of selenium supplementation on oxaliplatin in colorectal cancer cell lines. 
A comparison in the number of Pt-DNA adducts in saliva and leukocyte samples obtained from 
patients undergoing Pt-based chemotherapy demonstrated a lack of correlation between the two 
sample types. Samples were taken pre- and post-treatment and analysed via SF-ICP-MS and 
significant inter-patient variability was observed as expected. In both leukocyte and saliva 
samples, not only was Pt from previous chemotherapy cycles observed, but Pt was detected in 
the DNA in both sample types 1 hour after treatment. However a lack of correlation between 
platinum levels seen in the blood and saliva, combined with unexpected difficulties obtaining 
patient adherence to the saliva sampling protocol, indicated that saliva does not at present offer 
a reliable alternative to leukocytes for this assay. 
The binding of oxaliplatin to short nitrogen and sulfur rich peptides was investigated. Platinum 
binding to the peptides was observed and no significant differences in the level of binding were 
observed between the range of N and S rich peptides studied in this investigation. Partly due to 
the inability to reproduce biological conditions in this study, oxaliplatin was observed as a whole 
molecule, and furthermore dimers and multimers were also observed. 
The effect of selenium supplementation on the total cellular uptake of platinum was investigated 
in cultured cells via ICP-MS and LA-ICP-MS. It was observed that selenium decreased the amount 
of Pt taken up by the cancer cells. This was seen in analysis of populations of cells as well as by 
single cell analysis. Furthermore, while problems were encountered measuring selenium in 
subcellular experiments, the effect of selenium on the subcellular distribution of platinum as well 
as the number of Pt-DNA adducts could be determined.  
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1. Introduction 
1.1 Objectives 
It is estimated that cancer now affects more than one in three people during the course of their 
lifetime.1 Such a prevalent disease is therefore naturally the subject of extensive research 
worldwide with the aim of both preventing and curing the disease.  Platinum-based anti-cancer 
drugs are among the most widely used in cancer chemotherapy treatments. While very effective, 
they are not without their limitations, including extensive side effects and the development of 
drug resistance. This thesis focuses on the use of platinum-based anti-cancer drugs, specifically 
oxaliplatin and cisplatin, and their interaction with DNA and proteins within the body. 
Three main objectives were set out to further our understanding on the way Pt-based drugs work. 
The first of these objectives was to investigate if the use of saliva was a viable alternative to blood 
for the investigation of Pt-DNA adducts in clinical patient samples. The work performed to 
achieve this is presented in Chapter 2. In this work, a method previously utilised to measure Pt-
DNA adduct levels in patient leukocyte samples was modified and adapted for the use in both 
blood leukocyte and saliva samples, with the aim of providing an alternative, more patient 
friendly and non-intrusive sampling technique for patients receiving Pt-based chemotherapy with 
the ultimate aim of providing clinicians with up-to date analysis of the level of adduct formation 
in patients. 
The second objective was to investigate the interaction of oxaliplatin with proteins found in the 
cytosol. It has been established that only a small amount (approximately 1%) of the Pt-drug given 
to a patient reaches the ultimate physiological target, the DNA, and is it theorised there are 
multiple ‘platinum sinks’ within the cell where platinum binds, thus potentially reducing the 
amount reaching the DNA.2–4 While the nuclear fraction within a cell only receives around 9% of 
the platinum, around 70% is found within the cytosol of the cell, making the cytosolic proteins 
very likely binding sites for the platinum5. In this work it was hoped to discover if there were 
potentially binding sites on proteins where binding of platinum was favoured over others, or if 
the binding was more uniform. The work carried out to achieve this objective is described in 
Chapter 3.  
The third objective was to investigate the effect of selenium on oxaliplatin, as detailed in Chapter 
4. While there is some evidence to suggest that selenium has some cancer-preventative 
properties at high enough concentrations, there has only been limited research into the effect 
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that selenium has on Pt-based drugs, despite many cancer patients taking herbal and vitamin 
supplements during treatment. In this work the effect on the level of Pt-DNA adducts was 
investigated caused by the presence of selenium at different concentrations, as well as the effect 
on the sub-cellular distribution of both platinum and selenium, and finally a competitive binding 
study was performed using a ubiquitous cytosolic protein. 
In the subsequent sections of this chapter, the history, use and importance of Pt-based drugs and 
selenium supplementation will be explored in more detail, alongside a review of the main 
instrumentation used in the study of these areas during this research primarily sector-field 
inductively coupled plasma mass spectrometry (SF-ICP-MS) and electrospray ionisation linear ion 
trap mass spectrometry. 
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1.2 Cancer Chemotherapy  
Cancer is, by definition, the uncontrolled growth of abnormal cells within the human body with 
the ability to migrate and invade other tissues around the body.6 There are currently three main 
forms of treatment for cancer, chemotherapy, radiotherapy and surgery, which are often used in 
conjunction with each other. And while over half of cancer patients currently receive 
chemotherapy treatment, the exact treatment a patient will receive is determined on an 
individual basis. 
Cancer chemotherapy works by killing cells by the use of chemicals which interfere and interrupt 
the process of cell division with the aim of causing cell apoptosis. By destroying the cancerous 
cells the aim is not only to stop the growth of the tumour but also to prevent metastasis (the 
spread of cancer from where it started (primary site) to other parts of the body). While in many 
cases it can be very effective, cancer chemotherapy is not without its problems. One of the 
primary drawbacks is the extensive range of side effects frequently experienced by patients, often 
caused by chemotherapy damaging non-cancerous cells as well as the cancerous, resulting in side 
effects that range from nausea, neuropathy, neutropenia and hair loss.7  As the level of side 
effects experienced by patients can result in lowering the dosage for the next treatment, or even 
in many cases the termination of treatment due to the severity of the side effects, one of the 
primary aims of ongoing cancer research worldwide is the development of new more effective 
chemotherapy drugs which kill less healthy cells and which will induce minimal side effects. 
Chemotherapy can be prescribed to patients either as part of a curative or a palliative regime. 
While the curative aims at ridding the patient of all cancerous cells so that the patient can be 
considered to be in remission, palliative care is designed to help to address symptom 
management or to extend life expectancy without significantly reducing or totally removing the 
cancer already present. As previously mentioned different treatment approaches are often used 
in conjunction with one another. Adjuvant chemotherapy is when chemotherapy is given after 
surgery has been performed to remove the tumour with the aim of killing any remaining 
cancerous cells to prevent cancer reoccurrence.  
It is difficult to date the first treatment of cancer with drugs as herbal medicines and other 
concoctions have been used in the past. The first chemotherapy drugs were originally based on 
mustard gas after it was observed that soldiers exposed to it died due to bone marrow damage 
and as a result Nitrogen mustard, an alkylating agent, was first used in 1942 to treat lymphoma 
patients with limited success.7 Since then the understanding of the mechanisms and mode of 
 
 
4 
 
action of chemotherapy drugs has increased enormously and has resulted in the development of 
many highly effective chemotherapy drugs. 
1.2.1 Platinum-based chemotherapy drugs 
1.2.1.1 History of platinum-based chemotherapy drugs 
Platinum-based chemotherapy drugs are an important type of anti-cancer drug as they are 
currently used in about half of all chemotherapy treatments.8 The possibility of using platinum-
based complexes in cancer chemotherapy was first uncovered by Dr Barnett Rosenberg at 
Michigan State University in the late 1960’s. He made the discovery by accident when 
investigating the effect of applying a magnetic or electric field on cell division with the use of 
platinum electrodes (which were believed to be inert) and observed some unexpected electrolysis 
products. These electrolysis products were analysed and found to contain two active complexes; 
the neutral cis-isomer [Pt(II)(NH3)2Cl2] (cisplatin) and a platinum(IV) analogue, cis-
diamminetetrachloroplatinum(IV). In 1968 cisplatin (cis-diamminedichloroplatinum(II)) was 
observed to cause tumour regression in mice and by 1971 was used to treat patients even though 
it wasn’t approved by the US Food and Drug Administration (FDA) until 1978.7,9 Since then it has 
become of the most widely used cancer chemotherapy drugs worldwide. 
The discovery of cisplatin resulted in a great deal of research into platinum-based drugs for use in 
cancer chemotherapy and as a result thousands of platinum complexes were synthesised with the 
aim of creating a drug which was safe for patients and which would hopefully reduce the severity 
of the nephrotoxicity (damage to kidneys) caused by cisplatin. While thousands of platinum 
derived complexes have been synthesised, to date, only two have been approved for use on 
patients worldwide; carboplatin (which was introduced as a second generation analogue of 
cisplatin in the 1980’s) and oxaliplatin. Oxaliplatin (see Figure 1), which is one of the primary 
drugs of interest in the work presented in this thesis, consists of a platinum centre which is bound 
to two bidentate ligands, a diaminocyclohexane (DACH) ligand and an oxalate ion. The structures 
of these platinum-based drugs can be seen in Figure 1, which also details some of the other 
platinum-based drugs which made some progression in clinical testing.   
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* Note: The dates provided are the dates when each drug was first administered to patients. 
Figure 1 - The development stages of platinum-based chemotherapy drugs. Used with permission. 9 
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1.2.1.2 Clinical use of platinum-based chemotherapy drugs 
While some of the drugs detailed in the previous section have now been available for decades 
they are still commonly used today. Cisplatin is still commonly used in the treatment of ovarian, 
testicular, cervical, head, neck and lung cancers, while oxaliplatin is used in the treatment of 
colorectal cancer. 10–14 Combination treatments, such as FOLFOX (a combination of Folinic acid, 5-
fluorouracil and oxaliplatin), have increased the efficacy and reduced some side effects, and are 
now common place. 
In clinics, dosage of such drugs are calculated based on two factors; body surface area and kidney 
function. Treatment tends to be given over a number of cycles (as determined by research and 
clinical trials for each drug combination regime) which are typically two to four weeks apart. By 
spacing the treatment cycles out this allows time for the normal healthy cells to recover.  
Currently oxaliplatin can be administered up to 85 mg/m2 on a two weekly cycle, or if a three 
weekly cycle is used dosage can be increased to 130 mg/m2. Cisplatin is typically administered 
every three to four weeks at a dosage level between 50 and 70 mg/m2.15–17 
Currently dosage levels are calculated per person based on their body surface area and kidney 
function, with the ability of adjusting the dose between chemotherapy cycles, much of the 
current research is aimed at identifying a means of creating a more personalised chemotherapy 
regime.  The need for this has been known for a long time due to large inter-patient variability in 
both response to treatment as well as toxicities being observed in multiple studies; however it is 
only now that the possibility of individualised chemotherapy treatments is truly being 
investigated. 
1.2.1.3 Mode of action 
In recent years the understanding of the mechanism of action of platinum-based anti-cancer 
drugs has grown, however there is still some uncertainty. Both cisplatin and oxaliplatin work by 
acting as complexing agents for DNA, and the generally accepted mode of action is the covalent 
binding of the drug to the DNA forming Pt-DNA adducts, which in turn distort the helical structure 
of the DNA signalling cell cycle arrest and causing cell apoptosis if the level of damage is too great 
to repair.9,16 
Cisplatin, for example, is taken up by the cells by passive diffusion and copper transporters. 
Cisplatin is introduced into the body intravenously before entering the cells. In order to become 
activated, a neutral cisplatin molecule will become aquated upon entering a cell via the loss of 
two chlorine atoms (see Figure 2). This hydrolysis, and activation, of cisplatin does not happen 
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easily in the blood stream due to high concentration of chloride ions, however it is easily 
performed within the cell due to lower concentrations (below 100 mM).5,18,19 
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Figure 2 - Hydrolysis of cisplatin 
Once inside the cell the activated cisplatin can bind to a multitude of ligands found within the cell. 
While the primary physiological target is the DNA, the binding to other ligands goes some way in 
accounting for the limited amount of platinum which reaches the DNA to form Pt-DNA adducts. 
When binding to DNA, cisplatin binds primarily to the N7 position of the imidazole ring of purine 
bases, primarily guanine (G) and adenine (A) to a lesser extent.9 This binding can occur as either 
mono- or bi-functional adducts (i.e. via one or both leaving groups).20 Studies have shown that 
the vast majority of the adducts formed are intra-strand crosslinks (adducts) between adjacent 
base pairs on the same DNA strand (1,2 intra-strand adducts), with around 60-65% of the total 
adducts formed between adjacent G-G base pairs, while A-G intra-strand adducts make up about 
20-25% of the total adduct formed. Other less common adducts recorded include the 1,3 intra-
strand G-G adduct (~2%), monofunctional guanine adduct (~2%) and G-G inter-strand adduct 
(~2%).9 It is these crosslinks/adducts that distort the structure of the DNA which result in cell 
cycle arrest, and if the repair cannot be completed due to high enough levels of damage, cell 
apoptosis occurs.21,22 The primary adducts are summarised in Figure 3. 
 
Figure 3 - Cisplatin adduct formation with DNA. Used with permission. 10 
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Oxaliplatin works in a very similar way, primarily differing in the loss of an oxalate group before 
becoming aquated.10,23,24  As it is inherently less stable at high chloride concentrations (such as 
that found in the blood) when compared to cisplatin, oxaliplatin first undergoes a ligand exchange 
where the oxalate ligand is replaced by two chloride ions forming [Pt(DACH)(Cl2)]. It is this 
complex which then penetrates the cell to become hydrolysed forming [Pt(DACH)(H2O)2]2+, which 
in turn binds with the DNA to form adducts. While there is some evidence suggesting that 
oxaliplatin forms fewer adducts than cisplatin, it was found that it distorted the DNA strands to a 
greater degree thus resulting in it being equally as potent and effective.10  
1.2.1.4 Side effects 
Cisplatin, while being the oldest of the platinum-based chemotherapy drugs, is still commonly 
used today, particularly for the treatment of testicular and ovarian cancers, as well as cancers of 
the neck and lung. However, it has two primary limitations; drug toxicity and tumour resistance. 
Drug toxicity can be defined as the adverse effects experienced by patients undergoing a drug 
treatment. The three most common side effects reported by patients undergoing cisplatin 
chemotherapy are nephrotoxicity (kidney damage), ototoxicity (problems with the ear and 
hearing) and neuropathy (nerve damage, often experienced as a numbness), with are 
experienced by approximately 20-41%, 23-50% and 30-62% of patients respectively for each of 
the side effects.10 Due to the severe side effects as detailed above, cisplatin is administered in 
small doses to try and limit such toxicities.17 
One of the primary advantages of carboplatin over cisplatin was the significant reduction in 
nephrotoxicity reported. Furthermore, reductions in number of patients experiencing ototoxicity 
(around 1% of patients) as well as neuropathy (6-25%) were also reported.10 However, an 
increase in reported cases of myelosuppression (decrease in bone marrow activity often leading 
to neutropenia) was higher than with cisplatin; a reported 20-40% at the standard dose, but 
increasing up to 90% at higher doses. 
The primary side effect experienced with oxaliplatin is neuropathy, with the other side effects 
detailed above being experienced only rarely.  While neuropathy is experienced in around 95% of 
all patients immediately after treatment, it is only experienced by 15% of patients on a 
cumulative or chronic basis.10 Therefore the peripheral neuropathy is considered to be the dose 
limiting side effect of oxaliplatin.  
While Pt-drugs are presently still frequently used there is a continuous need for the development 
and improvement of chemotherapy drugs not only in an attempt to alleviate the level of side 
effects but also to tackle the problem of tumour resistance (both acquired and intrinsic 
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resistance). Furthermore, there is great interest in improving patient care at point of care by 
attempting to understand and potentially predict individual patient responses. Currently patients 
receive a standardized dose calculated by measuring the body surface area and kidney function of 
the patient, and while this dose is often reduced between cycles due to toxic side effects 
experienced by patients, it is estimated that around 40% of patients receive an unsuitable or 
inappropriate dose or drug.25 Consequently currently there is an aim to be able to achieve 
personalised chemotherapy doses, with the aim of ultimately improving patient care dramatically.   
Consequently currently there is a desire to be able to achieve personalised chemotherapy doses, 
with the aim of ultimately improving patient care dramatically.   
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1.3 Selenium supplementation 
The use of supplements, such as dietary antioxidants, during chemotherapy and radiation therapy 
remains a controversial issue despite years of research investigating their efficacy and safety. 
While several randomised clinical trials have shown some evidence that administration of 
antioxidants with chemotherapy or radiation treatments can reduce some treatment related side 
effects, however some data suggested the tumour as well as healthy cells were protected from 
oxidative damage while other data has contradicted this. 
Selenium is just one of the many antioxidants under investigation by researchers. At present the 
characterisation of the interaction between selenium and chemotherapy drugs is still limited and 
unclear. The work presented below outlines the use, dosage and possible effects of using 
selenium as well as previous trials conducted. 
1.3.1 Selenium 
Selenium is a trace element found within the body, being used within the body for functions from 
immune defence, metabolism and body growth, as well as being researched for its potential role 
in disease prevention, such as cancer. Selenium was first discovered by Jons Jakobs in 1817, 
however it was believed to be toxic to humans up until the 1950’s, and it wasn’t until the 1970’s 
that the link between selenium deficiency and diseases, such as Keshan disease, was made.26–28 
The human body obtains the selenium it requires from food, with some of the richest sources 
being garlic, onions and brazil nuts, with the average nutritional intake found to be between 50-
350 µg per day.29,30 
Selenium has many functions within the body, and can be found in around 30 different known 
selenoproteins, with selenium being found primarily in the form of L-selenomethionine and L-
selenocysteine.27 These selenoproteins have various roles within the body (see Table 1). The role 
of selenium within cells is primarily associated with oxidative metabolism, and in particular 
glutathione peroxides (and potentially selenoproteins P and W) which exhibit antioxidant 
properties. These antioxidant properties reduce the damaging reactive oxygen species to 
harmless products via coupling their reaction with the oxidation of glutathione. 27 
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Table 1 - Selenoproteins and selenoenzymes and their functions. Used with permission. 28 
Selenoprotein Function 
Glutathione peroxidises, 
GPx, (GPx1, GPx2, GPx3 and 
GPx4) 
Antioxidant enzymes: remove hydrogen peroxide, lipid and 
phospholipid peroxides (thereby maintaining membrane 
integrity, modulating eicosanoid synthesis, reducing 
inflammation and the likelihood of propagation of further 
oxidative damage to biomolecules such as lipids, lipoproteins and 
DNA). 
(Sperm) mitochondrial 
capsule selenoprotein 
Form of glutathione peroxidase (PHGPx): shields developing 
sperm cells from oxidative damage and later polymerises into a 
structural protein required for stability/motility of mature sperm. 
Iodothyronine deiodinases Production of active thyroid hormone T3, from thyroxine, T4. 
Selenophosphate 
synthetase, SPS2 
Required for the biosynthesis of selenophosphate, the precursor 
of selenocysteine, and therefore for Selenoprotein synthesis 
Selenoprotein P 
Found in plasma and associated with endothelial cells against 
damage from peroxynitrate. 
Selenoprotein W Needed for muscle function. 
Prostate epithelial 
selenoprotein (15kDa) 
Found in epithelial cells of the ventral prostate. Seems to have a 
redox function (resembles PHGPx). 
DNA-bound spermatid 
selenoprotein  (34kDa) 
Glutathione peroxidise-like activity. Found in stomach and in 
nuclei of spermatozoa. May protect developing sperm. 
18kDa selenoprotein 
Important selenoprotein found in kidney and large number of 
other tissues. 
 
1.3.2 Selenium and cancer 
Selenium is believed to have a role within the prevention of some diseases; however it has also 
been investigated in relation to cancer prevention as well as the effect of taking it during 
treatment for cancer.  
The first attempt at investigating the relationship between selenium and cancer incidence levels 
was made by Shamberger et al.31 where it was observed that areas of higher selenium in crops 
within the USA had a lower rate of cancer mortality, thus sparking an interest and resulted in 
further research in both animal and human populations. Further epidemiological studies in 
multiple countries followed this initial study, reaffirming the results.32–34 
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From epidemiological studies, the interest in selenium spread to work with small animals, and to 
date over 100 investigations into the relationship between cancer incidence and selenium levels 
have been performed on animals. A review by Whanger35 concluded that two-thirds of the 
studies showed a significant reduction in the number of tumours observed. In fact, it was found 
that in half of the studies reviewed, reductions of 50% or more were observed when selenium 
levels were larger than the control samples. 
The results from the animal and epidemiological studies gave sufficient positive results to warrant 
the progression onto clinical trials. By 2004 8 human trials had taken place, 7 of which showed 
that selenium supplementation had a positive effect and an overall reduction in levels of cancer 
incidence.35 These studies also discovered that on average cancer patients tended to have slightly 
lower levels of selenium when compared to the healthy control groups.32,36 In China, the results 
from three separate clinical trials supported the concept of selenium as a cancer preventative 
agent; the first study utilised a selenium-enriched yeast (200 mg Se per day) and recorded a 
reduction in cancer incidence over a two year period, the second added 15 ppm (as Na2SeO3) to 
salt resulting in incidence of liver cancer decreasing from 54.8 to 34.5 per 100,000 people over a 6 
year period, while the third study again used selenium-enriched yeast (50 mg per day) along with 
β-carotene and vitamin E and saw a slight reduction in total cancer mortality.32,37 
Clinical trials and animal studies such as those discussed above indicate that it is possible that a 
link between the level of selenium and incidence of cancer exists, and further large scale studies 
are still being carried out. However, having already established that selenium has some efficacy in 
the prevention of some types of cancer, the next step was to determine how it provided this 
protection. There are many forms of selenium, and the bioavailability of selenium is dependent 
on the chemical form, which in turn determines where in the body the selenium is found. It is 
thought that the chemical transformation of selenium is an important step in the chemo-
preventative action of selenium. As a result, many different selenium compounds have been used 
in trials (both human and animal) in an attempt to determine the most effective form. 
Selenomethionine (SeMet), which is found in enriched yeasts and cereal grains, as well as Se-
methylselenocysteine (SeMCYS), which is the primary seleno-compound found in plants, garlic 
and broccoli are just two of the forms which have been investigated. From this research it was 
found that SeMCYS was the most effective form at reducing mammary tumours, however, its 
efficacy against other cancer types was not determined in the same study. 35 
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Figure 4 - Structures of seleno-compounds of interest 
The SELECT trail (Selenium and Vitamin E Cancer Prevention Trial)38 chose selenomethionine 
(Figure 4), while a lower homolog of SeMet, methylselenocysteine (MSC) was used in another 
study and was found to double mammary tumorigenesis suppression in rodents when compared 
to SeMet (50% reduction compared to 20%).35,39,40 Other trials have identified methylselenol as a 
potentially very important metabolite in cancer prevention, however due to its high reactivity 
precursors such as MSC and MSA (see Figure 4) have been used to create methylselenol 
endogenously. 32,40–43 
Theories as to how selenium provides a level of cancer prevention are still being investigated, 
however one theory is that selenium blocks the clonal expansion of transformed lesions (the 
ability to reduce cell proliferation of transformed clones). 40 In one study, MSC, while being tested 
on early stage mammary carcinogenesis, was found to block clonal expansion and increased cell 
apoptosis by nearly 3 fold.40 However, the use of MSC in in vitro studies highlighted the high 
concentrations required, and as a result, a different seleno-compound was investigated; 
methaneseleninic acid (MSA) (Figure 4), which required only µM concentrations to generate 
methylselenol endogenously. Furthermore, one study found that MSA inhibited the growth of 
human premalignant breast cells, with a 5 fold increase in the level of apoptosis after 24 
hours.40,42,43 
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Supranutritional levels of selenium have frequently been associated with the chemopreventive 
actions observed, reportedly up to around 10 times the level of selenium required to prevent 
selenium deficiency or to allow the correct function of selenoenzymes.40,44 The mechanism by 
which selenium aids in the prevention of cancer is still unclear; however the results from studies 
suggest that it could be via two main routes - as part of antioxidant enzyme mechanisms and as 
part of anti-carcinogenic metabolites. Figure 5 shows the different modes, based on dose, by 
which selenium can work as a chemopreventative agent. 
 
Figure 5 - A suggested model for the two-stage role selenium plays in cancer prevention. Used with permission. 32 
While the majority of current literature suggests that selenium works as chemopreventative 
agent by acting as an antioxidant, some research suggests that it could also work a pro-oxidant. 
Drake45 proposed that sodium selenite and MSA oxidise thiol-containing substrates resulting in 
pro-oxidative apoptosis of cells. 
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While the studies to date have presented some varied results and there is still a lot unknown 
about which form of selenium is best and how it works, the majority of research has shown a 
reduction on the incidence of cancers. While research also suggests that selenium is most 
effective at early stages of carcinogenesis or as a cancer preventative agent, the interactions 
between selenium and platinum-based drugs has to be investigated. 40 
Due to the possibility of selenium having a role in cancer prevention, it is also frequently taken by 
patients during the course of chemotherapy or radiotherapy with the hope that it will be 
beneficial to them. In fact, one European study carried out over 14 countries determined that an 
average of 35.9% (ranging from 14.8 – 73.1%) of cancer patients were taking some form of 
complementary or alternative medicine.46 This ranged from vitamins and minerals, such as 
selenium, to medicinal teas and homeopathy. Due to the large number of patients taking 
supplements during the course of their treatment it is vital to have an understanding of the 
interactions of these supplements and the chemotherapeutic drugs to ensure they do not 
interfere with the treatment or cause the patients harm. 
It has been theorised that selenium supplements could aid in the reduction of some toxicities 
associated with platinum-based chemotherapy drugs. Platinum-based chemotherapy drugs are 
well documented to induce a range of side effects and toxicities, for example, cisplatin, one of the 
most extensively investigated drugs, primarily causes toxicity via the formation of free radicals 
(e.g. hydroxyl radical) which cause oxidative damage. Antioxidants, such as selenium and vitamins 
E and C, in theory have the ability to combat this damage. However, studies have shown that 
levels of antioxidants in the plasma drop significantly during treatment with cisplatin.27,47–50 
Olas et al.51 investigated the effect of administering selenium during treatment with cisplatin, and 
reported a reduction in toxicity with an apparent lack of inhibitory effect on the anti-tumour 
properties of the drug. Weijil et al.48 reported similar findings and it was shown that high 
selenium, vitamin C and vitamin E plasma levels corresponded to a decrease in ototoxicity and 
nephrotoxicity caused by cisplatin. However, not all patients had a high level of the supplements 
in their plasma and it was unclear whether this was due to poor compliance or from inadequate 
dosage levels. Another study gave ovarian cancer patients selenium over 3 months and observed 
a rise in the level of white blood cells as well as a reduction in some side effects, including loss of 
appetite and hair loss.52 
Similar results were also observed in another cisplatin study where it was found that selenium 
could be used to reduce nephrotoxicity and leukopenia.53 Patients were given 4000 µg of Se per 
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day over the course of either their first or second cycles, and the level of nephrotoxicity was 
determined via enzymes in urine. It was also found that the levels of white blood cells were 
higher when selenium was used, however optimal dosage requirements still needed further 
investigation.53 
Studies such as these have shown that taking supplements during platinum-based chemotherapy 
can potentially provide some relief from the side effects and a reduction in the toxicity, however, 
in most studies selenium was given in combination with other antioxidants and is therefore 
difficult to determine how much of these benefits were caused by selenium alone. 
There have also been significantly less studies investigating the effect of selenium with other 
platinum-based drugs, such as oxaliplatin. Furthermore, there is still a lot of uncertainty as to 
whether the supplements bind to or have any interaction with the drugs which could result in 
lower levels reaching the tumours. 54–56 Additionally, there is still a lot of uncertainty as to how 
selenium may reduce toxicity resulting from the platinum-based drugs. While it is believed that 
the toxicity of some of the drugs is linked to specific oxidative metabolites of valproic acid, VPA, 
due to the formation of hydrogen peroxide and hydroxyl radicals, each drug works slightly 
differently and has a tendency to cause varying side effects, and therefore a lot more research 
into the matter is required.57 Analytical techniques such as ICP-MS can now be used to study the 
effect of selenium in new ways by taking direct measurements and studying the pharmacokinetic 
pathways of the various selenium compounds under investigation. 
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1.4 ICP-MS 
Inductively coupled plasma mass spectrometry (ICP-MS) is a highly sensitive analytical technique 
used for the determination of trace metals, by the introduction of a sample into a plasma where 
it is desolvated, atomised and ionised. Following which the resulting ions are extracted through a 
vacuum interface before being separated according to their mass to charge ratio (m/z) and 
detected. 
Previously other atomic spectrometric techniques, such as atomic absorption spectrometry (AAS), 
were used for the detection and analysis of clinical and biological samples.58–60 ICP-MS is not 
without limitations, especially in relation to biological samples. Spectral and non-spectral 
interferences are some of the major limitations, and as biological samples often have very 
complicated matrices this can cause problems such as the formation of polyatomic ions.61,62 
Spectral interferences arise from atomic or molecular ions having a similar nominal mass as the 
analyte or analytes of interest. Some interferences can also be induced from the plasma gas or 
solvents used during analysis. 
Biological samples tend to contain a relatively high concentration of organic species which can 
cause a multitude of spectral interferences. Matrix interferences arise from a combination of 
ionisation energy and plasma conditions as well as the sample matrix.63 However, it is worth 
noting that a lot of the polyatomic interferences found in biological samples can be overcome by 
utilising an ICP-MS with a medium and high resolution capability.61,64 Furthermore, there are 
several methods which enable for the correction of non-spectral interferences such as internal 
standardisation, standard addition and matrix-match methods.61–64 Despite its limitations, ICP-MS 
is considered such a valuable technique as it has the ability to offer a wide linear range, low 
detection limits for most elements, lesser interferences, speed, high throughput and a high level 
of precision.65 Moreover, while ICP-MS is most commonly used for solution based work via 
sample nebulisation, it can also be coupled with other chromatographic techniques, such as HPLC, 
and laser ablation.66–69 For the reasons detailed above, ICP-MS is an ideal technique for the 
quantification of the low levels of Pt observed in clinical and other biological samples.70 The basic 
instrumentation of ICP-MS is discussed briefly in the sections below. 
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1.4.1 ICP-MS instrumentation 
There are 4 major parts to a SF-ICP-MS instrument, as utilised in the research presented in this 
thesis; sample introduction, plasma, vacuum interface and the mass analyser and detector region 
(see Figure 6), and which are described in the following sections.  
 
 
 
Figure 6 - Schematic diagram of a SF-ICP-MS with reverse Nier-Johnson geometry 
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1.4.1.1 Sample introduction 
Various different interfaces have been developed to allow the introduction of solid, liquid and 
gaseous samples into an ICP-MS. The primary focus of this work was the use of a nebuliser and 
spray chamber to introduce a liquid sample into the system.  In this set up, a peristaltic pump is 
also used to ensure constant flow of the sample. The nebuliser utilises a high velocity gas 
(typically argon with a flow rate between 0.5-1 L min-1) to aspirate a solution into a fine aerosol. 
The spray chamber is used to sort the droplets by size via gravity, with droplets around 5 µm or 
larger getting separated out and taken to waste, and consequently only around 1-2% of the 
sample enters into the plasma. The spray chamber also aids in the creation of a smoother sample 
to be transported to the plasma, as some pulsing can occur at the nebuliser. The aerosolised 
sample produced in the section of the ICP-MS is transported to the plasma by a flow of argon gas. 
In this set up a sample uptake flow rate can be set to an appropriate value for the work. While 
typical flow rates can be around 1 mL min-1, significantly lower rates, such as 20 µL min-1 can also 
be used. Lower flow rates such as this are highly useful when only a limited amount of sample is 
available, which is often the case with clinical samples.71   
One of the primary ways to introduce a solid sample in to an ICP-MS is via laser ablation (LA). 
Laser ablation utilises a laser beam (typically from a Nd:YAG laser) to generate an aerosol 
containing nanometer and micrometer sized particulates of the sample. 72 
 
1.4.1.2 The plasma – formation and ion generation 
The plasma, which is an ionised gas that is overall neutral, is where the sample is ionised. The 
plasma is formed using an inert gas inside a quartz torch. Argon is typically used as it is cheap and 
relatively abundant, and furthermore has the ability to excite and ionise most elements due to its 
relatively high ionisation potential. The gas passes through three concentric tubes within the 
torch (see Figure 7). The inner tube, the injector, carries the sample aerosol, or sample gas, to 
create a central sample channel through the plasma, sometimes referred to as the ‘punch 
through’, and is used to deliver the sample into the plasma itself. The middle tube contains the 
plasma or auxiliary gas, whose main function is to prevent the plasma from making contact with 
the injector. Typical auxiliary gas flows are between 0.5 and 1.2 L min-1. The outer tube contains 
the cool gas, which has a typical flow rate of 15-20 L min-1, which is designed to cool the outer 
parts of the torch to ensure that the plasma shape is maintained.  
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Figure 7 - Schematic diagram of an ICP-MS torch  
In order to create the plasma, firstly the argon gas is allowed to flow through the torch where a 
high spark voltage (a Tesla spark) is introduced. This strips electrons from the argon atoms, which 
are then accelerated using a magnetic field from a radio frequency (RF) coil which surrounds the 
torch. The accelerated electrons ionise the argon gas via collisions between the electrons and the 
argon atoms, resulting in a chain reaction which forms the ICP discharge. The plasma will be 
maintained as long as the RF field is present.   
The cool gas destabilises the base of the plasma allowing the sample gas to ‘punch through’ the 
base of the plasma and introduce the sample, via the injector, directly into the centre of the 
plasma. Due to the conditions and temperature (6000-8000 K) within the plasma, as the sample 
passes through it becomes desolvated, atomised and ionised, before being introduced into the 
mass spectrometer via the vacuum interface region. Almost the entire sample is transformed into 
singly charged atomic ions, and with the ionisation efficiency of most elements in the plasma 
close to 100%, it makes an ICP-MS a highly valuable analytical technique.68,69,71 
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1.4.1.3 The interface region 
The plasma, and ionisation of the sample, is at atmospheric pressure (760 Torr), however as mass 
spectrometers require reduced pressure (10-6 Torr) an interface region is required in the ICP to 
allow the movement of ions between the two different pressures. This is arguably one of the 
most crucial areas within the instrument. 
The interface region operates at around 3-4 Torr via the use of a roughing pump. In order to allow 
for the reduction in pressure between the plasma and mass spectrometer regions, two cones, the 
sampler and skimmer, are placed in the interface region (see Figure 8). The ions generated from 
the plasma move from atmospheric pressure, through the sampler cone, into an area of reduced 
pressure (3-4 Torr).  Due to entering an area with a lower pressure, the ions expand and increase 
in velocity, exceeding the speed of sound forming a supersonic jet called the zone of silence.73 
The sample then begins to slow (mach disk) and is forced through a second cone, the skimmer 
cone, and into an area of even lower pressure. The sampler cone typically has an orifice of around 
1 mm whereas the skimmer cone has a smaller orifice around 0.8 mm in diameter. The cones are 
typically made from nickel or platinum as they are designed to be resistant to corrosive liquids, 
such as acids, commonly used in ICP-MS.  
 
 
Figure 8 - Schematic drawing of the cone interface region 
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1.4.1.4 The mass analyser and detector 
There are three main types of mass analysers used in ICP-MS; the quadrupole, the time of flight 
and the double-focussing magnetic sector. While the quadrupole (QMS) is perhaps the most 
common due to its speed, lower price and robustness, it only has the ability to be operated in a 
low resolution mode, and thus is unsuitable for the measurement of certain sample types. Time 
of flight mass spectrometers (TOFMS) separate ions based on their kinetic energy (which is 
directly proportional to its mass and velocity), and while all masses can be monitored 
simultaneously, sensitivity can be a problem due to ions only being injected in short nanosecond 
bursts as opposed to a continuous stream. As only a magnetic sector ICP-MS was utilised in the 
work presented in this thesis, only this form will be discussed in more detail here.  
There are two designs used in magnetic sector instruments, the forward (or standard) and 
reverse Nier-Johnson design. In a reverse Nier-Johnson instrument the magnetic analyser is 
placed before the electrostatic analyser (ESA) whereas in a forward instrument the ESA is placed 
before the magnetic analyser. The ICP-MS used in this work was a Thermo Element 2 XR, a high 
resolution sector field ICP-MS, utilising a reverse Nier-Johnson (see Figure 6). 
Upon exiting the skimmer cone, the ion beam is focused and accelerated via the ion optics into 
the mass analyser housing, where samples are separated according to their m/z ratio.  The ion 
optics also ensure that no photons, particulates or neutral species enter the mass analyser and 
detector, as this would cause larger backgrounds and signal instability. The originally circular ion 
beam becomes rectangular as they are focussed and enters, through a slit, into the magnetic 
sector of the instrument. The slit can be used to control mass resolution (low, medium or high) by 
adjusting the width of the slit, and thus the ion beam dispersion. The magnetic sector generates a 
field perpendicular to the ion beam, but parallel to the slit, causing the ions to deviate from the 
path and follow a curved trajectory. The magnetic sector is dispersive with respect to ion energy 
and mass (momentum), allowing for separation of ions by the m/z ratio as ions separate out and 
follow different angles of curvature within the magnetic sector. By keeping the radius of the 
magnetic sector constant and varying the field strength, the ions of varying m/z can be focused 
onto an intermediate slit, thus stopping the transmission of any ions of higher or lower m/z than 
the desired analyte. 
However ions of the same mass can differ in kinetic energy (due to formation position in the 
plasma), and thus have a different curvature through the magnetic sector, resulting in peak 
broadening and loss of resolution. Therefore to overcome this, a second mass analyser, an 
electrostatic analyser (ESA), is used. This electrostatic sector is dispersive with respect to ion 
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energy only, and not mass. The ESA utilises two curved plates with opposing voltages placed 
either side of the ion beam causing the ions to deviate into a curved path. The inner plate has a 
negative polarity applied to it resulting in the attraction of the positively charged ions towards it, 
while the outer plate repels the ions due to its positive charge.74 By using a combination of the 
magnetic and electrostatic sectors, where the energy dispersion is equal in magnitude but 
opposite in direction, it allows for the focussing of ions based on the m/z ratio. 
Upon exiting the ESA housing, the ion beam passes through a third slit, the exit slit, and enters 
the detector region. The Element XR contains two detectors, a Secondary Electron Multiplier 
(SEM) and a Faraday Cup. Before entering the SEM the ion beam comes into contact with a 
conversion dynode, resulting in an electron being ejected from it. This electron goes on to hit the 
first of 18 dynodes comprising the SEM, resulting in the ejection of one or more electrons. The 
dynodes are laid out to allow the electrons to follow a zig-zag path through the SEM causing an 
exponential growth in the number of electrons, and as a result the original signal is amplified.  
If all of the dynodes are used, this is denoted as the counting mode of the detector and can be 
used to detect up to 5x106 counts per second (cps), but when only a few dynodes are required in 
the amplification of the signal, this allows for detection between 5x106 and 1x107 cps, and is 
referred to as the analogue mode. If an even higher count rate is required (up to 1.5 x107 cps), the 
Faraday cup can be utilised. Once ions enter the Faraday cup they strike a metal detector plate. 
As the ions become neutralised, a current is generated and the change in potential is measured, 
and the current is directly proportional to the number of ions.  The detection mode will be 
dependant of the count rate. 
As previously mentioned, one of the major advantages of the SF-ICP-MS is the ability to switch 
between the three resolutions; low, medium and high. Resolution is defined as the ability of the 
instrument to separate one mass peak from another, and is calculated using the equation below: 
𝑅 = 𝑚
∆𝑚
 
Where R is the resolution, m is the mass of the analyte of interest, and ∆m is the peak width of 
the mass at 5% peak height. For the Element XR ICP-MS the resolutions are given as 
approximately 300 for low, 3000 for medium and 10,000 for high.74 While the higher resolutions 
allow for greater separation of peaks, the trade-off is that as the ion beam becomes smaller (due 
to size of the slit) the number of ions transmitted is reduced, and thus a reduction in sensitivity is 
experienced. 
 
 
24 
 
With the change in resolution a change in peak shape is also experienced. Low resolution peak 
shapes are trapezoidal (i.e. flat topped) while medium and high resolutions become Gaussian.  As 
a result, the precision at low resolution is deemed to be very high due to the flat topped nature of 
the peaks, and consequently the relative standard deviation (RSD) values tend to be in the range 
of 0.01-0.05% in low resolution. Due to the more Gaussian peak shapes observed in medium and 
high resolutions the precision does decrease, however and RSD values of around 0.1% can be 
achieved.75 
One of the primary advantages of using a SF-ICP-MS for biological work as presented in this thesis 
is the ability to resolve elements such as 31P from polyatomic interferences. This is particularly 
useful when the sample of interest contains a large amount of 31P such as DNA (which is 
composed of roughly 10% P) and phospholipids and peptides. In order to separate 31P from 
common interferences, such as 15N16O a resolution of around 1455 is required, and thus on this 
instrument it is possible to measure 31P with medium resolution.76 
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1.5 Electrospray ionisation mass spectrometry  
One of the downsides of ICP-MS technology is the loss of all structural data within the plasma, 
and thus while elemental data can be obtained, structural elucidation and molecular weight 
information for compound identification is lost. Therefore, the use of molecular mass 
spectrometry techniques such as electrospray ionisation mass spectrometry (ESI-MS) can be used 
instead.  
There are a multitude of molecular mass spectrometers available which have the ability to 
analyse a variety of biological materials, including single quadrupole, triple quadrupole, time of 
flight (TOF) and ion trap mass spectrometers. Linear ion trap (LIT) mass spectrometers are 
sensitive and highly versatile, and also have the advantage of being able to perform tandem mass 
spectrometric experiments. Due to its high mass range (made possible by the multiple charging of 
molecules by ESI) and resolution, linear ion trap mass spectrometry is ideal for the study of 
biomolecules such as peptides and proteins. A Thermo-Finnigan LTQ (a linear ion trap mass 
spectrometer) with an electrospray ionisation source (ESI) was used, and therefore the 
instrumentation of this shall be discussed in more detail below. 
 
1.5.1 LTQ Instrumentation 
The major components of a linear ion trap instrument are the ion source (ESI in this case), the ion 
optics, the mass analyser and the detector (see Figure 9), each of which are described briefly 
below.
 
Figure 9 - Schematic diagram of a linear ion trap mass spectrometer77 
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1.5.1.1 Ionisation – Electrospray ionisation 
Linear ion trap mass spectrometry is commonly used in combination with electrospray ionisation 
(ESI), which is a powerful technique for the production of intact ions. Other techniques such as 
atmospheric pressure chemical ionisation (APCI) and atmospheric pressure photo ionisation 
(APPI) can also be used, however they tend to be utilised when small low polarity compounds are 
of interest, whereas ESI is suitable for polar compounds of a larger molecular weight range. 77 As 
only ESI was used in the work presented in this thesis, only this will be discussed further. 
ESI is a soft ionisation technique, and thus produces very limited fragmentation of molecules 
within the sample, making it an ideal ionisation technique for biological samples. It has been 
shown that larger biomolecules such as proteins can produce multiply charged ions allowing them 
to be determined on instruments with lower mass range capabilities. Furthermore, due to the 
soft ionisation, it is useful for analysis of ligand-protein complexes. 78,79 
 
Figure 10 - Principles of electrospray ionisation droplet formation. Used with permission. 80 
Electrospray ionisation creates ions at ambient pressure by passing an analyte through a capillary 
tube on to which a strong electric potential is applied. The analyte is usually dissolved in a mixture 
of water and organic solvent (often methanol), with another chemical added to aid ionisation, 
typically formic or acetic acid for positive ionisation or ammonia for negative.  The sample is 
introduced at a slow flow rate through a needle, on which the strong electric potential is applied. 
The applied potential, which can be positive or negative depending on the mode of ionisation 
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desired, results in the formation of an ion enriched cone (known as a Taylor cone) at the tip of the 
needle, as shown in Figure 10. 
The electrically charged sample droplets are released from the Taylor cone and evaporate and 
decrease in size due to the flow of nitrogen gas, resulting in an increase in the charge density. As 
the charge density increases, the charges begin to repel each other to a greater extent resulting in 
the division of the droplets in to more numerous smaller droplets, and an equilibrium is reached 
when the forces of surface tension and ion repulsion within the droplet are equal (the Rayleigh 
limit). This process continues until individual sample ions enter the gas phase.78,79,81  
The mechanism by which gaseous ions are formed is still widely debated, and two alternate 
models have been suggested for the formation of gaseous ions from the condensed phase; the 
ion evaporation model (IEM) and the charge residue model (CRM) (see Figure 11). In both models 
as solvent droplets reach the Rayleigh limit they undergo a number of fission events resulting in 
the formation of smaller droplets as mentioned above, and it is after this point that the theories 
separate.  The charge residue model (CRM) considers the distribution of ions within each solvent 
droplet to be even and thus it suggests that continuous cycles of droplet evaporation and the 
Rayleigh limit being reached and subsequent solvent fission until each droplet contains only a 
single analyte ion. It is theorised that this droplet containing a single ion then completely 
evaporates resulting in the deposition of the analyte into the gaseous phase. 
 
 
Figure 11 - The two models for gas-phase ion generation by ESI; the ion evaporation model (IEM) and the charge 
residue model (CRM). Used with permission. 82 
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The ion evaporation model (IEM) assumes that the shape of the droplet will vary and thus affect 
the distribution of the ionised analytes within the droplet. The IEM mechanism proposes that if 
the droplet is not spherical the ions will be unevenly distributed, and thus the ions could be closer 
in proximately to each other at a point on the surface of the droplet than in the middle. Therefore 
the charge distribution at the surface point could exceed the solvation forces and thus be 
released as individual ions in the gaseous phase from the droplet. 
 
1.5.1.2 Interface region and ion optics 
The ions produced in the ESI source are transported using a heated ion transfer capillary which is 
seated behind the ion sweep cone. The capillary is heated to aid in any remaining desolvation of 
the ions that may be required. This interface region works at approximately 1 Torr and allows the 
ions to be transported efficiently to the skimmer which acts as a gate between this region of 
medium pressure to the lower pressure of the ion optics and detector.77 
The LTQ ion optics consist of two sets of quadrupoles (Q00 and Q0) and one octapole (Q1) (see 
Figure 9) which act as guides and focus the ions towards the mass analyser. A gate lens is located 
before the Q1 octapole which controls when ions are allowed into the ion trap.  
 
1.5.1.3 Ion trap 
The LTQ employs a 2D ion trap analyser, which utilises an oscillating electric field to trap ions. It 
consists of two pairs of rods that create a hollow space in the centre in which the ions are 
trapped. The rods are divided into three sections to allow different voltages to be applied along 
the ion trap, enabling the trap to move the ions towards the centre. In two of the opposing rods, 
the exit rods, a small slit allows for ions to be released for detection.77 
When conducting a full mass spectrum scan all ions are collected in the trap and then ejected and 
detected. If single ion monitoring (SIM) is required, the ions are collected in the trap before 
altering the voltages allowing only a single m/z to be released through the exit rods for detection. 
In the tandem MS mode (MS/MS or MSn mode), ions are isolated as above, however the ions are 
then excited via the application of voltages, causing them to collide with a gas (typically helium) 
resulting in fragmentation. The daughter or product ions are then ejected towards the detector. If 
multiple fragmentation steps are required (MSn) then the isolation and excitation steps can be 
repeated before the ejection step. 
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1.5.1.4 Detectors 
This system uses two off-axis ion detection systems, each of which is composed of a conversion 
dynode and an electron multiplier. Ejected ions hit the surface of the conversion dynodes which 
have a positive or negative potential applied to them depending on acquisition mode (negative 
potential is applied when detecting positive ions), resulting in the release of electrons which in 
turn encounter the electron multiplier.77 The electron multipliers amplify the signal which is then 
recorded and the signals displayed on the computer screen. 
1.6 Summary 
The sections above have summarised some of the theory and instrumentation that formed the 
basis of this research. There have been a great number of advances in recent years in progressing 
not only our understanding of Pt-based anti-cancer drugs and supplementation but also in the 
development of analytical instrumentation. This has enabled us to detect lower levels of trace 
elements in biological samples, making research such as this possible. The work presented in the 
following chapters is aimed at addressing the objectives outlined in Section 1.1, and each of the 
three main work streams has been split into separate chapters. 
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2. A comparison of blood and saliva as a source of DNA for the 
investigation of Pt-DNA adducts in patients undergoing Pt-based 
chemotherapy 
2.1 Introduction 
As outlined in Chapter 1, the use of Pt-drugs in the field of cancer chemotherapy is extensive due 
to its efficacy at destroying cancer cells via the formation of Pt-DNA adducts. It is these adducts 
which have been the subject of much research and which are the main focus of this chapter.  
While the level of cytotoxicity caused by Pt-DNA adducts is of primary interest, they can also aid 
in the understanding of drug uptake, repair, resistance and toxicity/side effects.83–88  However, 
while increasing our understanding in these areas is very beneficial, it is at the clinical stage 
where there is a limited understanding of how the level of Pt-DNA adducts affects each patient 
individually. Many studies in several fields have highlighted the issue that there is great inter-
patient variability and how a patient will respond to treatment is dependant of a range of factors, 
and include some host-specific factors. 5,89–91 Some research studies have indicated that there is a 
relationship between the levels of Pt-DNA adducts formed and the patient’s response, tumour 
resistance, drug toxicity and overall clinical outcome. 5,92–97 
As useful as the determination of Pt-DNA adduct levels in patients can be there are many 
problems associated with their detection and quantification. One of the primary issues associated 
with the quantification of Pt-DNA adducts is the low levels found both in vitro and in vivo.  More 
than 90% of the drug administered during treatment will bind to blood proteins resulting in it 
being inactive in the treatment of the cancer,98,99 and only around 1% of the Pt drug will ever 
reach and bind with the DNA to form adducts,3,4 while the rest of the drug binds to proteins in the 
cytoplasm and cell membrane and other higher affinity biomolecules within the cell, and 
consequently very sensitive techniques are required for the determination of adducts in human 
cells. 
Typical Pt-DNA adduct levels in leukocytes have been reported in the range of 1-7 Pt adducts per 
106 nucleotides for oxaliplatin and cisplatin, 5,100,101 and as the amount of clinical sample obtained 
is usually limited, detection of Pt-DNA adducts has proved problematic in the past. The Comet 
assay and ICP-MS are amongst the most frequently used techniques however other methods 
include AAS, immunoassays (e.g. ELISA assay) and post-labelling assays. 88,102–108 However due to 
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limitations in sample quantity, some of these techniques are only useful when conducting 
experiments in vitro.  
ICP-MS, being a highly sensitive technique, has proved to be very useful in the determination of 
Pt-DNA adducts. While as a technique it proves a speedy and robust method for determination of 
adducts at low levels found in clinical samples, it too is not without its drawbacks. Unfortunately 
all structural data is lost and therefore only the overall level of Pt associated with the DNA can be 
measured, and cannot be further divided into the level of different adducts formed. 
In this research project a Thermo Element 2 XR, which is a high resolution SF-ICP-MS was used in 
investigating the level of Pt-DNA adducts in clinical samples. Previous work on the quantification 
of Pt-DNA adducts to that presented in this chapter has been performed at Loughborough 
University. This work lead to the development of a fast, sensitive and robust ICP-MS assay which 
can be applied to in vivo Pt-DNA adduct formation. The first researcher in the group at 
Loughborough University to investigate Pt-based drugs was Dr Peter Winship.109 In his research, 
the Pt-DNA adducts of both cisplatin and oxaliplatin in calf thymus DNA (ctDNA) was successfully 
measured down to levels of 1 Pt per 500,000 nucleotides using a quadrupole ICP-MS, however his 
work was performed entirely on ctDNA where it was possible to use large quantities of DNA 
(around 1000 µg of DNA) which is simply not obtainable from clinical samples. 
Dr Samantha Kerr110  followed on this work using a high resolution SF-ICP-MS, and was therefore 
able to lower the limit of detection of platinum, as well as significantly reduce the level of matrix 
effects observed when analysing whole DNA and overcoming the problematic viscosity of DNA 
solutions by refining sample preparation methods and introducing a sample digestion process 
(outlined in Section 2.3.7). As a result of this work, it was possible to measure Pt doses in as little 
as 130 µg of DNA with excellent results, and some success was had at levels as low as 12 µg of 
DNA.  
Her work lead onto the application of these methods on clinical samples by Dr Aref Zayed.111 
During his research not only did he refine the assay and apply the use of the digestion procedure 
to clinical samples, but added the use of an internal standard (europium) to increase the 
reliability of the data. 
The progression of this work within the research group has been towards the overall aim of 
developing a robust and rapid technique for the quantification of Pt-DNA adducts in clinical 
samples with the aim of being able to determine the level of adducts during and between cycles 
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in order to better predict and influence the outcome of chemotherapy by adjusting and 
personalising doses on a patient to patient basis. 
As discussed above, the work by Zayed111 included a study where the level of Pt-DNA adducts was 
measured in leukocytes obtained from patients undergoing Pt-based chemotherapy treatment. 
His work uncovered some interesting observations, including the significant inter-patient 
variability, evidence of significant repair in some patients 24 hours post infusion and ability to see 
some correlation between adduct levels of toxicity and outcome experienced by patients. As well 
as the adduct level after 24 hours showing significant levels of repair in some patients, a low level 
of carryover of platinum between cycles was also observed. This work highlighted some 
important issues for further investigation; specifically how adduct levels change in the hours and 
days following Pt-drug infusion. Some studies have shown a peak in adduct formation around 6 
hours after infusion, 103 therefore not only were the hours immediately post infusion desirable to 
investigate but also how the levels changed and decreased between cycles.  
While there is some debate about the use of healthy cells (such as patient leukocytes) over 
cancerous tumour tissues, tumour tissues are not easy to obtain, and furthermore, as this project 
is primarily interested in the toxicity experienced by patients (where the effect of the drugs on 
healthy cells plays an important role) and how this varies over time, the use of leukocytes was 
deemed to be a suitable study material. However, the work by Zayed was not without its 
limitations, with the primary problem being obtaining the clinical samples themselves. To obtain 
blood leukocyte samples, trained personnel are required and furthermore in order to prevent the 
movement or change of platinum within the blood sample prior to analysis, the leukocytes have 
to be extracted as quickly as possible, which is a time consuming process. However the biggest 
challenge was obtaining the samples at times which were convenient for patients, and 
consequently an investigation into adduct formation levels over many hours and days post-
infusion using leukocyte samples would prove to be highly difficult unless a patient was 
hospitalised. 
Therefore, the main aim of the work presented in this chapter was to investigate the possibility of 
the use of an alternative biological sample which would be less intrusive and a more patient 
friendly means for the analysis of adduct levels. Saliva was chosen as it has been shown to be a 
viable alternative source of DNA for various applications112,113 and most importantly it can be 
obtained non-intrusively and does not require the presence of trained personnel to obtain the 
sample and can therefore be done in the privacy of a patient’s home. Consequently the work 
presented in this chapter was designed to aid in achieving this goal. Firstly, method development 
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is discussed followed by the application of these methods to clinical samples from patients 
undergoing Pt-based cancer chemotherapy treatment. 
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2.2 Experimental design 
In order to investigate the possibility of using saliva as an alternative to leukocytes for 
determining the number of Pt-DNA adducts in clinical patient samples with the ultimate aim of 
carrying out a study of the level of adducts over an extended time period, a trial experiment was 
set up to determine the correlation of adduct levels in blood and saliva in a small number of 
patients undergoing Pt-based chemotherapy. 
Firstly, ethical approval was obtained from the Leicestershire and Rutland Research Ethics 
Committee allowing the collection of both blood and saliva samples from patients undergoing Pt-
based chemotherapy.  A total of 10 patients were wanted for this initial trial, from which both 
saliva and blood samples would be obtained.  
A commercially available saliva kit (OG-500 kit obtained from Oragene) was chosen for the use in 
this investigation for the collection of saliva for several reasons. Firstly, it has been used 
successfully in previous DNA studies in other fields, and secondly because the use of the kit does 
not require the presence of trained personnel to obtain the samples, and could therefore be used 
in the privacy of a patients home, while allowing the DNA to be kept stable for extended periods 
of time before the DNA had to be extracted.114–118 
Blood and saliva samples were taken pre- and 1 hour post infusion, which would allow for a direct 
comparison in the level of Pt-DNA adducts at these time points. These time points were chosen 
primarily for patient convenience. A further saliva sample was taken 24 hours post infusion, and 
where possible a blood sample was also taken at this point, however this was usually not feasible 
unless a patient was hospitalised in the days following their treatment. 
DNA was then extracted from these samples, digested and were analysed via SF-ICP-MS to 
determine the Pt-DNA adduct levels, the details of which are given in the following sections. This 
investigation was not designed to be statistically powered, but rather as a proof of concept 
experiment before a larger scale experiment would take place. 
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2.3 Methodology 
Some of the methodology used in this chapter was developed by previous members of this 
research group and adapted for use on the samples presented.109–111 These methods are outlined 
and referenced below where appropriate; however some further method development was 
required, the details of which are also presented in the following sections. 
2.3.1 Patient sampling – patient criteria and ethics 
As previously stated, ethical approval was granted by the Leicestershire and Rutland Research 
Ethics Committee. Following this, patients were recruited at Leicester Royal Infirmary by Dr Anne 
Thomas and Dr Joanna Wood, who obtained informed consent from the patients undergoing Pt-
based chemotherapy.  Following this approximately 15 to 20 mL of blood and 2 mL of saliva were 
collected from the patients immediately prior to treatment and 1 hour post treatment. A further 
24 hour post treatment sample was also obtained for the saliva, and where possible, blood 
sample.  
The patients recruited in this trial were all suffering from cancers of the gastro-intestinal system 
and were on palliative care, and were on different Pt-based chemotherapy treatment regimes 
and on different cycles. Full details of patient treatments are given in Table 30 (Appendix A), 
however briefly they included FOLFOX (5-fluorouracil, folinic acid and oxaliplatin), FOLFOX and 
Bev (bevacizumab), EOX (epirubicin, oxaliplatin and capecitabine), ECX (epirubicin, cisplatin and 
capecitabine) and Cis/etop (cisplatin and etopside). 
2.3.2 Collection of saliva samples from patients 
Saliva samples were collected using a commercially available saliva collection kit, OG-500 
(Oragene, Ontario, Canada). Following the manufacturers recommendations, patients were kindly 
asked to abstain from eating food, drinking anything, smoking or chewing gum for 1 hour prior to 
donating a saliva sample. 
The OG-500 kits contain a sample collection tube which is marked to indicate how much sample is 
required (2 mL). A small funnel supplied is attached to the top of the collection tube allowing 
easier donation of saliva sample. Patients were encouraged to allow saliva to pool naturally at the 
front of their mouths and allow it to pass into the funnel as opposed to attempting to force the 
production of saliva. 
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Having filled the sample tube with 2 mL saliva (excluding bubbles), the lid of the funnel was 
snapped shut, allowing the release of a stabilising solution (2 mL) into fresh saliva sample, 
producing a final sample with a volume of 4 mL. The funnel was then removed and a simple, but 
secure, screw cap replaced it, ensuring the sample did not leak out of the tube. The tube was 
then inverted repeatedly for 5 seconds to ensure proper mixing of the saliva and stabilising 
solution. 
While the exact chemical breakdown on the stabilising solution is not known due to it being 
proprietary information, it is known that the DNA is stabilised by causing the cells to lyse. 
Oragene have conducted experiments to show that the DNA collected is stable for up to at least 5 
years from collection. 118 
While the pre- and 1 hour post-infusion samples were donated while patients were in the 
hospital, the 24 hour post infusion sample was donated by the patients while at home. They were 
offered free secure posting or could bring the sample with them to their next appointment. 
The stabilised saliva solutions were stored upright at room temperature (as per manufacturer’s 
instructions119) until the DNA extraction was performed. 
2.3.3 DNA extraction from saliva 
PrepIT.L2P solution was purchased from Oragene (Ontario, Canada) for the purpose of extracting 
the DNA from the OG-500 saliva collection kits. The manufacturer’s protocol was followed and 
was conducted as follows.119 Firstly, to ensure the DNA is properly released from the cells a heat-
treatment step was required, and therefore all samples were incubated in air at 50°C overnight. 
The full 4 mL of sample was then transferred to a 15 mL Falcon tube and 160 µL of PrepIT.L2P 
solution was added. To ensure complete mixing, the sample was vortexed for a few seconds. At 
this stage the sample became turbid as cell debris was precipitated out. The samples were then 
incubated on ice for 10 minutes, allowing for complete precipitation of the cell debris.  
Samples were then centrifuged at room temperature at 15000 x g, following which the clear 
supernatant was carefully collected using a pipette being careful not to disturb the pellet (which 
contained the impurities). The supernatant was placed in a clean 15 mL Falcon tube where 2.4 mL 
of 99% ethanol (BioUltra pure, purchased from Sigma Aldrich, Poole, UK) was added before being 
mixed gently by inversion. The added ethanol triggered the DNA precipitation, and the samples 
were allowed to stand for 10 minutes to allow full precipitation. The DNA at the point was usually 
visible as small clump of fibres. 
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The samples were centrifuged again at room temperature for 5 minutes at 15000 x g and the 
resultant supernatant was disposed of. The remaining DNA pellet was washed once with 70% 
ethanol and after ensuring that all ethanol was removed the remaining DNA pellet was dissolved 
in 200 µL distilled water. The manufacturer recommends TE as a DNA storage buffer (10 mM Tris-
HCl, 1 mM EDTA, pH 8.0), especially for longer term storage, however to keep contaminants and 
lower backgrounds for the ICP-MS analysis distilled water was chosen for this study. While water 
is not an ideal storage medium for DNA as it will evidentially result in the breakdown of DNA over 
time, for the purposes of this investigation where the DNA is digested prior to analysis and no 
structural information of DNA is required, this was not a major concern. However, having ensured 
that the DNA was fully dissolved, the DNA was quantified using UV absorbance at 260 nm and 280 
nm before the sample was stored at -20°C before digestion and subsequent analysis via SF-ICP-
MS. 
2.3.4 Collection of blood samples from patients 
Blood samples were taken from patients immediately prior and 1 hour post infusion by either Dr 
Joanna Wood or one of the nurses working on the Chemotherapy Suite at Leicester Royal 
Infirmary. The samples were taken in vials containing potassium EDTA (SARSTEDT, Germany) as 
an anti-coagulant (with final concentration being 1.2-2 mg EDTA/ mL of blood).  To prevent 
further movement or change of the Pt-based chemotherapy drugs within the blood samples, the 
leukocytes were extracted from the whole blood samples as quickly as possible, with the whole 
process usually being completed within 2 hours of the sample being taken. 
2.3.5 Leukocyte isolation 
In order to extract the leukocytes from the whole blood samples, Ficoll-Paque PLUS (GE 
Healthcare, Chalfont, UK) was used. The blood samples were transferred into a 50 mL Falcon tube 
and equal volume of room temperature RPMI 1640 media was added (purchased from Sigma 
Aldrich, Poole, UK). The mixture was mixed well using a pipette.  
To four clean 50 mL tubes, 12 mL Ficoll-Paque PLUS was added. Very carefully, and ensuring no 
mixing occurred, approximately 10 mL of the blood/media mixture was added on top of the Ficoll-
Paque PLUS. The samples were then centrifuged at 20°C for 30 minutes at 1700 rpm, using a low 
or no break setting.  The resulting fractions are depicted in Figure 12.  
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Figure 12 – Layers obtained during the isolation of leukocytes from whole blood using Ficoll-Paque PLUS 
The leukocyte layers for each sample were very carefully collected using a clean Pasteur pipette 
and washed using RPMI 1640 media. A haemocytometer and microscope was used to provide a 
cell count which was in turn used to re-suspend the leukocyte samples in fresh RPMI 1640 media 
containing 20% FCS (Foetal calf serum) and 10% DMSO to a final concentration of around 4-5 
million cells per mL. The isolated leukocyte samples were then frozen at -80°C until DNA 
extraction was to be performed. 
2.3.6 DNA extraction from leukocytes 
DNA was extracted from the leukocytes using the QiaAmp DNA Blood Mini Kit purchased from 
Qiagen (Crawley, UK). While this kit can be used for the manual extraction of DNA, in this case an 
automated DNA extraction system, a QIAcube (Qiagen, Crawley, UK) was used in an attempt to 
reduce hands-on preparation time as well as reduce human error and human introduced 
contamination while extracting DNA from clinical samples.  
The DNA Blood Mini Kit was used as per the manufacturer’s instructions, with only a couple of 
minor modifications, including changing the final elution buffer to distilled water and adding in an 
RNase clean up step. An overall outline of the extraction procedure is detailed below. 
The frozen leukocyte samples were thawed and washed with PBS before being placed into the 
QIAcube where the DNA extraction process was completed. The overall extraction process 
consists of 4 main stage; lysing of cells, binding of DNA to silica membrane, washing and elution. 
Firstly, in the lysis step, Buffer AL and protease enzyme are added to the sample, which is heated, 
to break down the cells to allow access to the DNA from within the nucleus. While the exact 
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chemical breakdown of the Qiagen buffers are not known due to it being proprietary information, 
the lysis buffer is known to contain Chaotropic salts which destabilise hydrogen bonds and 
hydrophobic interactions resulting in the disruption of the interactions of nucleic acids and water 
which in turn prepares for the binding of the DNA to the membrane. The lysis buffer is also 
believed to contain a detergent causing protein lysis and solubilisation.  
The next step is to separate the DNA from remaining cell material and to bind the DNA to the 
silica-based membrane. This is achieved by the addition of ethanol and when the sample is 
loaded onto the column and centrifuged, the DNA binds well to the membrane and the remaining 
impurities from the lysate are removed. 
A wash step aids in the purification of the DNA. During this step any further residual proteins or 
salts on the membrane are washed way using buffers AW1 and AW2. The first wash (buffer AW1) 
uses a low concentration of Chaotropic salts to remove remaining proteins, while the second 
wash (buffer AW2) uses ethanol to remove remaining salts. All of the ethanol must be completely 
removed before the DNA elution step so the membrane, which is housed in a column, is 
centrifuged until dry. 
Finally, during the elution step, the DNA is hydrated using buffer AE (this was exchanged for 
distilled water in this investigation) and is released from the membrane. A final elution volume of 
200 µL was set. As discussed previously, water is not a suitable storage media for DNA long term, 
but for the purposes of this investigation was preferable. A small aliquot of the DNA was then 
quantified using UV absorbance at 260nm and 280 nm before being stored at -20°C for analysis 
via SF-ICP-MS. 
2.3.7 Sample preparation 
A digestion method originally described by Yamada et al.120 and modified by Kerr110 was used for 
the extracted DNA samples for both blood and saliva. This method has also previously been used 
and validated for DNA from leukocytes by Zayed111.  
This digestion procedure was accomplished by the addition of 0.8 volume of ultrapure 70% nitric 
acid (Romil, Cambridge, UK) to 1 volume of sample and heated at 70°C for one hour. Before use, 
the small Eppendorf vial lids were pierced using a sterile needle to prevent pressure build up 
during heating.  Following this one hour heating with nitric acid, 0.8 volume of ultrapure 30% 
hydrogen peroxide (Sigma Aldrich, Poole, UK) was added to each sample and heated for a further 
4 hours at 70°C. 
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Following this, the digested sample was evaporated to dryness while being heated at 70°C and 
under a gentle stream of oxygen free nitrogen gas. This evaporation to dryness was carried out on 
a TurboVap Concentration Workstation (Biotage, Uppsala, Sweden).  
The dry sample was reconstituted to 350 µL prior to analysis on SF-ICP-MS using 2% nitric acid 
(HNO3) containing 0.5 ppb europium (153Eu). The use of europium as an internal standard for Pt 
and P was previously validated by Zayed.111 
The digestion procedure is used to solve the viscosity problem of DNA solutions associated with 
thin auto sampler tubing as found in this instrumental set up. Furthermore it also was found to 
lower the background and reduce matrix effects.110,111 
2.3.8 Instrumentation  
Having reconstituted the digested DNA samples as above, the samples were analysed using 
sector-field inductively coupled plasma mass spectrometry (SF-ICP-MS) (Thermo Scientific, 
Element 2 XR, Bremen, Germany). This instrument can be set up to aid lower or higher sample 
flow rates, as well as other variables. In this case, the instrument was set up to accommodate a 
flow rate of approximately 80 µL/min. This was achieved by attaching a PFA nebuliser (PFA-ST 
Elemental Scientific, Omaha, USA) and a Cyclonic spray chamber (Glass Expansion, Victoria, 
Australia).  As an autosampler was used, a low flow (80 µL/min) probe was utilised (Elemental 
Scientific, Omaha, USA). Nickel sampler and skimmer cones were used throughout this work 
(ICPMS cones Ltd., Chester, UK). 
A method previously developed by Zayed to measure the three elements of interest, 153Eu (LR), 
195Pt (LR) and 31P (MR) was used.5,111 This method measured 13 passes per run and 3 runs per 
sample. The data obtained via SF-ICP-MS was used to calculate the level of Pt associated with 
DNA (Pt-DNA adducts) as detailed in the next section. 
The ICP-MS nebuliser gas flows and torch positions were tuned every day to optimise conditions 
and maximise signal intensity, however typical conditions are summarised in Table 2.  
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Table 2 – Typical operating conditions for analysis via SF-ICP-MS 
Parameter Setting 
Radio frequency (RF) power 1215 W 
Cool gas flow rate 15.50 L min-1 
Auxiliary gas flow rate 0.95 L min-1 
Nebuliser (sample) gas flow rate 1.0 L min-1 
Sampler cone Nickel 
Skimmer cone Nickel 
Detection mode Triple mode 
Low resolution 153Eu, 195Pt 
Medium resolution 31P 
 
2.3.9 Quantification of DNA from UV absorbance 
During this investigation, the DNA was quantified via two methods; UV and ICP-MS. An 
experiment was performed by Zayed as part of his research to determine if ICP-MS could be used 
to accurately quantify DNA.111 His experiments were successful and found that DNA quantification 
via ICP-MS was actually more reliable and reproducible than UV as the Pt and P measurements 
were more robust against matrix effects and thus produced consistent data. In this investigation, 
both UV and ICP-MS were used to quantify DNA to ensure the results corroborate, however the 
final calculation of Pt-DNA adducts will be performed using the data obtained from the ICP-MS. 
To measure DNA concentration and purity via UV analysis, the absorbances of the DNA samples 
was measured at 260 and 280 nm. The samples were diluted with water to provide readings 
between 0.1 and 1 to ensure that the readings fell within the linear range defined by Beers law. In 
order to calculate the concentration of DNA in the solution, the following equation was used: 
𝐷𝐷𝐷 µ𝑔/µ𝑙 =  𝐷260 𝑥 𝐷𝐷 𝑥 501000  
In the equation above A260 is the absorbance measured at 260nm and DF is the dilution factor. 
The equation is based on a 50 µg/ml sample of double-stranded DNA which has an absorbance of 
1 at 260 nm. The DNA purity can be calculated using the ratio of A260/A280, where the absorbance 
ratio should be between 1.6-1.8 (1.6 is ideal).  
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2.3.10 Quantification of DNA via ICP-MS 
To be able to quantify the number of Pt-DNA adducts formed via ICP-MS, the P and Pt 
concentrations had to be calculated from the data obtained from the ICP-MS. Firstly this 
information was used to calculate the number of Pt atoms per nucleotide by the use of the 
following equations. 
While investigating the number of Pt-DNA adducts formed, two methods were investigated. 
Firstly, by taking the P and Pt concentrations calculated from the ICP-MS data, the number of Pt 
atoms per nucleotide was calculated by using the following equations:109,111 
𝑃𝑃 𝑝𝑝𝑝 𝑛𝑛𝑛𝑙𝑝𝑜𝑃𝑜𝑜𝑝 =  𝐷𝑛𝑚𝑁𝑝𝑝 𝑜𝑜 𝑃𝑃 𝑎𝑃𝑜𝑚𝑎 𝑝𝑝𝑝 𝑙𝑜𝑃𝑝𝑝
𝐷𝑛𝑚𝑁𝑝𝑝 𝑜𝑜 𝑛𝑛𝑛𝑙𝑝𝑜𝑃𝑜𝑜𝑝𝑎 𝑝𝑝𝑝 𝑙𝑜𝑃𝑝𝑝  
𝐷𝑜. 𝑜𝑜 𝑛𝑛𝑛𝑙𝑝𝑜𝑃𝑜𝑜𝑝𝑎 𝑝𝑝𝑝 𝑙𝑜𝑃𝑝𝑝 =  𝑃 𝑛𝑜𝑛𝑛𝑝𝑛𝑃𝑝𝑎𝑃𝑜𝑜𝑛  (µ𝑔 𝐿⁄ )1000  𝑥 0.00130.974   𝑥 𝐷𝐴𝑜𝑔𝑎𝑜𝑝𝑜𝑎 𝑛𝑜𝑛𝑎𝑃𝑎𝑛𝑃 
Alternatively, the UV data in conjunction with the Pt data obtained from the ICP-MS data could be 
used.  To do this, an adjustment to the above formula for the calculation of the number of 
number of nucleotides per litre would be changed to: 
𝐷𝑜.𝑜𝑜 𝑛𝑛𝑛𝑙𝑝𝑜𝑃𝑜𝑜𝑝𝑎 𝑝𝑝𝑝 𝑙𝑜𝑃𝑝𝑝 =  𝐷𝐷𝐷 𝑛𝑜𝑛𝑛𝑝𝑛𝑃𝑝𝑎𝑃𝑜𝑜𝑛 (𝑚𝑔/𝐿) 𝑥 0.001307.61   𝑥 𝐷𝐴𝑜𝑔𝑎𝑜𝑝𝑜𝑎 𝑛𝑜𝑛𝑎𝑃𝑎𝑛𝑃 
Where 307.61 is the average molecular weight of a nucleotide polymerised in a DNA molecule. 
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2.4 Saliva method development 
The DNA extraction, digestion and analysis methods detailed above in Section 2.3 were previously 
used and validated on clinical patient leukocyte samples by Zayed.5,111 As the ICP-MS assay 
contained several sample preparation steps, including the harsh acid digestion, the overall assay 
from start to finish was investigated to ensure that a high recovery and reproducibility was 
obtained.  
Firstly, an investigation was performed by Zayed where the digestion procedure, evaporation and 
reconstitution was performed and analysed via ICP-MS using platinum standards at a range of 
concentrations. The level of Pt recovery and relative error was found to be good, and the 
investigation was extended to look at a Pt-based drug being digested with and without the 
presence of ctDNA. This brought to light an issue of slight signal enhancement, thought to be 
caused by DNA matrix effects. This was overcome by the introduction of europium as an internal 
standard. 
This method was later used successfully on patient leukocytes5,111, however to ensure that the 
experiment design (as detailed at the start of this chapter), aim and outcome would not be 
compromised by the unknown interaction or degradation of platinum based chemotherapy drugs 
in saliva, a stability study was conducted. 
According to the manufacturer, the DNA from a saliva sample stored within an Oragene OG-500 
saliva collection kit is stable for at least 5 years at room temperature, but could also be stored in 
the freezer if the user required119, however to ensure that this was the case, and that the 
platinum in the sample, in particular the Pt-DNA adducts, would be stable as well, a 12 month 
stability test was performed.  
2.4.1 Experimental design 
Firstly, to determine the stability of Pt-DNA adducts within saliva sample stored within an 
Oragene OG-500 kit, a yearlong stability study was set up. A set of sampling time points were 
chosen  to allow storage of samples for 0 days (immediate), 1 week, 2 weeks, 1 month, 2 months, 
3 months, 6 months, 9 months and 12 months. At each of these time points a healthy volunteer 
would donate 2 mL of saliva having not drunk or eaten anything for the previous hour. The 
sample was then spiked with 100 µL of oxaliplatin (8.64E-7M) and left for 1 hour to allow the Pt-
drug to interact with the DNA before the stabilising solution in the lid of the OG-500 kits was 
added in and the sample inverted to ensure proper mixing. The sample was then stored upright at 
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room temperature until analysis was performed. All samples, including procedural blanks were 
analysed at the same time. 
2.4.2 Methodology 
The DNA from the saliva was extracted, digested, evaporated and reconstituted as per the 
methods described in Section 2.3.  
The ICP-MS was tuned in both low and medium resolutions to optimise signal intensity on the day 
of analysis and the instrument set up and analysis method described in Section 2.3 was utilised in 
this investigation.  
Previous work in this research group has shown that while overall background Pt and P levels are 
low, digested samples over non-digested samples have a slightly higher background; however it is 
still significantly lower than the levels measured in samples. To ensure that this was the case with 
the saliva samples, digested water blank as well as saliva blanks (no added platinum) were 
analysed. 
2.4.3 Results and discussion 
The ICP-MS calibration data for platinum (195Pt) using europium (153Eu) as an internal standard 
(Figure 13) shows excellent linearity. For each sample the platinum concentration was calculated 
in ppb based on the calibration graph, and the theoretical platinum concentration based on level 
of oxaliplatin added and the recovery was calculated as a percentage (see Table 3 and Figure 14). 
 
Figure 13 - Pt calibration graph using 153Eu as an internal standard 
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Table 3 - Platinum recovery in saliva stability study 
Time point Measured Pt (ppt) 
Pt spike 
concentration (ppb) 
Recovery (%) 
Water blank 1 2.56 0.00 - 
Water blank 2 2.95 0.00 - 
Saliva blank 1 3.93 0.00 - 
Saliva blank 2 3.84 0.00 - 
Immediate 48.24 4.23 1.14 
1 week 43.43 4.20 1.04 
2 week 40.77 4.23 0.96 
1 month 43.12 4.21 1.02 
2 month 41.63 4.23 0.98 
3 month 36.62 4.25 0.86 
6 month 34.60 4.21 0.82 
9 months 40.51 4.26 0.95 
12 months 36.69 4.35 0.84 
 
 
Figure 14 - Platinum recovery in saliva stability study 
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While at first glance the platinum recovery seems very low (around the 1% mark), this was to be 
expected. Previous work has shown that within cell cultures the sub-cellular fractionation of cells 
has shown that only around 9-17% of all cellular proteins can be found within the nuclear fraction 
of the cell, depending on the cell type, and furthermore only around 9% of Pt-based drugs 
exposed to cell cultures ends up in the nuclear fraction, however in patient leukocyte samples this 
value increased to the range of 20-26%.5,111  
While these values are significantly higher than the recoveries observed in this experiment, this 
can be explained as the values stated for the nuclear fraction includes not just DNA, but proteins 
found within the nuclear fraction. Furthermore, previous research has suggested that only around 
1% of the Pt given to patients reaches the DNA.3,4,71 This is in approximate agreement with the 
results observed in this experiment. 
The level of platinum recovery observed was not the primary aim of this experiment however, as 
no matter how low the recovery of platinum observed in the DNA, the main aim of this 
experiment was to observe if the levels of recovery changed over time that the kits could be 
stored for. As can be seen from Figure 14 and Table 3 the levels of Pt recovery over the 12 month 
period remained relatively stable.  
Ensuring drug stability over time within the OG-500 kits was essential as the primary aim of the 
comparison of Pt-DNA adduct levels in blood and saliva is to establish if there is a correlation 
between the two measurements or not and for that to be achieved the samples had to be kept as 
uniform as possible. Therefore, while the ICP-MS results for the measured Pt concentrations 
showed a low level of Pt when compared to the spike level, the results were quite consistent and 
stable.  This combined with the observation of very low background levels of Pt observed in both 
the digest blank (water blanks) as well as the DNA extraction blanks is a positive indication for the 
suitability of the OG-500 kits in the clinical study. 
2.4.4 Conclusion 
The recovery and stability were determined to be within an acceptable range and it was 
concluded that the OG-500 saliva kits would be stable enough for the purpose of the investigation 
into the comparison on the level of Pt-DNA adducts in saliva and blood.  
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2.5 Comparison of Pt-DNA adducts in patient leukocyte and saliva 
samples 
2.5.1 Results and Discussion 
The collection of samples of both blood and saliva for this trial proved to be very problematic. As 
is often the case when working with human samples a level of patient drop out was experienced. 
Patients were entitled to withdraw consent from the trial at any point and there were 5 
incidences where not all samples were obtained as the patients withdrew from the study. 
However, there were some specific problems associated with each form of sampling. Firstly, with 
regard to blood samples, as was anticipated very few patients were willing to donate a 24 hour 
blood sample due to the inconvenience of having to return to the hospital the day following their 
treatment. Considering the patients’ poor health this was completely understandable and in the 
end only one patient of the final 23 patients sampled was able to donate a 24 hour blood sample.  
In contrast, and proving that for patients’ saliva was a much more patient-friendly sampling 
technique, nearly all patients provided a 24 hour saliva sample. However, problems were 
experienced in gaining patient compliance with the sampling protocols. While initially the aim 
was to obtain a sample set from 10 patients, due to problems collecting correct saliva samples, in 
total 23 patients were recruited for this study before 10 complete sample sets had been 
obtained.  
The most common problem encountered while collecting saliva samples was patients not 
providing a full 2mL saliva sample. While this in theory would not cause a problem with the 
quality of the DNA provided, it could result in a lower yield of DNA being recovered and no 
replicate analysis being possible. The second most common issue found with this sampling 
technique was the failure to add all or some of the stabilising solution contained within the kit.  If 
no or little stabilising solution was added there was potential for sample degradation or 
movement in Pt within the sample to occur, which would affect the results of this experiment. On 
occasions samples would be returned to the lab short of the final 4 mL sample and it was 
impossible to know if the sample was small due to there being too little saliva donated or 
whether not all of the stabilising solution was added.  
The final, and least common, problem encountered in saliva sampling was the failure to swap the 
funnel to the leak free screw cap lid after donating sample and addition of stabilising solution. 
This resulted in either the complete loss and/or contamination of the sample and those samples 
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were therefore useless. A full list of all samples taken (both complete and incomplete) is shown in 
Table 29 (Appendix A). 
As it was uncertain whether or not all of these problems would affect the final result, samples 
were continued to be collected to ensure 10 complete and correct sets. Below the results from 
the 10 complete sample sets are analysed first, before looking at all of the samples obtained.  
2.5.1.1 Comparison of Pt-DNA adducts in 10 complete sample sets 
The patients from whom 10 complete blood and saliva sample sets were obtained were from 
patient numbers 34, 35, 39, 48, 49, 50, 51, 53, 54 and 55. The results for these 10 complete 
sample sets were run in 4 batches on the ICP-MS (2 batches for each blood and saliva). For each 
batch a calibration graphs for both phosphorus (31P) and platinum (195Pt) using europium (153Eu) 
as an internal standard were produced. While all calibration graphs pertaining to this section can 
be found in Appendix A, all of which showed excellent linearity, an example of a P and Pt 
calibration graph for the blood samples is shown below (Figure 15 and Figure 16). 
The calibration graphs and the raw intensity data (cps) for the elements measured were then 
used to calculate the number of Pt-DNA adducts per 106 nucleotides for both blood and saliva 
samples from all 10 patients. Three replicates were obtained for the blood samples (the leukocyte 
samples were split into aliquots prior to DNA extraction); while two replicates were run for the 
saliva samples (the extracted DNA sample dissolved in water was mixed thoroughly then split into 
two equal aliquots). The results from this as summarised in Table 4, Figure 15 and Figure 16.  
 
Figure 15 - Example Phosphorus Calibration Graph 
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Figure 16 - Example Platinum Calibration Graph 
Table 4 - Pt-DNA adduct data obtained from 10 patient blood and saliva samples 
Patient ID Time point 
Average number of Pt-DNA adducts  
(per 106 nucleotides) 
Blood Saliva 
34 
Pre 0.21 0.45 
1 Hour 4.10 5.60 
24 Hour 5.10 6.22 
35 
Pre 0.42 0.39 
1 Hour 3.84 3.74 
24 Hour - 2.36 
39 
Pre 0.56 0.59 
1 Hour 3.35 4.44 
24 Hour - 1.43 
48 
Pre 0.38 0.76 
1 Hour 5.32 3.34 
24 Hour - 2.78 
49 
Pre 0.65 1.17 
1 Hour 7.11 4.24 
24 Hour - 3.24 
50 
Pre 0.13 0.29 
1 Hour 4.53 4.00 
24 Hour - 1.57 
51 
Pre 0.28 0.76 
1 Hour 3.35 3.04 
24 Hour - 5.35 
53 
Pre 0.44 0.60 
1 Hour 3.35 3.17 
24 Hour - 3.99 
54 
Pre 0.27 0.68 
1 Hour 1.68 5.81 
24 Hour - 6.47 
55 
Pre 0.37 0.37 
1 Hour 2.87 4.07 
24 Hour - 4.16 
y = 0.0004x + 0.0002 
R² = 0.9995 
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Figure 17 - Number of Pt-DNA adducts formed in pre- and post-infusion leukocytes samples in patients. Error bars 
produced 2x standard deviation, n=3 
 
Figure 18 - Number of Pt-DNA adducts formed in pre- and post-infusion saliva samples in patients. Error bars 
represent range of samples 
Figure 17 and Figure 18 show the average number of Pt-DNA adducts measured in the blood and 
saliva samples respectively for all 10 patients at the different sampling time points. The error bars 
shown were calculated either as two times the standard deviation of the replicates or represent 
the range of the results. With the exception of patient number 34, no 24 hour blood samples 
could be obtained, and therefore only the pre- and 1 hour post-infusion data is presented for the 
blood samples from the remaining patients. To enable an easier visual comparison between the 
two data sets, they were combined onto one graph (see Figure 19). 
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Figure 19 - Comparison of Pt-DNA adduct formation levels in saliva and leukocyte patient samples 
Figure 17, Figure 18 and Figure 19 show very clearly that it is possible to measure Pt-DNA adducts 
in blood and saliva samples obtained from clinical patients. However, a comparison of the level of 
Pt-DNA adducts in both blood and saliva samples from the same patients at the same time point 
showed a poor correlation between the two sample types. 
However, one positive observation is that the adduct levels recorded in saliva were of a similar 
level (i.e. same order of magnitude) as measured in the blood samples. With the exception of 
patient 54, the range of adducts per 106 nucleotides recorded was within a factor of 2 at the 1 
hour time point. This is suggestive that with further method development and adjustments that 
saliva could be a viable alternative to blood sampling. While a visual inspection of the adduct 
levels between sample types indicated poor or no correlation, correlation scatterplots for pre-
infusion and 1 hour post-infusion were drawn to aid in assessing the correlation for the two 
sample types (see Figure 20 and Figure 21). As only one 24 hour blood sample was obtained, no 
comparison between the 24 hour samples could be drawn. 
Pearson correlation coefficients were calculated for the data sets presented; as shown in Figure 
20 and Figure 21 and Table 5. While there is some correlation between the pre-infusion samples 
for the blood and saliva samples (r = 0.6143), there is no correlation (or in fact a slight negative 
correlation, r = -0.2598) between the 1 hour post infusion blood and saliva samples.  
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Figure 20 - Scatterplot showing the correlation between the pre-infusion samples from blood and saliva samples 
 
 
Figure 21 - Scatterplot showing the correlation between the 1 hour post-infusion samples from blood and saliva 
samples 
 
r = 0.6143 
r = -0.2598 
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Table 5 - Pearson correlation coefficient values for complete patient data set 
 Blood Pre Blood 1 Hour Saliva Pre Saliva 1 Hour 
Blood Pre 1.0000 0.4054 0.6143 -0.2019 
Blood 1 Hour 0.4054 1.0000 0.5272 -0.2598 
Saliva Pre 0.6143 0.5272 1.0000 -0.0884 
Saliva 1 Hour -0.2019 -0.2598 -0.0884 1.0000 
 
Reasons for the lack of correlation require further investigation, however, studies have shown 
that DNA obtained from saliva does not originate exclusively from buccal epithelial cells as once 
thought and is instead a mixture of a range of cells. This mixture of cell types can be dependent 
on such factors as the condition of the mouth. One study found that saliva frequently contains a 
significant quantity of leukocyte cells. In this study, the number of leukocyte cells in saliva has 
been measured and varied greatly from 2 to 136,000 cells/mL to 1.1x106 cells/mL where a patient 
has had an inflamed oral cavity.121,122 Oral mucositis, which is a side effect of chemotherapy 
experienced by some chemotherapy patients, can result in sores and ulcers leading to an 
increased level of blood in the mouth.  Theoretically if a higher level of leukocytes were present in 
the saliva samples the correlation between the two sample types should be better, however the 
extent of oral mucositis was not fully known for the patient group in this investigation and 
therefore the number of leukocytes in each sample remains unknown. Other potential reasons 
for the lack of correlation were also considered, such as a potentially different mechanism of 
uptake of platinum by buccal cells compared to blood cells, as well as the possibility of different 
types of leukocytes within the two sample types which could act differently. On top of this there 
is also the potential for DNA contamination from bacterial organisms from within the mouth. 
However without further knowledge of the samples contents no firm conclusions could be made. 
It is therefore feasible that the lack of correlation observed in this study could potentially be due, 
at least in part, to the unknown and variable mixture of cells and leukocyte contamination level in 
each saliva sample. Unfortunately, the level of leukocyte contamination and mixture of cells was 
unknown for these samples and without this knowledge further data analysis on these samples 
was not possible.  Any future studies would have to employ the use of cell sorting on saliva 
samples before DNA extraction was performed to see if any better correlation could be obtained.  
In this investigation cell sorting was not an option as the saliva collection kits (OG-500) prevented 
such a step and the stabilising solution added to preserve the sample induced cell lysis. A cell 
sorting procedure, such as flow cytometry, would have to be performed on a fresh DNA sample, 
thus potentially coming across the issue of having to analyse the sample immediately which was 
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one of the inconveniencies of blood sampling, however would still remain a less intrusive and 
more patient friendly sampling technique. 
While a lack of correlation was observed in the 1 hour post-infusion samples, a significantly higher 
level of correlation was observed in the pre-infusion samples. All 10 of the patients in this part of 
the study had already received at least one previous cycle of chemotherapy, and consequently 
had a very low level Pt-DNA adduct level in their pre-infusion samples. Due to the fact that these 
levels are low (typically lower than 0.5 Pt-DNA adducts per 106 nucleotides), even if the actual 
number of adducts were not exactly the same between sample types, they were at least closer to 
each other, resulting in a higher level of correlation observed. 
While investigating the correlation between the Pt-DNA adduct levels was the primary aim of this 
investigation, the data set presented also highlighted some other interesting insights. Firstly a 
significant amount of inter-patient variability was observed. Speculated reasons for this variation 
are two-fold. Firstly, the 10 patients in this study were receiving different doses of varying 
combination treatments for various types of cancer (these details are summarised in Table 6, 
however full details can be found in Appendix A). Secondly, large variation in human and other 
biological studies is not uncommon, particularly when considering the mixture of gender and age 
as in this study. When this is considered in relation to Pt-DNA adduct formation, it is suggestive 
that patient-specific factors play a role in how a patient is affected by and how effective the 
cancer chemotherapy treatment is.123–126  
Previous studies have shown some, often limited, correlation between adduct levels and toxicities 
experienced by patients.5,86,94,96,127 Toxicities are graded according to the Common Toxicity 
Criteria (CTC), and any grade 3/4 toxicities observed during the course of chemotherapy were 
recoded (see Appendix A), however in this study, no particular correlation between adduct levels 
and grade 3/4 toxicities were noted. Furthermore, as a mixture of adjuvant and non-adjuvant 
patients (i.e. mixture of metastatic and non-metastatic patients) were recruited for this trial, it is 
difficult to compare survival data.  
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Table 6 - Patient regiment and cycle numbers 
Patient Regiment Cycle Cancer Type Dose Reduction (cycle number) Toxicity reported 
34 EOX 4 Adeno carcinoma oesophagus 75 %  (3 onwards) - 
35 FOLFOX and Bev 10 Colorectal cancer 75%  (2 onwards) Diarrhoea cycle 1 
39 FOLFOX and Bev 8 Colorectal cancer 
70% (4 onwards) 
0% (10 onwards) Neuropathy cycle 3 
48 FOLFOX 2 Colorectal cancer 75% (3 onwards) Neutropenia and neuropathy cycle 2 
49 FOLFOX and Bev 7 Colorectal cancer 
80% (4 onwards) 
75% (8 onwards) 
Stopped cycle 12 
Neuropathy cycle 3 
 
50 FOLFOX 2 Colorectal cancer 
75% (2 onwards) 
50% (7 onwards) 
0%(8) 
Neuropathy cycle 1 
 
51 FOLFOX and Bev 11 Colorectal cancer - - 
53 ECX 53 Gastric oesophageal junction cancer - - 
54 Cis / etop 3 Small cell oesophagus 85%  (4 onwards)  
Deterioration in hearing 
cycle 3 
55 EOX 2 Gastric 
75% (2 onwards) 
50% (4 onwards) 
 
Fatigue, diarrhoea, 
neutropenia, vomiting, 
neuropathy cycle 1 
 
As previously mentioned, a low number of Pt-DNA adducts were observed in each pre-infusion 
sample measured in this part of the study. This was not surprising as none of these 10 patients 
were on their first cycle. This carry-over effect of platinum in patients between cycles has been 
observed before, and shows that at least a low level of platinum stays within the blood stream 
(and other bodily cells, such as saliva) between cycles which are typically two to three weeks 
apart.5 This phenomenon has a lot of potential for future investigation as it is unclear what, if any, 
effect the number of Pt-DNA adducts persisting in the body between cycles has on patient 
response or side effects experienced. 
Another key observation from these results was the rapid appearance of platinum within the 
saliva samples as was evident by the increase in the level of Pt-DNA adducts as seen in the 1 hour-
post saliva samples compared to the pre-infusion samples. While this was expected in the blood 
samples (see Figure 17), given that the treatment is administered intravenously, and thus is 
visible at measurable levels at the first post-treatment sample time point, it is evident from Figure 
18 that the platinum also reaches the DNA within the saliva within a 1 hour time period. Even 
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though the results of this work showed a poor correlation between the two sample types, the 
rapid movement of platinum into the saliva is a positive observation for the possibility of using 
saliva as a research sample for this type of work.112 
From Figure 18 it can also be noted that that in some cases the number of adducts measured at 
the 24 hour time point had increased when compared to the 1 hour post-infusion sample, where 
as in other patients the level had decreased. This could potentially be evidence of repair of the 
DNA, or potentially due to instability of the guanine adducts. Guanine adducts (which comprise of 
large percentage of adducts formed, see Chapter 1) are labile and can undergo depurination.  And 
therefore the stability of the adducts and the repair efficiency may be the key factors resulting in 
inter-patient variability. While this effect has been seen in leukocyte samples previously, some 
studies have suggested that adduct levels are at their highest around 6 hours post drug 
infusion.5,71,100 While in this study it would have been possible to collect a saliva sample at 6 hour 
post-infusion time point, it would not have been feasible to collect a corresponding blood sample 
to compare it to, and thus would not have helped in determining whether saliva is a viable 
alternative to leukocytes.  
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2.5.1.2 Comparison of Pt-DNA adducts in the 13 remaining incomplete 
sample sets 
As previously discussed, in total 23 patients were recruited for this study before a final of 10 
complete patient sets were obtained. A sample set was determined to be incomplete if one or 
more of the samples were missing (either blood or saliva) or if too little sample was provided. 
When samples containing too little saliva sample were returned it wasn’t always clear whether 
this was because the patients had just donated less saliva than we had asked for (which would 
result in a lower yield of DNA) or whether the stabilising solution had not been added (and 
therefore the sample would not have been stable). Thus it was decided not to include such 
samples in the complete data sets described above, but rather to analyse them as part of the 
‘incomplete’ sets, using the preparation and analysis methods detailed in Section 2.3. 
The calibration graphs for the remaining blood and saliva samples (patient numbers 33, 36, 37, 
38, 40, 41, 42, 43, 44, 45, 46, 47 and 52) are shown in Appendix A. The results of these are 
outlined below (Table 7, Figure 22, Figure 23 and Figure 24). 
 
Figure 22 - Number of Pt-DNA adducts formed in pre- and post-infusion leukocytes samples in incomplete patient 
sample sets. Error bars produced 2x standard deviation, n=3 
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Figure 23 - Number of Pt-DNA adducts formed in pre- and post-infusion saliva samples in incomplete patient sample 
sets. Error bars represent the range of samples 
 
 
Figure 24 - Comparison of the number of Pt-DNA adducts formed in pre- and post-infusion leukocytes and saliva 
samples in incomplete patient sample sets 
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Table 7 - Average Pt-DNA adduct formation in 13 incomplete patient blood and saliva sets 
Patient ID Time point Average adducts (per 10
6 nucleotides) 
Blood Saliva 
33 
Pre 0.35 0.36 
1 Hour 2.63 4.54 
24 Hour - 3.80 
36 
Pre 0.34 0.40 
1 Hour 2.23 1.25 
24 Hour - 1.46 
37 
Pre 0.34 0.41 
1 Hour 5.01 - 
24 Hour - - 
38 
Pre 0.33 0.43 
1 Hour 2.45 4.36 
24 Hour - 3.71 
40 
Pre 0.44 0.26 
1 Hour 5.01 3.41 
24 Hour - - 
41 
Pre 0.01 0.01 
1 Hour 2.36 - 
24 Hour - - 
42 
Pre 0.46 0.35 
1 Hour 4.33 6.51 
24 Hour - 4.32 
43 
Pre 0.47 0.40 
1 Hour 3.11 2.46 
24 Hour - 2.86 
44 
Pre 0.01 0.01 
1 Hour 3.26 4.90 
24 Hour - - 
45 
Pre 1.03 1.35 
1 Hour 4.63 1.84 
24 Hour - 2.35 
46 
Pre 0.23 0.17 
1 Hour 1.98 3.81 
24 Hour - - 
47 
Pre 0.34 0.68 
1 Hour 4.33 3.18 
24 Hour - 3.01 
52 
Pre 0.28 0.35 
1 Hour 3.63 4.34 
24 Hour - 4.67 
 
These results were treated in the same way as the complete sample sets were and the scatter 
plots and Pearson correlation coefficients were calculated (see Figure 25 and Table 8). 
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Figure 25 - Scatter plots comparing the adduct levels in both blood and saliva levels in pre- and 1 hour post infusion 
time points 
 
Table 8 - Pearson correlation coefficient values for incomplete patient data set 
 Blood Pre Blood 1 Hour Saliva Pre Saliva 1 Hour 
Blood Pre 1.0000 0.4047 0.7353 -0.1754 
Blood 1 Hour 0.4047 1.0000 0.3336 0.0738 
Saliva Pre 0.7353 0.3336 1.0000 -0.3032 
Saliva 1 Hour -0.1754 0.0738 -0.3032 1.0000 
 
For the pre-sample scatterplot and Pearson correlation coefficient calculation patient number 45 
was removed from the calculation. This was due to an error occurring during sample donation 
which resulted in the pre-infusion sample only being taken immediately at the end of the 
treatment and the 1 hour post infusion sample being taken 1 hour after that, and therefore the 
pre- sample was not a true reflection of the pre-infusion adduct levels. 
When examining the correlation coefficients measured in the incomplete sets, slightly better 
correlation was observed in both pre- and 1 hour post-infusion samples. While the condition and 
stability of some of these saliva samples is unclear and therefore does question some of these 
results, there are some potential explanations for the slight differences in results observed. 
Firstly, in this second set of samples there were 3 patients on their first cycles of treatments. 
These patients by definition should only have had background levels of platinum in their samples, 
resulting in the very low (virtually zero) number of adducts per 106 nucleotides. As one of these 
patients was patient number 45 where the pre- sample was taken late this sample can be 
r = 0.7353 r = 0.0738 
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discounted when making these observations.  The two remaining first cycle samples were below 
the LLOQ of 0.2 adducts per 106 nucleotides as determined by Zayed.111 These very low results 
likely aided the correlation as the difference between the two recorded values was noticeably 
smaller. 
The reason for the slight change in correlation in the 1 hour post-infusion samples (from a slightly 
negative correlation to virtually no correlation) is unclear, however when considering how great 
human variation is and the potential error associated with some of the stability of the saliva 
samples, this change seems very slight and not of great significance. 
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2.6 Conclusions 
This chapter described the application of an ICP-MS assay to the quantification of Pt-DNA adducts 
in both blood leukocyte and saliva samples in patients receiving platinum based chemotherapy 
drugs. While this assay had previously been successful in the determination of Pt-DNA adducts in 
leukocyte samples, it was for the first time successfully used in determining the number of 
adducts in saliva samples as well.  
This work aimed to be able to directly compare adduct levels in two different sample types from 
the same patients in order to determine whether saliva DNA (which can be obtained less 
invasively and is thus a more patient friendly technique) could be used as an alternative to 
leukocyte sampling for the determination of adduct formation. To do so, leukocyte and saliva 
samples were obtained from patients both pre- and 1 hour post-infusion with an additional 24 
hour post-infusion saliva sample being obtained. While the initial aim was to collect 10 sample 
sets for comparison of adduct levels, problems encountered in gaining patient compliance with 
the saliva sampling protocol resulted in a total of 23 patients sets being acquired before a set of 
10 complete sets were eventually obtained. The lack of patient adherence to the sampling 
protocol, as detailed in the sections above, was an unforeseen difficulty and is something that 
would need to be addressed if saliva was to become a viable alternative sampling technique for 
this application. 
A direct comparison of the 10 complete (and 13 incomplete sets) was performed but while a 
limited correlation was observed between the adduct levels in blood and saliva pre-infusion 
samples, a lack of correlation was observed in the 1 hour post-infusion samples. Possible reasons 
for this were discussed, however it was concluded that a feasible explanation was the unknown 
mixture of cell types found in the saliva samples as well as a potentially different uptake 
mechanism for other types of cells.  
While a direct comparison could be made for the pre- and 1 hour post-infusion time points, it had 
been hoped to be able to collect a few 24 hour blood samples to compare the 24 hour post 
infusion saliva samples, however unfortunately only one patient was able to donate a 24 hour 
blood sample. While unfortunate, this was not wholly unexpected and does reinforce the idea 
that more patient friendly and less intrusive sampling methods, such as saliva, would help in the 
study of adduct levels over extended periods of time when patients are not in hospital. One 
positive observation from the saliva sampling was the high yield of DNA collected. In clinical 
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sampling often sample size can be a limiting factor, however while the DNA yield from saliva 
between patients was variable, more DNA was extracted from the saliva than the leukocytes. 
The number of participants in this study was small and consequently only limited statistical data 
can be obtained from it. Only 10 patients were chosen from the outset for this investigation as 
this experiment was not designed to be statistically powered but rather act as a proof of concept 
that saliva could be a viable alternative to blood sampling. Had this investigation yielded positive 
results, a further more extensive study could have been carried out using a greater number of 
patients and further time points to aid in the understanding on how adduct formation over time 
is correlated to patient outcome and side effects, with the ultimate aim of eventually creating an 
ex-vivo test for predicting toxicity and aiding in personalised chemotherapy doses. 
Overall this work has shown that not only was it possible to determine the level of Pt-DNA 
adducts in DNA obtained from both white blood cells and saliva clinical samples using ICP-MS, but 
that it was also possible to observe platinum from previous chemotherapy cycles in both sample 
types. Significant inter-patient variability as well as some evidence of repair between the 1 and 24 
hour time points was observed.  The purpose of this investigation was to determine whether 
saliva could be used as a less invasive and more patient friendly sampling technique for the 
measurement of Pt-DNA adducts. DNA adducts were quantified, but the correlation found 
between sample types was poor, leading to the conclusion that while saliva showed promise as a 
technique for DNA extraction, it is not at present a viable alternative to blood sampling for the 
quantification of Pt-DNA adducts. 
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3. The binding of Pt-based chemotherapy drugs to cytosol proteins 
3.1. Introduction 
Colorectal cancer is one of the four most commonly diagnosed cancers worldwide and as it has 
long been considered to be moderately resistant to chemotherapy. As a result new drugs and 
combination treatments, as well as other ways to improve the efficacy of the drugs, are 
constantly being investigated.128,129 Oxaliplatin, often in combination with 5-fluorouracil, is still 
widely used in the treatment of colorectal cancers.13,129,130 
Previous studies have discovered that only about 1% of the platinum drugs reach the DNA, and 
furthermore that the cytosol is the largest ‘sink’ for platinum-based drugs, such as that 
demonstrated in Figure 26. 4,5,131 
 
Figure 26 - Percentage of platinum found in the different sub-cellular fractions of various colorectal cancer cell lines 
following treatment with the Pt-based drugs indicated. Used with permission. 5 
 
It is the binding of Pt-drugs, such as oxaliplatin, to proteins found in the cytosol of colorectal 
cancer cells that is the primary focus of this chapter. By investigating the potential binding sites 
on proteins found within the cytosol of cells it was hoped to identify the preferred binding sites of 
oxaliplatin. 
Pt- drugs, such as oxaliplatin and cisplatin, are known to bind in particular to ligands which are 
nitrogen and sulfur rich, and therefore short peptide sequences rich in sulfur and nitrogen were 
chosen for this investigation.4,132–134 Once oxaliplatin has entered the cell, the intracellular 
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environment has to be considered, in particular the sulfur-containing nucleophiles, as oxaliplatin 
has been found to exhibit a higher reactivity towards sulfur-containing compounds than 
cisplatin.132 The analysis of both nitrogen and sulfur rich peptides were of interest as there is 
evidence to suggest that the binding of oxaliplatin to nitrogen is not only possible, but 
energetically competitive to the binding with sulfur.134 
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3.2 Experimental design 
The overall aim of this section of work was to identify which, if any, proteins and peptides in the 
cytosolic fraction have a higher affinity for binding with platinum-based anti-cancer drugs. As a 
step towards achieving this aim, this section of work identified potential target peptides and by 
modelling their interaction with oxaliplatin it was hoped to result in the identification of specific 
targets of oxaliplatin which could be further investigated. 
Previous attempts to carry out a tryptic digest of the cytosol from cells exposed to oxaliplatin and 
to directly identify Pt-peptides using HPLC-ICP-MS had been made within this research group. The 
results were not reproducible and therefore the top-down approach was temporarily abandoned 
in favour of a bottom-up approach starting with simple peptides, such as glutathione134 and 
carnosine135, and then moving on to sequences that were represented in proteins that had been 
identified as having altered abundances in cancer patients. A fellow researcher within the group 
at Loughborough University, Dr Claire Camp, had previously identified a list of cytosolic proteins 
of interest, which was used as a basis for this work.136  Firstly a literature search was conducted 
searching for proteins and peptides up-regulated in cancer patients. Proteins were then chosen 
based on a search using the Uniprot database using the search criteria of human, cytosol and 
colon, resulting in a few proteins being chosen which had also been cited in related journal 
articles. 5,9,15,84,136–152 Short peptide fragments from these proteins were then chosen by 
undergoing a theoretical tryptic digest using ExPASy peptide cutter before residues of an 
appropriate length which were rich in either nitrogen or sulfur were chosen for analysis, these 
being the potential primary binding sites for oxaliplatin. 
The following short peptides were chosen for analysis: 
• Sulfur rich: GCMR, AMMK, MSMK, MMTK, MCAAR, CVK 
• Nitrogen rich: NNIK, ENQK, QHEK, YRPR 
The fragmentation and full mass spectrum of each peptide was analysed, before the binding of 
the peptides with oxaliplatin was measured immediately after mixing and at 24 hours.  
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3.3 Methodology 
The peptides listed above in Section 3.2 were synthesised by and purchased from Generon 
(Maidenhead, UK). Each peptide (3mM) was dissolved in 50:50 MeOH:H2O with 0.1% formic acid, 
before a full mass spectrum was obtained. Following this, oxaliplatin was added to the solution in 
a 2:1 mM ratio (peptide: oxaliplatin) before being analysed again immediately after mixing and at 
24 hours. The oxaliplatin, formic acid, HPLC grade water and methanol were all purchased from 
Sigma Aldrich (Poole, UK). 
The samples were analysed primarily on an LTQ linear ion trap mass spectrometer with an 
electrospray ionisation source, with some also being analysed on an ‘Orbitrap’ high resolution Q-
Exactive fourier transform mass spectrometer (Thermo Electron, San Jose, CA, USA). The Q-
Exactive was equipped with a Tri-Versa NanoMate ESI chip nanospray (Advion, New York, USA). 
The LTQ was operated in the positive mode at 5.20 kV and 260°C, having been calibrated prior to 
use as per the manufacturer’s recommendations. The resolving powers achieved were in the 
order of 1500 while the upper instrumental error limit in measurements was 0.2 m/z units. The 
LTQ auto-tune function was used following this to obtain lens, quadrupole and octapole voltages 
for maximum transmission of the ions of interest. Helium gas was used as a buffer gas within the 
ion trap (at approximately 10-3 Torr) to improve the trapping efficiency as well as the collision gas 
for collision induced dissociated experiments (CID). 
Samples were introduced into the instrument at the rate of 10 µL min-1 into the electrospray 
source which utilised nitrogen as a nebulising gas. Auxiliary and sheath gases were tuned daily to 
enable maximum signal transmission. 
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3.4 Results and Discussion 
The 10 peptides were analysed as detailed in Section 3.3. Full mass spectra were generated in 
positive ion mode for the peptide and oxaliplatin mixtures performed without allowing any 
incubation time. The mixture was stored at room temperature and analysed again after 24 hours 
to ensure that no significant alterations to the predominant peaks occurred. This data, along with 
analysis of the full peptides only can be found in Appendix B. 
 
3.4.1 Nitrogen rich peptides 
Analysis of the four nitrogen rich peptides (NNIK, ENQK, QHEK, YRPR) is presented below. The 
structures of these four peptides are shown in Figure 27. 
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Figure 27 – Structures of the four nitrogen rich peptides 
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The first peptide analysed was NNIK. The full mass spectrum is shown in Figure 28 and the main 
peaks assigned in Table 9. 
 
Figure 28 – Full mass spectrum for peptide 1 (NNIK) and oxaliplatin 
Table 9 – Peak assignments for peptide 1 (NNIK) and oxaliplatin 
Most abundant isotope m/z Assignment 
399.08 [OxPt + H]+ 
488.25 [NNIK + H]+ 
602.25 [(NNIK+N) + H]+ 
794.92 [(OxPt)2 + H]+ 
886.33 [NNIK+ OxPt + H]+ 
*N denotes the amino acid asparagine  
As can be seen from Figure 28 the base peak was peptide 1 (NNIK) on its own (m/z 488.3), with a 
small peak observed for oxaliplatin as the second largest peak. A small peak was observed at m/z 
886.3, which was assigned as the peptide and oxaliplatin complex, indicating that while some 
binding occurred, this binding was not strong as plenty of free oxaliplatin remained. When 
compared to the spectrum of that obtained 24 hours later (Figure 92, Appendix B), while a few 
new peaks were observed, the primary peak of interest (m/z 886) did not appear to be 
significantly larger. This pattern was seen with the other peptides described later in this chapter, 
and can therefore be concluded that the binding between the peptides and oxaliplatin are not 
altered significantly with a 24 hour incubation time. 
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A significantly lower signal intensity was observed in all of the spectra for [OxPt+H]+ relative to 
those of the peptides. Some potential reasons for this are as follows. Firstly, the ratio of peptide: 
oxaliplatin was in favour of the peptide, using a 2:1 ratio, and therefore being at a higher 
concentration to begin with, a larger intensity signal would be expected. Secondly, the ionization 
efficiency of the species may not be equivalent, and furthermore as the signal for oxaliplatin is 
split over a larger isotopic range when compared to that of the peptides, it is feasible to suggest 
this as a potential reason for the smaller observed signals for oxaliplatin and oxaliplatin-peptide 
complexes. Additionally, work by Shoeib et al.134 investigated the interaction between oxaliplatin 
and the protein glutathione and observed a similar trend and theorised another potential reason 
for the lower oxaliplatin signal was due to the two ligands not competing equally for proton 
sources within the solution. With the aid of computer modelling they reported that glutathione 
had a higher proton affinity than oxaliplatin (255.3 and 233.5 kcal mol-1 at 298K respectively).  
Glutathione is a small, tri-peptide protein found abundantly within the cytosol, and is similar in 
size and structure to many of the peptides studied in this chapter, and it is plausible to suggest 
that the peptides used in this study have a higher proton affinity than that of oxaliplatin.153  
Computational analysis for two peptides presented in this chapter were performed by 
collaborators at the American University in Cairo, the results of the modelling are presented in 
Section 3.4.3. 
Another interesting observation noted from the spectrum of peptide 1 (and subsequent spectra 
of the remaining peptides below) is the presence of whole/intact oxaliplatin as opposed to what 
is considered to be the biologically active form (oxaliplatin minus the oxalate group). This could 
potentially be accounted for by the difference in biological conditions which enable the oxalate 
group to leave when compared to the acidic solution used in this experiment (replicating 
biological conditions was beyond the scope and possibility of this study). Additionally, the 
formation of a [peptide + OxPt + H]+ species forming before the dissociation of the oxalate ligand 
has been seen in previous studies where other biological materials were used, namely glutathione 
and carnosine.134,135 And furthermore, there has been some reports in the literature of Pt-drugs 
remaining intact even in biological environments.154,155 
Aside from the peaks of interest (peptide only, oxaliplatin and peptide-oxaliplatin complex), in the 
study of each peptide several other species were observed, usually with significantly lower 
abundances, and which have been assigned in the respective tables. These ions were usually 
protonated dimers and multimers of oxaliplatin, multimers of the peptides and several different 
combinations of the peptide and oxaliplatin species. Some of these minor peaks were poorly 
 
 
71 
 
resolved, but were assigned where possible based on theoretical isotopic patterns and m/z 
observed. 
While the assignment of most peaks by m/z and isotope pattern correlated well, some exceptions 
were found relating to the oxaliplatin  and oxaliplatin-peptide peaks. A typical theoretical [OxPt + 
H]+ pattern is shown in Figure 29, where the three largest (but similar in intensity) peaks are at 
m/z 398, 397 and 399. However in some of the experimental data, while the observed m/z range 
for oxaliplatin [OxPt + H]+ was correct the most abundant peak was not at m/z 398.  The reason 
for this remains unclear, however as the relative abundance of the three main peaks at m/z 397, 
398 and 399 are similar it is possible that a slight problem with the mass calibration occurred. 
However, this effect was seen only intermittently and was most probably due to an instrumental 
issue that has now been resolved. For example, in peptide 2 (ENQK), the immediate 
measurement of the peptide/oxaliplatin solution produced the most abundant peak at m/z 397, 
but the same solution measured 24 hours later observed the oxaliplatin most abundant peak at 
m/z 398. 
 
 
Figure 29 – Theoretical isotope pattern of protonated oxaliplatin in stick and peak profiles 
To investigate the possibility of a calibration issue, where possible, left over samples were run on 
high resolution Q-Exactive fourier transform mass spectrometer. For example, the full mass 
spectrum at high resolution of peptide 1 (NNIK) is shown in Figure 30. As can be seen, the mass of 
A 
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the free oxaliplatin [OxPt + H]+ is now at the correct m/z of 398, and by comparing to the 
theoretical pattern can be identified as oxaliplatin (Figure 31). 
 
Figure 30 - Orbitrap spectrum of peptide 1 (NNIK) and oxaliplatin 
Table 10 – High resolution Orbitrap data peak assignments for peptide 1 (NNIK) and oxaliplatin 
Most abundant isotope m/z Assignment 
398.07 [OxPt + H]+ 
488.28 [NNIK + H]+ 
602.32 [(NNIK+N) + H]+ 
885.33 [NNIK+ OxPt + H]+ 
*N denotes the amino acid asparagine  
As can be seen from Figure 30 and Table 10, the oxaliplatin and oxaliplatin and peptide (m/z 398 
and 885 respectively) are at the correct m/z now when compared to the original LTQ data. 
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Figure 31 - Comparison of experimental data (A – LTQ, B - Orbitrap) and theoretical peak profile (C) for oxaliplatin as 
seen in peptide 1 (NNIK) samples 
2013_1087 #1 RT: 0.00 AV: 1 NL: 1.62E7
T: FTMS {1,1}  + p NSI Full ms [100.00-2000.00]
395 396 397 398 399 400 401 402
m/z
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
R
el
at
iv
e 
A
bu
nd
an
ce
398.07
397.06
399.07
401.07
400.07
395.20 402.07396.15 399.31398.12 399.69397.15
A 
B 
C 
 
 
74 
 
As can be seen in Figure 31, the peak profile obtained for peptide 1 (NNIK) from the initial LTQ 
work (label A) was not a perfect match for the theoretical (label C), as the relative peak heights 
for the 3 most abundant peaks (m/z 397, 398 and 399) were incorrect, potentially due to an 
instrumental error. However when the high resolution data was obtained (panel B) it is a correct 
match with the theoretical isotopic profile, and thus can confidently be assigned as oxaliplatin.  
The high resolution data obtained made it possible to assign peaks with confidence (especially 
with the nitrogen rich peptides where the intermittent instrumental problem was observed) and 
compare isotopic peak profiles more easily. This was done for the remainder of the peptides, 
some examples for peptide 1 (NNIK) are shown below.  
 
Figure 32 - Comparison of experimental (A) and theoretical (B) peak profiles of m/z 488 [NNIK + H]+ 
A 
B 
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Figure 33 - Comparison of experimental (A) and theoretical (B) peak profiles of m/z 885 [NNIK + OxPt + H]+ 
A 
B 
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In the case of peptide 2 (Figure 34 and Table 11), the base peak was the protonated peptide 
[ENQK + H]+ at m/z 518, and the main peptide and oxaliplatin complex was observed at m/z 916. 
Several dimer and multimer complexes were also observed.  
 
Figure 34 - Full mass spectrum for peptide 2 (ENQK) and oxaliplatin 
Table 11 - Peak assignments for peptide 2 (ENQK) and oxaliplatin 
Most abundant isotope m/z Assignment 
296.25 [ENQK + C4H11N + 2H]2+ 
397.08 [OxPt + H]+ 
518.25 [ENQK + H]+ 
591.42 [ENQK + C4H11N + H]+ 
632.33 [ENQK + (ENQK-C4H11N) + H]+ 
916.33 [ENQK + OxPt + H]+ 
1035.42 [(ENQK)2 + H]+ 
1313.08 [ENQK + (OxPt)2 + H]+ 
1432.75 [(ENQK)2 + OxPt + H]+ 
1710.83 [ENQK + (OxPt)3 + H]+ 
1829.67 [(ENQK)2 +(OxPt)2 + H]+ 
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Peptide 3, QHEK, (Figure 35 and Table 12), the base peak was the protonated peptide [QHEK + H]+ 
at m/z 541, and the main peptide and oxaliplatin complex was observed at m/z 938 as expected. 
Several dimer and multimer complexes were also observed.  
 
Figure 35- Full mass spectrum for peptide 3 (QHEK) and oxaliplatin 
Table 12 - Peak assignments for peptide 3 (QHEK) and oxaliplatin 
Most abundant isotope m/z Assignment 
262.67 [QHEK – NH3 + 2H]2+ 
271.17 [QHEK + 2H]2+ 
398.08 [OxPt + H]+ 
413.25 [(HEK) + H]+ 
524.42 [QHEK – NH3 + H]+ 
541.33 [QHEK + H]+ 
794.83 [(OxPt)2 + H]+ 
938.25 [QHEK + OxPt + H]+ 
1085.42 [(QHEK)2 + H]+ 
1193.08 [(OxPt)3 + H]+ 
1335.08 [QHEK + (OxPt)2 + H]+ 
1478.92 [(QHEK)2 + OxPt + H]+ 
1731.17 [QHEK + (OxPt)3 + H]+ 
1879.67 [(QHEK)2 +(OxPt)2 + H]+ 
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Peptide 4, YRPR, (Figure 36 and Table 13), the base peak was the protonated peptide [YRPR + H]+ 
at m/z 591, and the main peptide and oxaliplatin complex was observed at m/z 989. Several 
dimer and multimer complexes were also observed.  
 
Figure 36 - Full mass spectrum for peptide 4 (YRPR) and oxaliplatin 
Table 13 - Peak assignment for peptide 4 (YRPR) and oxaliplatin 
Most abundant isotope m/z Assignment 
296.17 [YRPR + 2H]2+ 
398.00 [OxPt + H]+ 
574.33 [(YRPR-OH) + H]+ 
591.42 [YRPR + H]+ 
794.00 [(OxPt)2 + H]+ 
989.25 [YRPR + OxPt + H]+ 
1386.17 [YRPR + (OxPt)2 + H]+ 
1579.75 [(YRPR)2 + OxPt + H]+ 
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3.4.2 Sulfur rich peptides 
Analysis of the six sulfur rich peptides (GCMR, AMMK, MSMK, MMTK, MCAAR, CVK) is presented 
below. The structures of these six peptides are shown in Figure 37. 
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Figure 37 – Structures of the six sulfur rich peptides  
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The data collected for the first of the sulfur rich peptides (Peptide 5), GCMR, is presented below 
(Figure 38 and Table 14). 
 
Figure 38 - Full mass spectrum of peptide 5 (GCMR) and oxaliplatin 
Table 14 - Peak assignments for peptide 5 (GCMR) and oxaliplatin 
Most abundant isotope  m/z Assignment 
175.08 [R + H]+ 
233.58 [GCMR + 2H]2+ 
398.08 [OxPt + H]+ 
409.25 [(GCMR-G) + H]+ 
466.25 [GCMR + H]+ 
482.17 [GCMR + NH2 + H]+ 
794.92 [(OxPt)2 + H]+ 
863.08 [GCMR + OxPt + H]+ 
931.00 [(GCMR)2 + H]+ 
1259.58 [GCMR +(OxPt)2 + H]+ 
1330.08 [(GCMR)2 + OxPt + H]+ 
1726.25 [(GCMR)2 + (OxPt)2 + H]+ 
 
Again the oxaliplatin did not bind strongly to the peptide, with unbound oxaliplatin being 
observed in the solution, and the peptide-oxaliplatin complex (m/z 863) being less than 5% of the 
relative intensity of the base peak. Furthermore, dimer and multimer complexes were also 
observed at low intensity. 
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Peptide 6, AMMK, showed evidence of unbound oxaliplatin and a small peak of the peptide-
oxaliplatin complex (m/z 877). A large amount of the peptide dimer (m/z 240) was observed as 
well the protonated peptide (m/z 480). 
 
Figure 39 - Full mass spectrum for peptide 6 (AMMK) and oxaliplatin 
Table 15 - Peak assignments for peptide 6 (AMMK) and oxaliplatin 
Most abundant isotope m/z Assignment 
240.58 [AMMK + 2H]2+ 
398.08 [OxPt + H]+ 
480.33 [AMMK + H]+ 
637.33 [AMMK + (OxPt)2 + 2H]2+ 
795.83 [(OxPt)2 + H]+ 
877.17 [AMMK + OxPt + H]+ 
958.75 [(AMMK)2 + H]+ 
1035.08 [AMMK + (OxPt)2 + 2H]2+ 
1274.92 [AMMK + (OxPt)2 +H]+ 
1356.83 [(AMMK)2 + OxPt + H]+ 
1672.92 [AMMK + (OxPt)3 + H]+ 
1754.00 [(AMMK)2 + (OxPt)2 + H]+ 
 
When compared to the spectrum obtained 24 hours later (Appendix B), it is clear that no 
significant increase in the peptide-oxaliplatin complex was present at m/z 877. 
 
 
Pep2_OxPt_FullMS1_130918110823 #1 RT: 0.00 AV: 1 NL: 1.00E7
T: ITMS + p ESI Full ms [50.00-2000.00]
200 400 600 800 1000 1200 1400 1600 1800 2000
m/z
0
10
20
30
40
50
60
70
80
90
100
R
el
at
iv
e 
A
bu
nd
an
ce
480.33
240.67
398.08 877.17637.33 1274.92175.08 1513.33958.83 1074.83 1754.00 1986.92795.83
 
 
82 
 
Peptide 7, MSMK, yielded a base peak of the peptide at m/z 496, and a small peptide-oxaliplatin 
peak at m/z 893, with several dimer and multimer complexes also being observed (Figure 40 and 
Table 16).  
 
Figure 40 - Full mass spectrum of peptide 7 (MSMK) and oxaliplatin 
Table 16 - Peak assignments for peptide 7 (MSMK) and oxaliplatin 
Most abundant isotope  m/z Assignment 
248.67 [MSMK + 2H]2+ 
365.25 [(SMK) + H]+ 
398.17 [OxPt + H]+ 
496.33 [MSMK + H]+ 
794.83 [(OxPt)2 + H]+ 
893.17 [MSMK + OxPt + H]+ 
990.58 [(MSMK)2 + H]+ 
1289.00 [MSMK + (OxPt) 2 + H]+ 
1387.22 [(MSMK)2 + OxPt + H]+ 
1785.08 [(MSMK)2 + (OxPt)2 + H]+ 
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Peptide 8, MMTK, as shown in Figure 41 and Table 17, yielded a base peak of the peptide at m/z 
510 as well as a large dimer peak (m/z 255), and a small peptide-oxaliplatin peak at m/z 907. 
Again the presence of unbound oxaliplatin was observed (m/z 398). 
 
Figure 41- Full mass spectrum of peptide 8 (MMTK) and oxaliplatin 
Table 17 - Peak assignment for peptide 8 (MMTK) and oxaliplatin 
Most abundant isotope  m/z Assignment 
255.75 [MMTK + 2H]2+ 
379.33 [(MTK) + H]+ 
398.33 [OxPt + H]+ 
454.17 [MMTK + OxPt + 2H]2+ 
510.33 [MMTK + H]+ 
907.17 [MMTK + OxPt + H ]+ 
1018.83 [(MMTK)2 + H]+ 
1305.08 [MMTK +(OxPt)2 + H]+ 
1416.50 [(MMTK)2 +OxPt + H]+ 
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Peptide 9, MCAAR, yielded a base peak of the peptide at m/z 551 as well as a large dimer peak 
(m/z 276), and a small peptide-oxaliplatin peak at m/z 948. Again the presence of unbound 
oxaliplatin was observed (m/z 398) as well as several peptide and oxaliplatin dimer complexes 
(Figure 42 and Table 18). 
 
Figure 42 - Full mass spectrum of peptide 9 (MCAAR) and oxaliplatin 
 
Table 18 - Peak assignment for peptide 9 (MCAAR) and oxaliplatin 
Most abundant isotope  m/z Assignment 
276.17 [MCAAR + 2H]2+ 
398.17 [OxPt +H]+ 
420.33 [CAAR + H]+ 
551.33 [MCAAR + H]+ 
673.00 [MCAAR + (OxPt)2 + 2H]2+ 
948.17 [MCAAR + OxPt + H]+ 
1101.17 [(MCAAR)2 + H]+ 
1346.08 [MCAAR + (OxPt)2 + H]+ 
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Peptide 10, CVK, yielded a base peak of the peptide at m/z 349 as well as a large dimer peak (m/z 
175). A peptide-oxaliplatin peak was observed at m/z 746 as well as several peptide and 
oxaliplatin dimer complexes (Figure 43 and Table 19). 
 
Figure 43 - Full mass spectrum of peptide 10 (CVK) and oxaliplatin 
 
Table 19 - Peak assignment for peptide 10 (CVK) and oxaliplatin 
Most abundant isotope m/z Assignment 
175.17 [CVK + 2H]2+ 
349.42 [CVK + H]+ 
398.25 [OxPt + H]+ 
572.00 [CVK + (OxPt)2 + 2H]2+ 
697.17 [(CVK)2 + H]+ 
746.25 [CVK + OxPt + H]+ 
795.08 [(OxPt)2 + H]+ 
1094.83 [(CVK)2 + OxPt + H]+ 
1143.17 [CVK + (OxPt)2 + H]+ 
1541.25 [CVK + (OxPt)3 + H]+ 
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3.4.3 Computational modelling of peptide-oxaliplatin interactions 
Based on the results presented in the previous two sections, it was felt that further investigation 
of the binding to both sulfur and nitrogen rich peptides was required. Two peptides were chosen 
for computational modelling to further investigate the interactions between the peptides and 
oxaliplatin, one from the nitrogen rich category and one from the sulfur rich category; peptide 3 
(QHEK) and peptide 5 (GCMR) respectively. 
This computer modelling work was done by Dr Tamer Shoeib at the American University in Cairo 
based on the previously obtained experimental data.  
All molecular orbital calculations were performed using GAUSSIAN09W. Structures were 
optimized without symmetry constraints by means of Hartree-Fock (HF) level of theory. The most 
energetically favoured conformations were further optimized by means of density functional 
theory (DFT) employing the hybrid Becke’s three-parameter exchange functional and the 
correlation functional from Lee, Yang and Parr (B3LYP).156–158 Optimizations at all levels of theory 
made use of the pseudo potential LANL2DZ basis set. The computational tractability of this 
theoretical method makes it suitable for calculations of systems containing relatively large 
number of heavy atoms such as those in this study.  Much more important however are the 
results of DFT calculations in systems involving transition metals, which are in many cases in 
better agreement with experimental data than those obtained from Hartree–Fock (HF) 
calculations. 
The modelled interactions of these peptides are presented below.  
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3.4.3.1 Nitrogen rich peptide – QHEK  
The structure of peptide 3 (QHEK) is shown in Figure 44 without the presence of oxaliplatin.  
 
Figure 44 - Structure of peptide 3 (QHEK) 
This structure was then modelled with oxaliplatin and the following favoured structures for 
binding were determined (see Figure 45 and Figure 46). The relative free energy for these four 
modelled structures were also calculated to determine which was the most favourable. This data 
is shown in Table 20. 
Table 20 - Relative free energy values for peptide 3 (GHEK) and oxaliplatin structures 
Structure Relative free energy (Kcal/mol) 
QHEKOxPtB 0 
QHEKOxPtA 5.6 
QHEKOxPtC 5.6 
QHEKOxPtD 12.4 
  
Lysine (K) 
Glutamic acid (E) 
Histidine (H) 
Glutamine (Q) 
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Figure 45 - Peptide 3 (QHEK) and oxaliplatin binding possibilities A-B 
A 
B 
Oxaliplatin 
Histidine (H) 
Oxaliplatin 
Lysine (K) 
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Figure 46 - Peptide 3 (QHEK) and oxaliplatin binding possibilities C-D 
C 
D 
Oxaliplatin 
Oxaliplatin 
Glutamine (Q) 
Histidine (H) 
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Oxaliplatin binds to peptide 3 on a N in the aromatic ring of histidine in structures A and D, while 
in structure B, the oxaliplatin binds to the terminal nitrogen of the lysine (K) amino acid, and in 
structure C binds to a N at the end of the chain in the glutamine. Table 20 shows that structure B 
is the most favourable structure with the lowest energy, followed by structures A and C which are 
equal in energy, and structure D being the highest in energy. However, the energy differences 
between the lowest three energy structures are small (5.6 Kcal/mol) (approximately the strength 
of a hydrogen bond) and therefore all four structures are possible and could have been found 
within the experimental data presented in Section 3.4.1. 
As no sulfur was present within the peptide no conclusions can be drawn about competitive 
binding of oxaliplatin to N or S binding sites, however it is clear that within the structure of this 
peptide certain nitrogen’s were favoured more than others.  
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3.4.3.2 Sulfur rich peptide – GCMR 
Peptide 5 (GCMR) was chosen for modelling as it contains both N and S binding sites, and thus 
any preferential binding of oxaliplatin to N or S could be investigated. The structure of peptide 5 
(GCMR) is shown in Figure 47  without the presence of oxaliplatin.  
 
Figure 47 - Peptide 5 (GCMR) and oxaliplatin binding possibilities A-D 
This structure was then modelled with oxaliplatin and the following favoured structures for 
binding were determined (see Figure 48, Figure 49 and Figure 50). The relative free energy for 
these five modelled structures were also calculated to determine which was the most favourable. 
This data is show in Table 21.  
Glycine (G) 
Cysteine (C) 
Methionine (M) 
Arginine (R) 
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Figure 48 - Peptide 5 (GCMR) and oxaliplatin binding possibilities A and B 
A 
B 
Oxaliplatin 
Glycine (G) 
Oxaliplatin 
Cysteine (C) 
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Figure 49 - Peptide 5 (GCMR) and oxaliplatin binding possibilities C and D  
C 
D 
Oxaliplatin 
Oxaliplatin 
Methionine (M) 
Arginine (R) 
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Figure 50 - Peptide 5 (GMCR) and oxaliplatin binding possibility E 
 
Table 21 - Relative free energy values for peptide 5 (GCMR) and oxaliplatin structures 
Structure Relative free energy (Kcal/mol) 
GCMROxPTE 0.0 
GCMROxPtA 12.0 
GCMROxPtD 17.7 
GCMROxPtB 19.5 
GCMROxPtC 35.3 
 
The modelling work for peptide 5 (GMCR) showed that binding of oxaliplatin to both N and S 
binding sites is possible. Oxaliplatin binds to peptide 5 (GCMR) at the terminal N of glycine (G) in 
structure A, the S of cysteine (C) in structure B, the S of methionine (M) in structure C and the 
terminal nitrogen’s of arginine (R) in structures D and E. Table 21 shows that structure E is the 
most favourable structure with the lowest energy, followed by structure A then structure D then 
structure B, with only a minor energy difference between D and B. Structure C is significantly 
higher in energy and therefore less favourable. When comparing the structures and the relative 
E 
Oxaliplatin 
Arginine (R) 
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free energy, it is clear that the three lowest energy structures (E, A and D) have oxaliplatin binding 
to a terminal nitrogen, while the two highest energy structures are where the oxaliplatin is bound 
to a S. However, the difference in energy between structures D and B (N and S binding sites 
respectively) is very small and both are certainly possible to have been found within the 
experimental data presented in Section 3.4.2. 
 
3.4.3.3 Modelling summary 
Platinum is a soft acid, and therefore is theoretically more likely to bind to a soft base (such as 
sulfur) compared to a hard base (such as nitrogen). However the experimental data produced in 
this chapter investigated this and found little/no significant differences in the level of binding 
observed between the two sites.  
Computer modelling further backed up the experimental data showing that binding to nitrogen 
binding sites is not only possible, but in some cases could be more favourable and lower in energy 
than binding to sulfur sites on the peptides.  
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3.5 Conclusions 
Binding to both nitrogen and sulfur rich peptides was observed as has been previously 
reported.134 However, no significant differences in level of binding was observed between the 
ranges of peptides studied in this investigation which was unexpected as binding to sulfur would 
be expected to be preferred over nitrogen (HSAB theory). Computational modelling on two 
peptides has shown that not only does oxaliplatin bind to both nitrogen and sulfur binding sites, 
but that in some cases binding to nitrogen could in fact be slightly more favourable than binding 
to sulfur. However in most cases the energy differences between the different binding 
possibilities were relatively small and therefore binding to both N and S sites is likely, and thus 
confirms the results seen in the experimental portion of this chapter. 
As discussed in the sections above, binding between the peptides and oxaliplatin was observed. 
When no incubation was allowed, oxaliplatin was seen in its unbound form as well as in various 
peptide-oxaliplatin complexes. In all cases unbound oxaliplatin was also seen at the 24 hour time 
point, however in some cases the relative intensity was slightly smaller, suggesting that no major 
time constraint played a role in this investigation.  
Reasons as to the lower signal intensity observed for oxaliplatin were discussed and were 
supported by available current literature. Not only was the ratio of peptide:oxaliplatin in favour of 
the peptide with a 2:1 ratio, and with oxaliplatin having a larger isotopic range than the peptides, 
this again would reduce the relative intensity of the peaks observed. Additionally, previous 
computational studies have highlighted the fact that there is a discrepancy between the proton 
affinities of short tri-peptides and that of oxaliplatin, where oxaliplatin had a lower proton affinity 
than that of the peptides.  
Although this study was not able to reproduce biological conditions due to the complexity of 
biological matrices, and as a result the binding of oxaliplatin was observed as a whole molecule 
(as opposed to binding after the loss of the oxalate group), it was shown that oxaliplatin can and 
did bind to both S and N binding sites. Oxaliplatin bound primarily in the form of a peptide-
oxaliplatin complex, however, several other species at lower abundances were observed as well, 
suggesting that the binding of oxaliplatin was spread out over these peptide dimers and 
multimers. However it worth noting that the ratio of oxaliplatin to peptide utilised in these 
experiments were significantly higher than would be found in biological conditions, and as such 
oxaliplatin is not likely to bind as dimers or multimers within the body.  
Overall, the work detailed in this chapter has shown that there is a large excess of potential 
binding sites for platinum. Binding to both sulfur and nitrogen binding sites are common and 
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consequently no species or functionality was found to dominate. Had one binding site been 
preferential, possibilities would have arisen to allow for therapeutic intervention via the 
modification of that species to ultimately improve the targeting of the Pt-based drug to the DNA. 
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4. Determination of the effect of selenium on the cellular 
distribution and uptake of oxaliplatin in cell cultures 
4.1 Introduction 
Every year millions of people worldwide are diagnosed with cancer, with the four most common 
types being breast, prostate, colorectal and lung cancers.128,159 As previously discussed in Chapter 
1 treatment options are primarily limited to surgery, radiotherapy and chemotherapy, however 
many patients undergoing treatment will take supplements during this time, many of which are 
not prescribed by their doctors. In fact, one study of over 14 different European countries 
revealed that 35.9% of the 956 cancer patients questioned in the study were taking/receiving 
some form of complementary or alternative medicine, including vitamins and minerals (including 
selenium), herbal medicines, homeopathy and medicinal teas.46 Furthermore, this study found 
that the number of patients taking supplements varied significantly between different countries, 
ranging from 14.8% to 73.1%, with England and Scotland averaging around 29%.46  
While a range of supplements are taken by patients, selenium in particular was chosen for study 
in this investigation as there is some evidence to suggest that it has some cancer-preventative 
properties (as detailed in Chapter 1), and furthermore there is potential for it to bind to 
glutathione, an abundant cytosolic protein where it is thought that Pt binds, which could 
potentially free up more Pt-drug to bind to the DNA within the nucleus, the ultimate physiological 
target. It is well characterised that glutathione bonds platinum-based chemotherapy drugs as well 
as selenium. It has been hypothesised that if selenium is used as a supplement in chemotherapy 
that the selenium-glutathione bonding may result in a reduction in platinum-glutathione binding, 
freeing the platinum to bind at other sites. 
While the most effective form of selenium for cancer prevention is still under investigation, a 
metabolism pathway (Figure 51) was constructed to aid in the understanding of how selenium 
compounds break down within the body and hopefully provide an insight into which form of Se 
provided the best protection against cancer. Research studies identified methylselenol as an 
important metabolite, however due to problems relating to its high reactivity, methaneseleninic 
acid (MSA, CH3SeO2H) could be used to generate methylselenol endogenously, and therefore this 
was selected for use in this investigation.29,42,43,160–163 
Due to the large numbers of patients taking such supplements and the limited knowledge of 
if/how they affect or interact with the anti-cancer drugs, the work detailed in the rest of this 
chapter was dedicated to furthering the understanding on how selenium affects the efficacy of 
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the platinum based anti-cancer drug oxaliplatin. Some initial work was performed as part of a 
Master’s degree research project before continuing and extending the project as part of this 
PhD.164 The main results from this investigation are summarised at the start of the results section 
to provide background for the rest of the work performed. Furthermore, a Masters student, Carl 
Cooper, also contributed some data towards this work, done in collaboration with the author of 
this thesis.165 The contributions from these projects are detailed in the relevant sections below. 
 
*Note: MSA provides a direct route to methyl selenol, an active anti-carcinogenic form of Se. 
Figure 51 – Metabolism pathway of selenium. Used with permission. 29 
 
Therefore, the main aim of the work presented in this chapter was to further the understanding 
of how Se effects and interacts with Pt-based anti-cancer drugs. Throughout this chapter a 
colorectal cancer cell line (HT-29) was chosen for use, and as oxaliplatin is still commonly used in 
the treatment of colorectal cancer, it was therefore chosen as the Pt-based drug of choice for this 
work.166,167 
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The work detailed in the following sections aimed to investigate various aspects of the effect that 
Se had on the Pt-based drugs, ranging from the effect of Se on the subcellular distribution of 
platinum, the number of Pt-DNA adducts formed as well as the effect on the total cellular uptake 
of platinum, to the competitive binding of selenium and oxaliplatin. 
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4.2 Effect of MSA on oxaliplatin in cell cultures 
4.2.1 Introduction 
This section of this chapter can be divided into four main sections. By exposing the human 
colorectal cancer cell line (HT-29) to MSA and/or oxaliplatin, several different experiments could 
be performed. Firstly, by using cells exposed to MSA or oxaliplatin and MSA and oxaliplatin 
together and extracting the DNA, the number of Pt-DNA adducts could be measured to 
investigate if Se had an effect, either positive or negative.  
Secondly, as previously mentioned, only around 1% of the platinum drugs that penetrate the cell 
will form adducts with DNA, but little is known about the other major platinum binding sites 
within the cell.2–4,111 And furthermore, previous work within this research group has shown that 
around 70% of platinum exposed to cultured cells can be found within the cytosolic fraction, 
while around 17% and 4% were observed in the membrane and cytoskeletal fractions respectively 
and finally around 9% was measured in the nuclear fraction.5,111 Therefore, by applying this sub-
cellular fractionation experiment on cells that were exposed to MSA as well as oxaliplatin, the 
effect of Se on the sub-cellular distribution of oxaliplatin could be determined. 
Thirdly, a piece of work is presented where were whole cells exposed to different combinations 
and doses of MSA and oxaliplatin to determine if selenium has an impact on the amount of Pt 
taken up by the cell as a whole. And finally, an attempt at single cell analysis was made using the 
whole cells exposed to Se and oxaliplatin as described above to determine the distribution within 
a population of cells. 
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4.2.2 Methodology 
4.2.2.1 Cell culture 
The human colorectal cancer cell line (HT-29) used in these experiments were obtained from 
colleagues at the University of Leicester, but were originally purchased from the American Type 
Culture Collection (USA).  
The cells were taken out of long term storage (ampoules stored under liquid nitrogen) and were 
rapidly thawed in a water bath at 37°C for 1-2 minutes before being transferred to a cell culture 
flask (150 cm2) which already contained cell culture growth media (RPMI 1640 media purchased 
from Sigma Aldrich, Poole, UK) pre-warmed to 37°C. The flask was subsequently placed in a 37˚C 
incubator with 5% CO2 atmosphere. Cells stored under liquid nitrogen have to be stored in media 
containing DMSO to prevent damage to the cells however once thawed it is damaging to the cells 
and therefore while diluting the DMSO with cell culture media helps to eliminate the DMSO, the 
media needs to be replaced after 24 hours with fresh media (containing 10% FCS). 
The HT-29 cell line grows adherently and therefore once the cell line had fully recovered from 
being resurrected from storage (typically 1-2 weeks), the HT-29 cell lines were sub-cultured until 
sufficient cells were obtained for the experiments detailed above at which point the cells could be 
exposed to/treated with the oxaliplatin and/or MSA before being harvested. 
Drug treatment of cells was performed as follows. Firstly, flasks were examined under a 
microscope to ensure around 70% confluent, following which the old media was removed from 
each flask and replaced with either 30 mL fresh media or 30 mL fresh media doped with the 
desired concentration of MSA and/or oxaliplatin (both purchased from Sigma Aldrich, Poole, UK). 
For some experiments the MSA and oxaliplatin were added simultaneously, while in later 
experiments cells were exposed to/grown in MSA for 24 hours before removing all MSA 
containing media and replacing it with fresh media containing only oxaliplatin. Unless otherwise 
stated, cells were exposed to the drugs for 1 hour in the incubator before fresh media was placed 
into the flasks and cells were allowed to recover for either 1 hour or 24 hours. These recovery 
time points were chosen based on work reported in previous studies and the hours when access 
to the cell culture laboratory was acceptable.5,103,111 
At the end of the appropriate recovery time point the cells were harvested, cell counted and 
aliquoted for each experiment to be carried out; typically 5 million cells per each cell partitioning 
experiment and 10 million for DNA extraction. 
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Cell harvesting was performed as follows. Firstly, cell growth media was removed from the flask 
and the remaining monolayer of cells was washed with PBS (20 mL for 150 cm2 flasks) to ensure 
all remaining media was removed from the cells. Following the PBS wash, around 5 mL of 
Trypsin/EDTA (Sigma Aldrich, Poole, UK) was added to aid in the removal of the cells from the 
flask. With the added trypsin, the flasks were returned to the incubator for about 5 minutes to 
allow the trypsin to detach the cells from the flask. Flasks were examined under a microscope to 
ensure that the majority of cells had been detached, following which 15 mL of media was added 
to each flask to dilute and deactivate the trypsin. The cell suspensions were transferred into 
labelled universal flasks and centrifuged for 5 minutes at 1500 rpm to form a cell pellet. The 
supernatant was then removed and the cells re-suspended in 5 mL media so that a cell count 
using a haemocytometer could be performed. Briefly, 10 µL of the cell suspension was added to 
an equal volume of trypan blue (Sigma Aldrich, Poole, UK) before pipetting the mixture under 
cover slip of haemocytometer and cells in each quadrant were counted and this related back to 
the number of cells in the original suspension by use of the following equation: 
 
𝐷𝑛𝑚𝑁𝑝𝑝 𝑜𝑜 𝑛𝑝𝑙𝑙𝑎 𝑝𝑝𝑝 𝑚𝑙 = 𝐷𝑜𝑙𝑛𝑃𝑜𝑜𝑛 𝑜𝑎𝑛𝑃𝑜𝑝 𝑥 𝑃𝑜𝑃𝑎𝑙 𝑛𝑝𝑙𝑙𝑎 𝑜𝑛 𝑎𝑙𝑙 𝑎𝑠𝑛𝑎𝑝𝑝𝑎
𝐷𝑛𝑚𝑁𝑝𝑝 𝑜𝑜 𝑎𝑠𝑛𝑎𝑝𝑝𝑎  𝑥 10000 
   
The cell suspension was spun down again (5 minutes, 1500 rpm) and could be re-suspended to an 
appropriate volume of PBS to allow easy aliquoting for subsequent experiments. 
 
4.2.2.2 DNA extraction 
The DNA extraction was performed manually unlike the automated extraction described in 
Section 2.3. The overall principal is similar, where a Genomic-tip/column utilises anion-exchange 
technology to extract purified high-molecular weight DNA from biological samples.168 Lysis buffers 
are used to denature proteins (e.g. nucleases, histones and DNA-binding proteins). DNA binds to 
the resin within the column due to specific pH and low-salt conditions provided by the buffers 
while allowing other cell constituents to pass through the column for removal. When a high salt 
buffer is added to the column, DNA is eluted off the column for use in further experiments or 
analysis. 
DNA extraction was performed using the Qiagen Blood and Cell Culture DNA Midi Kit (Qiagen, 
Crawley, UK) following the manufacturers guidelines which are outlined below:168 
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1. 2 mL ice cold Buffer C1 and 6 mL ice cold distilled water was added to each 10-20 million 
cell aliquot of harvested cells after drug exposure and recovery times and mixed 
thoroughly by inverting the tube several times. Buffer C1 causes cell lysis while stabilising 
and preserving the nuclei.  
2. This mixture was incubated on ice for 10 minutes before being centrifuged at 4°C for 15 
minutes at 3000 rpm after which the supernatant was discarded. 
3. 1 mL of Buffer C1 and 3 mL distilled water (both ice cold) was added to each sample, 
which was then mixed thoroughly on a vortex which also aided in re-suspending the 
pelleted sample. This wash step aims to remove all residual cell debris from the nuclear 
pellet. 
4. Samples were then centrifuged for 15 minutes at 4°C at 3000 rpm following which the 
supernatant was discarded. 
5. Buffer G2 (5 mL) was added to each sample while ensuring that the nuclei were 
completely re-suspended with the aid of a vortex. This buffer lyses the nuclei and 
denatures proteins. 
6. Protease enzyme solution (95 µL) was added to each sample and was then incubated at 
50°C for 60 minutes. The Proteinase K in combination with buffer G2 removes all bound 
proteins from the DNA. 
7. One column (Qiagen genomic tip 100/G) was equilibrated for each sample by allowing 4 
mL of Buffer QBT to filter by gravity through each column. Once equilibrated a sample 
mixture was loaded onto the column (after being vortexed briefly to ensure thorough 
mixing) and was then allowed to pass through the column with the run off being collected 
into a waste container. 
8. Buffer QC was used to wash the sample to remove all remaining contaminants (3 x 5 mL) 
and allowed to pass through the column via gravity.  
9. To elute the DNA off of the column, 5 mL Buffer QF (pre-warmed to 50°C) was added to 
the column and the resulting solution collected into a clean tube. The DNA was 
precipitated with the addition of 3.5 mL of isopropanol (room temperature), and aided by 
the gentle inversion of the tube. The DNA was then spooled using a pipette tip and 
moved to a clean, labelled Eppendorf tube containing 200 µL of distilled water. To ensure 
the DNA was fully dissolved, the samples were heated at 55°C for 2 hours.  
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4.2.2.3 Cell partitioning 
Cell partitioning on cultured cells was performed using a ProteoExtract® Subcellular Proteome 
Extraction Kit (Merck, Watford, UK).  This kit contained buffers which when added in sequence to 
cells resulted in four subcellular compartments being solubilised and extracted which could then 
be individually analysed. The four subcellular fractions, in order of extraction, are the cytosolic 
fraction (containing primarily cytosolic proteins), the membrane and organelles, the nuclear 
faction and finally cytoskeletal matrix.169 
After harvesting the confluent cells after drug exposure as detailed in the Section 4.2.2.1, an 
aliquot containing 5 million cells was spun down to form a pellet and the supernatant discarded. 
From this point, the manufacturers’ protocol for the extraction was followed and is detailed 
below.169  
1. Buffer 1 (1 mL x n, where n is the number of samples) was mixed with Protease Inhibitor 
Cocktail (5 µL x n). 1 mL of this resulting mixture was added to each cell pellet. Thorough 
mixing was required to ensure full re-suspension of the cells.  
2. This resulting mixture of Buffer 1 and cells was incubated on ice for 10 minutes with 
shaking using a rotary shaker to prevent formation of cell clumps. 
3. Samples were centrifuged at 1000 g for 10 minutes at 4°C, after which 1 mL of 
supernatant was removed to a clean pre-labelled Eppendorf tube (Fraction 1 – cytosol) 
and stored on ice. 
4. Buffer 2 (1 mL x n) was mixed with Protease Inhibitor Cocktail (5 µL x n), following which 1 
mL was added to each cell pellet (left over from previous step). Sample was re-suspended 
and then incubated on ice for 30 minutes with gentle shaking. 
5. Samples were centrifuged at 6000 g at 4°C for 10 minutes following which the resulting 1 
mL of supernatant (Fraction 2 – cell membrane) was transferred to a clean pre-labelled 
tube and stored on ice. 
6. Buffer 3 (0.5 mL x n) was mixed with Protease Inhibitor Cocktail (5 µL x n) and Benzonase 
Nuclease (1.5 µL x n), following which 0.5 mL was added to each cell pellet (left over from 
previous step). Sample was re-suspended and then incubated on ice for 30 minutes with 
gentle shaking. 
7. Samples were centrifuged at 7000 g at 4°C for 10 minutes following which the resulting 
0.5 mL of supernatant (Fraction 3 – nuclear fraction) was transferred to a clean pre-
labelled tube and stored on ice. 
 
 
106 
 
8. Buffer 4 (0.5 mL x n) was mixed with Protease Inhibitor Cocktail (5 µL x n), of which 0.5 mL 
was immediately added to each cell pellet (left over from previous step). Sample was re-
suspended thoroughly and labelled as Fraction 4 (cytoskeletal). 
9. All four fractions for each sample were then stored at -20°C until needed. 
The protease inhibitor cocktail provided with the kit prevented any protein degradation during 
the extraction of each of the four subcellular fractions while the benzonase nuclease enzyme 
removed nucleic acids.  
4.2.2.4 Digestion 
The acid digestion, based on the method of Yamada et al.120 which was modified by Kerr110 as 
described in Section 2.3 was used for this work. 
4.2.2.5 Spinning cells onto slides 
To perform laser ablation ICP-MS (LA-ICP-MS) on cultured cells approximately 50,000 cells in 0.5 
mL media were spun down onto Polysine slides (Thermo Fischer Scientific, Loughborough, UK). To 
do this the cell aliquots were taken after cells had been harvested and counted. The cells were 
left in suspension and stored on ice before being spun down within a few hours onto slides. To do 
this a special cyto bucket rotor fitted with a chamber and filter card (DJB Labcare, Newport 
Pagnell, UK) was used in a Hettich Universal 320R centrifuge (Sigma Aldrich, Poole, UK). The cell 
aliquots were thoroughly mixed and placed into the slanted chamber with a pre-labelled slide and 
spun at 500 x g for 5 minutes to allow the cells to be spread over the surface of the slide while 
removing the media onto the filter card. Once spun onto the slides, the cells were stable and 
could be analysed by LA-ICP-MS at a later stage. 
4.2.2.6 Instrumentation 
The instrumentation set up used in the work presented in this chapter is very similar to that as 
described in Section 2.3, however slightly different methods and sets ups were used as detailed 
below. 
For the solution based work, the SF-ICP-MS was set up for a slightly higher flow rate than used in 
Section 2.3. A PFA nebuliser (Elemental Scientific, Omaha, USA) and a Cyclonic spray chamber 
(Glass Expansion, Victoria, Australia) were used, along with a 100 µL min-1 auto-sampler probe 
(Elemental Scientific, Omaha, USA) and nickel sampler and skimmer cones (ICPMS cones Ltd., 
Chester, UK). 
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Samples evaporated to dryness using the above digestion methods (Section 4.2.2.4), were 
reconstituted in 400 µL of 2% nitric acid with 1 ppb europium added as an internal standard for Pt 
and P. 
An ICP-MS method was utilised which measured 4 elements of interest; either 78Se (LR) or 82Se 
(LR), 153Eu (LR), 195Pt (LR) and 31P (MR) was used. While 80Se is the most abundant isotope (49.7%), 
this isotope could not be used due to spectral interferences with the 40Ar2 peak.170,171  Previous 
work investigated different isotopes of selenium; in particular 77Se and 78Se and their relative 
responses and given that 78Se has the higher natural abundance (23.6% as opposed to 7.6%) and 
it yielded a better response, this isotope was initially chosen and was used for the first few 
experiments detailed below, before a move to 82Se was made (abundance 9.2%) for all further 
work due to a lower background being observed.164,165  
As stated in Section 2.3, nebuliser gas flows and torch position were tuned daily, and typical 
conditions were shown in Table 2. 
For the laser ablation (LA-ICP-MS) work a commercially available laser ablation system, UP-213 
(Electro Scientific Industries, Cambridgeshire, UK), was connected to the SF-ICP-MS (Thermo 
Scientific, Element 2 XR, Bremen, Germany). The laser system was fitted with a low volume, tear-
drop shaped cell as described by Horstwood et al.172 High purity helium was used as the ablation 
gas with a flow rate around 0.55 L/min. Argon sample gas (at a flow rate of 0.9 L/min) was 
introduced and mixed with the helium using a Y-piece between the ablation cell and the ICP-MS. 
NIST 611 glass was used to tune the system for maximum 238U signal intensity while maintaining 
the Th/U ratio around 1. Typical operating conditions for LA-ICP-MS analysis are shown in Table 
22. 
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Table 22 – Typical operating conditions for analysis via LA-ICP-MS 
Parameter Setting 
Radio frequency (RF) power 1260 W 
Cool gas flow rate 15.50 L min-1 
Auxiliary gas flow rate 0.95 L min-1 
Sample gas flow rate 0.90 L min-1 
Ablation gas flow rate 0.55 L min-1 
Sampler cone Nickel 
Skimmer cone Nickel 
Laser spot size 30 µm 
Repetition frequency 1 Hz (single shot) 
Laser power setting 100 % 
Laser fluence 26 J cm-2 
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4.2.3 Results and Discussion 
4.2.3.1 Cell partitioning and formation of Pt-DNA adducts in cultured cells 
This work built on and extended work carried out as part of the author’s previous MChem 
project.164 To aid in providing suitable background to the work performed a short summary of the 
previous work carried out is provided below, before progressing onto the new work. 
In the first experiment conducted, four different drug exposure conditions were set up using HT-
29 cells; control (no oxaliplatin or MSA), 50 µM oxaliplatin only, 20 µM MSA only and 50 µM 
oxaliplatin and 20 µM MSA. Replicates flask were prepared, and enough cells for use in both Pt-
DNA adduct formation experiments as well as cell partitioning were grown, as shown in Figure 52. 
HT-29 cells 
 
 
 
 
 
 
 
               Oxaliplatin         Oxaliplatin and MSA    MSA             Control 
 
                                            
         Cell partitioning              Cell partitioning           Cell partitioning            Cell partitioning 
 
                   
       Adduct formation          Adduct formation  
            experiment              experiment 
 
Figure 52 – In vitro treatment of cell lines with 50 µM oxaliplatin and 20 µM MSA 
These drug doping concentrations were chosen for several reasons. A 20 µM MSA concentration 
was chosen based on work by Goenaga-Infante et al.161 while a 50 µM oxaliplatin concentration 
was chosen based on previous work by Zayed et al. 111 with the aim of extending and comparing 
against this work. This dosage level is higher than what would be considered to be a clinically 
relevant concentration to compensate for the short incubation time (1 hour) when compared to 
the extended periods of time a drug can circulate around the body in a clinical patient. 
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Cells were exposed to the drugs, allowed to recover and were harvested before either having the 
DNA extracted from them or being cell partitioned as described in Section 4.2.2.  
The results obtained showed good linearity from the calibration graphs for all elements and good 
reproducibility was observed for the Pt response. Unfortunately, difficulties were experienced in 
observing Se in the samples, usually recording only background levels and therefore only the Pt 
data was examined further. 
For determining the subcellular distribution of platinum, the amount of Pt (nanograms (ng) per 
million cells) was calculated, and when combining the data for all 4 fractions, the percentage of Pt 
in each fraction could be expressed. While two flasks were prepared for each condition, from 
which 3 replicates were prepared, this data was averaged out and condensed to form Figure 53. 
 
Figure 53 - Percentage of Pt determined in each subcellular fraction in HT-29 human colorectal cancers after 
exposure for 1 hour to 50uM OxPt and 20uM MSA (error bars calculated using 2x standard deviation, n=6) 
The error bars were produced by calculating two times the standard deviation, but it is worth 
noting that biological samples are renowned for larger variation, and therefore a larger error is to 
be expected.173 Even though Se was not successfully measured, Figure 53 still allowed for a 
comparison of Pt position within the cell with and without the cells being exposed to MSA. 
Firstly, when looking solely at the distribution of Pt within a cell, a similar trend to that reported 
by Zayed was observed where a very high level of Pt was observed within the cytosolic fraction 
when compared to the protein content.111 It was speculated that the presence of other non-
protein molecules (such as glutathione) that reside within the cytosol and have a high binding 
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affinity for Pt-based drugs could be the reason for this, as well as the possibility of some 
free/unbound drug still lingering within that fraction.5,111,174  
When directly comparing the Pt distribution with and without the presence of Se, while it appears 
that a slight shift in the Pt from the cytosol to the cytoskeleton and cell membrane was observed, 
this shift was not considered to be statistically significant. Furthermore, and most importantly, 
the level of Pt reaching the nuclear fraction appears to be unaltered, suggesting that the Se 
supplementation had not altered the amount of drug reaching the nuclear fraction containing the 
DNA. 
The Pt-DNA adduct information obtained yielded similar results. Figure 54 shows the average 
number of Pt-DNA adducts formed under the two conditions, and while it appeared that a small 
decline in the number of Pt-DNA adducts formed when MSA was present, this shift was not 
determined to be large enough to be statistically conclusive. 
 
Figure 54 – Number of Pt-DNA adducts formed in HT-29 cells exposed to 50 µM oxaliplatin and 20 µM MSA for 1 hour 
with 1 hour recovery (error bars produced 2x standard deviation, n=6) 
The experiment detailed above was repeated, with a couple of adjustments. Firstly a 100 µM MSA 
concentration was introduced as well as repeating the experiment at 20 µM, and a 24 hour 
recovery time point as well as the previously used 1 hour was used. Both a 1 and 24 hour 
recovery time points were chosen for the study of the formation and repair of adducts for two 
reasons, firstly as these correlate to when the collection of patient samples was usually possible 
(see Chapter 2) and secondly due to practical limitations and access to the cell culture laboratory.  
Even with this increased selenium level problems were still experienced when trying to determine 
the level of Se in the samples, however the selenium’s effect on Pt-DNA adducts could still be 
observed (see Figure 55). 
0
2
4
6
8
10
12
14
16
18
OxPt OxPt and MSAA
ve
ra
ge
 n
um
be
r o
f P
t a
to
m
s p
er
 1
06
 
nu
cle
ot
id
es
 
Drug exposure conditions 
 
 
112 
 
 
Figure 55 - Number of Pt-DNA adducts formed in HT-29 cells exposed to 50 µM oxaliplatin and either 20 or 100 µM 
MSA for 1 hour with 1 and 24 hour recovery. Error bars produced 2x standard deviation, n = 4. 
As Figure 55 shows, a drop in the number of adducts formed at the highest selenium dosing level 
was observed following just a 1 hour recovery period, however, when examining the 24 hour 
recovery data little difference was observed, indicating that Se at high enough doses could retard 
the amount of Pt reaching the DNA initially, but this effect could be negated over a longer time 
period.  
The work summarised above highlighted issues for further study, and consequently the topic was 
revisited. Some of the work detailed below was done in collaboration with an MChem student, 
Carl Cooper.165 
As well as wanting to repeat the above experiments to ensure their validity and accuracy, other 
adjustments to the experimental design were made, primarily the growth of the cells in media 
containing MSA for 24 hours prior to exposure to oxaliplatin as opposed to doping the cells with 
both drugs simultaneously to better simulate the scenario of patients taking selenium 
supplements every day. Furthermore, this would remove the possibility of the any Pt-Se 
interaction outside of the cells which could affect the Pt uptake by the cells. 
One of the problems found in the first set of experiments was the inability to accurately record 
the selenium concentration. It was theorised that the problems associated with measuring the 
selenium previously could have been due to the harsh conditions experienced by the samples 
under the acid digestion conditions used, and that the selenium was being lost due to its 
volatility. Therefore selenium recovery using different isotopes was investigated using ctDNA as 
part of an MChem project.165 Briefly, replicate solutions of ctDNA were spiked with MSA before 
being digested using the method detailed in Section 4.2.2.4 and analysed via ICP-MS. Cooper165 
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reported that while 78Se provided good recovery data, it was 82Se that produced the best 
response, with recoveries averaging 102%. Therefore as 82Se was determined to be the best 
isotope for future analysis, despite being low in abundance (9.2%), the lowest background was 
achieved with this isotope.165,170  
Based on the results detailed above, a second attempt at measuring both Se and Pt in cultured 
cells was made to determine the effect of Se on the subcellular distribution of Pt-based anti-
cancer drugs. A similar experimental design was set up with one flask being prepared for DNA 
extraction and one for cell partitioning for each exposure condition (control, 20 µM MSA, 50 µM 
oxaliplatin and 20 µM MSA and 50 µM oxaliplatin). As previously mentioned, cells were exposed 
to MSA for 24 hours once confluent before being exposed to oxaliplatin (if necessary) in fresh 
media for 1 hour before being allowed to recover for either 1 or 24 hours. 
Unfortunately, problems and errors were encountered during both the DNA extraction as well as 
the cell partitioning experiments and for the most part the results had to be discarded. The 
extraction of DNA encountered problems when loading the sample on to the columns. The 
columns appeared to be overloaded and consequently some samples were lost and from others 
only a limited amount of DNA was recovered. Therefore, unfortunately, not enough data was 
obtained to enable a good comparison to the work previously conducted. 
The cell partitioning experiment had limited success. The 1 hour recovery data was compromised 
by the accidental addition of a contaminating buffer, however data was obtained for the 24 hour 
recovery experiment (see Figure 56). 
The subcellular distribution was slightly different from that seen previously with a lower 
percentage being recorded in the cytosol and higher in the cytoskeleton. However without the 
presence of the 1 hour data it was unclear as to whether the results observed were due to the 24 
hour recovery or whether an error occurred. 
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Figure 56 - Percentage of Pt determined in each subcellular fraction in HT-29 human colorectal cancers after 
exposure for 1 hour to 50uM OxPt and 20uM MSA with 24 hour recovery. Error bars produced using 2x standard 
deviation, n = 4. 
Even though the data obtained in this work was incomplete and largely had to be discarded, in 
some of the whole cell pellet samples (designed to be used as part of a mass balance experiment 
for the cell partitioning) selenium was successfully measured (it was not seen in the DNA samples 
or in the partitioning fractions), which would lead on to the next piece of work. 
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4.2.3.2 Whole cell analysis 
As detailed in the previous section, limited success at measuring the effect of Se on Pt-based 
drugs within the cell has been obtained. Having ruled out the digestion procedure as the reason 
for the lack of selenium signal, it was theorised that the selenium was potentially lost during 
either the DNA and cell partitioning experiments. As a result it was decided to investigate an 
earlier stage in the process, and therefore the uptake of Pt by whole cells and the possible effect 
of Se on this uptake was investigated. 
In total, 15 flasks (150 cm2) of HT-29 cells were prepared where the effect of 3 different 
concentrations of MSA on the total cellular uptake of Pt-based drugs could be investigated (see 
Table 23). Three different MSA concentration levels were chosen (25, 50 and 75uM) in order to 
provide a larger Se concentration range which was hoped to allow the successful measurement of 
Se as well as Pt (oxaliplatin exposure concentration was kept constant at 50 µM). One flask for 
each condition was set up, from which replicates could be obtained.  
Table 23 – Number of flasks and conditions set up for investigating the effect of Se on the uptake of Pt on whole cells 
Condition 1 hour recovery 24 hour recovery 
Control 1 - 
MSA 3 3 
Pt 1 1 
MSA and OxPt 3 3 
* Note: 1 flask of each MSA concentration (25, 50 and 75 µM) was prepared.  
The HT-29 cells were grown in RPMI 1640 media (as per Section 4.2.2.1) until around 70% 
confluent at which point the used media was removed and fresh growth media doped with MSA 
was placed into the flasks. The flasks were placed back into the incubator and allowed to grow in 
the presence of MSA for 24 hours before adding fresh media (containing 50 µM oxaliplatin if 
required) and left for 1 hour before fresh media was once again put into every flask and left for 
either 1 or 24 hours to recover. 
After the desired recovery time has passed, cells were harvested (see Section 4.2.2.1) and 
pelleted down in to three aliquots of 5 million and one 10 million cell aliquot (where possible) for 
solution analysis via ICP-MS, while a 50,000 cell aliquot (diluted in approximately  0.5mL media) 
was taken for analysis via LA-ICP-MS (see Section 4.2.3.3). 
Cells were digested as in Section 4.2.2.4 and reconstituted to a final volume of 500 µL of 2% nitric 
acid with 0.5 ppb Eu as an internal standard. The calibration graphs showed good linearity (see 
Figure 57 as an example and Appendix C) and the data obtained allowed for the calculation of the 
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concentration of Pt and Se per million cells for all conditions, as displayed in Table 24 and Figure 
58 and Figure 59.  
 
Figure 57 – 82Se calibration graph for Se determination in whole cultured cells 
 
Table 24 – Average concentration per million cells of Pt and Se measured in cultured cells exposed to oxaliplatin 
and/or MSA 
Sample name Pt (ppb) per million cells RSD Se (ppb) per million cells RSD 
Control 0.058 0.012 0.865 0.152 
Pt 1 hr 6.711 0.452 0.866 0.028 
25uM MSA 1 hr 0.080 0.047 5.966 0.489 
50uM MSA 1 hr 0.055 0.012 8.132 0.575 
75uM MSA 1 hr 0.055 0.013 9.269 0.476 
25uM MSA + Pt 1 hr 4.777 0.151 6.260 0.248 
50uM MSA + Pt 1 hr  5.047 0.192 7.134 0.196 
75uM MSA + Pt 1 hr 4.554 0.245 9.606 0.292 
Pt 24 hr 4.687 0.410 0.855 0.019 
25uM MSA 24 hr 0.054 0.013 4.871 0.108 
50uM MSA 24 hr 0.054 0.013 7.686 0.366 
75uM MSA 24 hr 0.056 0.015 8.515 0.297 
25uM MSA + Pt 24 hr 2.745 0.266 5.226 0.248 
50uM MSA + Pt 24 hr 3.401 0.107 6.705 0.461 
75uM MSA + Pt 24 hr 3.447 0.302 6.746 0.292 
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Figure 58 – Concentration of Pt and Se per million cells in 1 Hour recovery and control samples. Error bars produced 
2x standard deviation, n = 3. 
 
 
Figure 59 – Concentration of Pt and Se per million cells in 24 Hour recovery samples. Error bars produced 2x standard 
deviation, n = 3. 
The error bars shown in the figures above were calculated using twice the standard deviation of 
the replicates. To aid in the direct comparison of Pt and Se levels at the different recover time 
points, Figure 60 was produced.  
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Figure 60 – Concentration of Pt and Se per million cells in all samples (control, 1 hour and 24 hour recovery samples) 
The first noticeable observation from Figure 58, Figure 59 and Figure 60 is the successful 
measurement of both Pt and Se. Even at the 25 µM MSA dosing level (the level closest to the 20 
µM used in previous experiments) Se above background was clearly measured, reinforcing the 
theory that the Se was being lost in both the DNA extraction and cell partitioning. Furthermore, 
the growing of the cells in MSA for 24 hours prior to dosing with oxaliplatin seems to have aided 
in the quantification of Se.  
There was however a significantly higher level of Se observed in the control cells than Pt. This was 
to be expected for two main reasons. Firstly, even though 82Se had the lowest background level of 
interferences of the isotopes measured in previous experiments the background was still 
significantly higher than that observed for 195Pt. And secondly, selenium is a trace element 
naturally found within the body and can be found in many selenoproteins and therefore a higher 
background level of Se would be expected.171,175,176 However, the concentrations determined in 
the MSA dosed cells were significantly higher than the background (observed in digest blank 
samples and control cells) and therefore can be assumed to be a real measurement of selenium. 
It is also evident that the selenium uptake by the cells does not linearly correlate with the amount 
of selenium used to dose the cells. While it can be seen that the Se levels did increase with the 
dosage levels, particularly evident at the 1 hour recovery time point, the measured Se level does 
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not rise by the same amount at each dosage jump (i.e. the concentration increase between 25 
and 50 µM does not equal that observed between 0 and 25 µM). This could suggest that the cells 
only have a limited uptake capacity for MSA. However, as the MSA dosage level is increased the 
Se concentrations observed did increase as well. Unfortunately as a result of the high MSA 
concentrations used to dose the cells, a greater number of cells were observed to have become 
detached from the flask overnight (the HT-29 cell line is an adherent cell line) as well as a slight 
increase in the ratio of dead: live cells as determined during the cell counting step, suggesting 
that using any significantly higher doses within a cell culture experiment could result in too high a 
concentration of dead cells to be considered a viable experiment. This effect did become 
progressively more pronounced as the concentration of MSA was increased. 
When comparing the level of Pt taken up by the cells, it is possible that a level of repair (or efflux 
of Pt from the cells) has occurred between the 1 and 24 hour oxaliplatin only samples. This effect 
has been seen before when examining the number of Pt-DNA adducts formed (as seen in Chapter 
2 and in studies such as those by Zayed and Almeida).103,111 While this data does not provide 
information of the number of adducts, it is possible that this reduction in platinum levels after 24 
hours recovery could correspond to a decrease in the number of Pt-DNA adducts. 
It is also clear that the MSA did have an effect on the level of Pt taken up by the cells. At the 1 
hour time point the level of Pt drops by approximately 1-2 ppb per million cells compared to the 
oxaliplatin only 1 hour samples. At the 24 hour time point, again Pt levels are lower in the 
samples containing MSA compared to those which did not indicating that repair occurred both 
with and without MSA being present. While the presence of MSA did reduce the amount of Pt 
taken up by the cell, the decrease in Pt taken up by the cells at each of the three MSA 
concentrations were not significantly different. The cells used in this investigation were exposed 
to MSA for 24 hours, before being washed and fresh media added for the dosage with oxaliplatin. 
This was done to remove the possibility of Pt-Se interactions outside of the cell reducing the 
uptake of platinum. 
Furthermore, MSA (as well as the Pt) levels had fallen at the 24 hour recovery time point in those 
samples dosed with both Se and Pt. This drop in level of Se was not seen to the same extent in 
those samples containing MSA only at the 24 hour recovery time point, possibly suggesting that 
the Pt and Se played a role in the others decrease in concentration over time. 
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4.2.3.3 Single cell laser ablation ICP-MS 
While the study of the properties of populations of cells has been frequently reported in the 
literature, little is known about the spread or variation within each cell population.177 Analysis of 
single cells by techniques such as laser ablation are starting to be reported in the literature.177–179 
Analysis of cell populations can provide useful information, however cell heterogeneity/variation 
is inescapable and therefore the analysis of single cells has the potential to offer new insights and 
more detailed studies of how cell systems can be affected.  Single cell analysis comes with the 
enormous advantage of reduction in biological noise. Furthermore, as cancer is a heterogeneous 
disease, the possibility of investigating cell-to-cell variation could potentially lead to insights into 
tumour initiation, propagation, metastasis and therapeutic response. 177 
Therefore to investigate the effect of MSA on the uptake of Pt-drugs on colorectal cancer cells a 
small aliquot (approximately 50,000 cells) of the cells from each flask prepared in Section 4.2.3.2 
were taken and spun down onto slides (as per Section 4.2.2.5). These cells were then analysed via 
LA-ICP-MS as described in Section 4.2.2.6.  
Due to the large number of slides and different conditions  it was decided to ablate 100 cells for 
Pt and Se on each slide as well as 25 slide blanks for each of the 15 slides. While laser ablation 
cannot provide accurate quantification of the concentration of elements within a single cell due 
to problems encountered with the creation of matrix matched standards, the distribution within a 
cell population can be determined, as can an approximate comparison between samples/slides 
run on the same day under the same conditions. As any data (cps) obtained on different days 
could not be directly compared due to slight differences in conditions experienced day to day, 
initially just one Se concentration (75µM) set was chosen for examination and comparison with 
oxaliplatin only and the control cells. 
A problem often encountered with LA-ICP-MS is the accidental knocking out of the plasma when 
changing over samples from within the laser ablation cell which would make the direct 
comparison of samples impossible. Therefore to reduce the likelihood of this happening, a shard 
from several different slides and a small piece of NIST glass (used for tuning) were placed into the 
cell together so that cells from each shard could be ablated without having to disrupt the sample 
gas and risk the plasma going out.  
Initially a test sample size of 10 cells for both Pt (using 1 hour oxaliplatin only slide) and Se (75uM 
MSA and 50 uM OxPt with 1 hour recovery) were chosen (see Figure 61 and Figure 62). Multiple 
Se isotopes were tested (including 77Se, 78Se and 82Se) but the only isotope with clear Se signal 
was 77Se (Figure 62). Screenshots of the other Se isotope responses can be found in Appendix C.  
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As each slide held a total of approximately 50,000 cells to ensure only a single cell was ablated 
each time a 30µm spot size was used to encompass the entire cell. Furthermore only cells which 
were on their own were targeted and any cells found in a cluster or too close together were not 
used.  
 
Figure 61 – 195Pt signals obtained from 10 cells exposed to 50 µM oxaliplatin for 1 hour with 1 hour recovery time 
 
Figure 62 – 77Se signals obtained from 10 cells exposed to 50 µM oxaliplatin and 75 µM MSA for 1 hour with 1 hour 
recovery time 
While a good 77Se signal was seen initially (as in Figure 62), when this was tested again (along with 
other isotopes), only the occasional spike above background was seen (see Appendix C). The 
reason for this remains unclear as several parameters were altered and other isotopes retested 
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but the signal constantly remained intermittent. It was theorised that the position of the slide 
shard within the cell could receive a different gas flow, and thus causing a reduced signal, or that 
the He ablation gas or heat from the lighting was causing the Se to be lost off the surface of the 
shard over the course of the day, however these factors were investigated thoroughly and still no 
constant signals were obtained. 
A further complication was the level of crystallisation of media around the edges of the cells as 
observed using the laser microscope. Figure 63 shows some examples of the worst crystallisation 
observed.  
    
Figure 63 – Examples of HT-29 cells with crystallised media present on slides 
The crystallisation was not consistent over the entire slide and was thought to possibly be due to 
the amount of media used to spin the cells onto the slides. This theory could not be tested as no 
fresh unspun samples remained at that point; however, a small amount (250 µL media) was 
added onto a couple of test slides (placed into the cytospin rotor buckets) and re-spun for 20 
minutes at 4000 rpm in an attempt re-dissolve the remaining media off the slides before being 
adsorbed by the filter card.  While this did remove a lot of the crystallised media, some still 
remained and a reduced number of cells on the slide were observed (see Figure 64). 
   
Figure 64 – Examples of HT-29 cells on slides having been re-spun 
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Due to the varying results and the fact that only whole slides (i.e. slides that had not already been 
cut down) could be washed using this method, only original and unwashed shards were used for 
the following work. Furthermore due to difficulties seeing selenium, it was therefore decided to 
look solely at the Pt signals. Initially, shards from slides containing oxaliplatin only and 75 µM 
MSA and 50 µM oxaliplatin both with 1 hour recovery time points as well as control were put into 
the ablation cell together and 100 cells on each shard was ablated looking at the platinum signal 
intensity as well as 25 slide blanks. 
The data obtained from these three slides is presented below.  The first observation is that the 
level of Pt taken up by the cells is not consistent as is evident in Figure 65 and Figure 66. These 
histograms depict the spread of the data which has been grouped into classes and plotted against 
the frequency. From Figure 65 (oxaliplatin only) a near Gaussian distribution is observed. 
However a slightly more distorted Gaussian distribution was observed in the cells dosed with 
both oxaliplatin and MSA (Figure 66), likely caused by the significantly lower intensities observed 
(often just above background). Both sets of data are slightly skewed from a normal Gaussian 
distribution with a slight tail on the right/ positive skew. 
 
Figure 65 – Histogram depicting the distribution of Pt measured in 100 cells exposed to 50 µM oxaliplatin 
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Figure 66 - Histogram depicting the distribution of Pt measured in 100 cells exposed to 50 µM oxaliplatin and 75 µM 
MSA 
While the complete data set for all 100 cells on each slide can be found in Appendix C, differences 
in intensities for Pt measured in the first set of 25 cells from the control, oxaliplatin only and 
oxaliplatin and MSA at 1 hour recovery time points are illustrated in Figure 67. 
 
Figure 67 – 195Pt intensities measured in 25 cells at three different dosing conditions 
Figure 67 indicates a significant drop in Pt intensity between cells exposed to MSA and those 
which were not. The position of the shard within the ablation cell (see discussion below) could 
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have impacted this. However as the drop in intensity was at a significant level, and is supported in 
part by evidence of a slightly smaller decrease in Pt uptake by cells observed in the solution ICP-
MS work, this was therefore thought to be a real effect. 
A further data set was obtained allowing the comparison of Pt intensities observed for cells dosed 
with oxaliplatin only at 1 hour and 24 hour recovery. Figure 68 shows the variation in Pt 
intensities observed, while the full data sets can be found in Appendix C. 
 
Figure 68 – Comparing the 195Pt intensities measured in 25 cells with 1 and 24 hour recovery times 
As with the solution based cell ICP-MS work, Figure 68 shows a decrease in the Pt intensities per 
cell at the 24 hour recovery time point, however the effect does seem to be exaggerated by LA-
ICP-MS (as with the addition of MSA above). One potential explanation for this phenomenon is 
the effect of the position of the shards within the laser ablation cell which would ultimately 
receive a different gas flow thus influencing the transport efficiency to the ICP-MS for analysis.  
To indicate how the effect of differing gas flows experienced at different parts within the ablation 
cell could cause a decrease in intensities measured, some gas flow modelling work of the ablation 
cell used in this experiment is shown below.180 The flow modelling was done using a He gas flow 
of 0.6 L min-1, which was slightly higher than that used in this experiment (0.55 L min-1) but 
illustrates the differing gas flows as determined by number of samples in the cell clearly.  
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Figure 69 - Gas flow modelling in teardrop cell with a single square slide fragment 
 
Figure 70 - Gas flow modelling in teardrop cell with 4 smaller shards 
Firstly with a single square slide placed in the centre (Figure 69) a relatively uniform gas flow is 
observed around the slide, with the fastest flow in the centre. However, when four smaller slide 
fragments were used (as in Figure 70) a non-uniform gas flow with a swirling effect is observed, 
and would thus affect the intensity of the signals observed.  
To overcome the non-uniform effect as observed in Figure 70, ideally each slide would be cut to 
the same size and placed in the chamber one at a time for analysis (as in Figure 69), however in 
this experiment this was not feasible. To reduce the impact of the gas flows as much as possible 
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in this experiment all shards of slides were placed as close the centre line of the cell where gas 
flows are at their best (a slightly different arrangement to that shown in Figure 70), however it is 
plausible to speculate that the exaggeration of the decrease in Pt signal observed by laser 
ablation is due to the position within the cell. 
Overall it is clear that analysis of 195Pt in single cells dosed with oxaliplatin is possible by LA-ICP-
MS. Furthermore, while this data is not quantitative, a comparison of intensities at different 
conditions supports the findings from solution based analysis of cell populations where the level 
of Pt measured decreased when the cells had been dosed with MSA and when looking at cells 
dosed with oxaliplatin only there was a decrease in Pt taken up by cells at the 24 hour recovery 
time point when compared to the 1 hour.  
It is also clear that the amount of Pt taken up by each cell is not the same and the spread is a 
slightly skewed Gaussian distribution. This distribution is similar to that observed in a study by 
Managh et al. where the distribution of gadolinium label was measured in cells.178   
Assuming total ablation of a cell, it can be said that the signal obtained from each ablated cell 
would be representative of the total amount of Pt taken up per individual cell. However with the 
variable level of media crystallisation on and around the cells, total ablation of every cell may not 
have been achieved. 
In conclusion, an attempt was made to measure Pt and Se in single cells. While initial success for 
measuring Se was made the signals were not seen consistently again and the reason for this 
remains unclear. With further method development and troubleshooting, it is feasible that Se, 
along with Pt, in single cells could be measured, which has not as yet been reported in the 
literature. Some success was achieved in measuring the Pt distribution within a cell population, 
however a full comparison at all dosing conditions was not possible. While this experiment 
encountered several problems throughout, and only limited Pt data was obtained there is 
potential for this technique to be useful in the study of Pt-based anti-cancer chemotherapy drugs. 
This work has shown the distribution in cellular uptake of Pt, and this work could potentially be 
expanded to investigate the minimum threshold for cell apoptosis. Furthermore, in larger cell 
types it has been observed that various labels and nanoparticles have centred around the nucleus 
within the cell, potentially making it possible to single out the nucleus and compare levels of Pt 
within the nucleus and the surrounding areas of the cell. 181,182 
 
  
 
 
128 
 
4.3 Competitive binding of oxaliplatin and MSA 
4.3.1 Introduction 
As previously discussed, Pt-based anti-cancer drugs such as oxaliplatin enter cells from the 
bloodstream by active transport or passive diffusion through the cell membrane.183  Once within a 
cell oxaliplatin, which had previously had its oxalate ligand substituted by chloride ions, 
undergoes hydrolysis and the resulting Pt species is believed to be the active form of the drug 
which forms adducts with the DNA.132,184–186 However it is well known that oxaliplatin reacts with 
other species within the cells as they are filled with an abundance of ligands which only have to 
displace the weakly bound water molecules on the activated drug. 
It is known that only around 1% of the drug ever reaches the DNA, and therefore it is these 
interactions of Pt complexes with non-DNA molecules that make up a substantial portion of the 
remaining interactions of the Pt-drugs. 3–5,71,187,188 One key intracellular component studied is the 
tri-peptide g-L-glutamyl-L-cysteinyl glycine (glutathione or GSH, Figure 71), which is the most 
abundant low molecular weight thiol containing molecule found within the cytosol. 16,174,189,190 
Currently it is thought that Pt-GSH complexes could potentially be a major cellular sink for Pt-
based drugs, with a reported approximation of 60% of the intracellular cisplatin being accounted 
for by Pt-GSH binding, thus potentially rendering much of the drug inactive.191,192 Furthermore, it 
is thought to potentially play a role in increasing cell resistance, and elevated levels of glutathione 
were found in cisplatin resistant tumour cells. 16,192,193 
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Figure 71 – Structure of glutathione 
With a significant number of patients taking supplements during cancer treatment, an 
understanding of the ramifications of any interactions between these supplements and the Pt-
based drugs is required. Selenium has been theorised to potentially have a role in reducing some 
of the side effects experienced by patients. Some side effects are thought to be caused by a 
decrease in antioxidant levels in the plasma which have a role in the prevention of oxidative 
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damage, while selenium (a dietary antioxidant) has the ability to scavenge free oxygen radicals 
thus reducing oxidative stress, and therefore potentially reducing the level of side effects 
experienced. 47,194,195 Furthermore, selenium compounds are known to bind to peptides and 
proteins in the cytosol (such as glutathione), thus potentially preventing as much Pt-based drugs 
(such as oxaliplatin) from binding to these proteins and leaving a greater amount free to bind 
with the DNA.191,196,197 
While a previous study, both practical and computational, has been carried out to investigate the 
binding of oxaliplatin and glutathione, the work presented in this part of this chapter focusses on 
the competitive binding of MSA and oxaliplatin with glutathione.134 While the previous work 
detailed in this chapter is suggestive that the presence of selenium has a slightly negative impact 
on the amount of Pt-based chemotherapy drugs taken up by cells, the reason for this effect hasn’t 
as yet been determined. Furthermore, the consequence of having a raised level of intracellular Se 
on the binding sites of Pt remains uncertain. This work aimed to investigate the interaction of 
oxaliplatin and MSA, and in particular if a competitive binding scenario exists when in the 
presence of biological material, in this case the cytosolic protein glutathione. 
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4.3.2 Methodology 
To investigate the competitive binding of MSA and oxaliplatin with glutathione (GSH), four 
different solutions were prepared and analysed as listed below: 
• 20 mM glutathione solution (GSH) 
• Glutathione and oxaliplatin mixture (GSH:OxPt, 2:1, 10 mM:5 mM) 
• Glutathione and MSA mixture (GSH:MSA, 2:1, 20 mM:10 mM) 
• Glutathione, oxaliplatin and MSA mixture (GSH:OxPt:MSA, 1:1:1, 5 mM) 
All solutions were prepared in 50:50 methanol:water mixture with 0.1% formic acid. The 
glutathione, oxaliplatin, MSA, HPLC grade water, formic acid and methanol were all purchased 
from Sigma Aldrich (Poole, UK). 
The samples were analysed on an LTQ linear ion trap mass spectrometer (Thermo Electron, San 
Jose, CA, USA) with an electrospray ionisation source (ESI). The LTQ was operated in the positive 
mode at 5.20 kV and 260°C. The instrument was calibrated prior to use with Ultramarks 1621, 
caffeine and Met-Arg-Phe-Ala (MRFA) in accordance with the manufacturer’s recommendations. 
The resolving powers achieved were in the order of 1500 while the upper instrumental error limit 
in measurements was 0.2 m/z units. The LTQ auto-tune function was used following this to obtain 
lens, quadrupole and octapole voltages for maximum transmission of the ions of interest. Helium 
gas was used as a buffer gas within the ion trap (at approximately 10-3 Torr) to improve the 
trapping efficiency as well as the collision gas for collision induced dissociated experiments (CID). 
Samples were introduced into the instrument at the rate of 10 µL min-1 into the electrospray 
source which utilised nitrogen as a nebulising gas. Auxiliary and sheath gases were tuned daily to 
enable maximum signal transmission. 
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4.3.3 Results and Discussion 
The mass spectra for the first three conditions tested (GSH only, GSH and oxaliplatin and GSH and 
MSA) can be found in Appendix C, however the main peaks of interest are listed in Table 25 -
Table 27. 
Table 25 – Peaks of interest observed in GSH only solution 
Most Abundant Isotope m/z Assignment 
308.17 [GSH + H] + 
615.00 [(GSH)2 + H] + 
921.83 [(GSH)3 + H]+ 
 
Table 26 – Peaks of interest observed in GSH:OxPt (2:1) solution 
Most Abundant Isotope m/z Assignment 
308.17 [GSH + H]+ 
398.17 [OxPt + H]+ 
614.92 [(GSH)2 + H]+  
704.92 [OxPt + GSH + H] + 
795.17 [(OxPt)2 +H] + 
922.08 [(GSH)3 + H]+ 
1012.17 [OxPt+ (GSH)2 + H] + 
1102.92 [(OxPt)2 + GSH + H] + 
1499.83 [(OxPt)3 + GSH + H] + 
 
Table 27 – Peaks of interest observed in GSH:MSA (2:1) solution 
Most Abundant Isotope m/z Assignment 
308.17 [GSH + H]+ 
402.17 [(MSA + G) +H] + 
613.25 [(GSH)2 + H] + 
800.73 [(MSA + G)2 +H] + 
 
As can be seen in Table 27, it is evident that under the conditions in this experiment the 
glutathione molecule is cleaved and loses fragments (represented as G in the tables as opposed 
to GSH), as was evident by the drop in the mass. However, it is not clear what this loss from the 
GSH molecule is, or if it remains constant. In some cases, a loss of m/z 32, which could indicate a 
loss of O2, while in other scenarios there was loss of m/z 33 which could indicate the loss of –SH, 
or potentially O2H. 
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To be able to identify which of oxaliplatin (OxPt) and MSA bound preferentially to the GSH, both 
chemicals were added to the GSH in equimolar concentrations and the mass spectrum recorded 
(see Figure 72 and Table 28). 
 
Figure 72 – Full mass spectrum of the competitive binding of MSA and OxPt to GSH 
 
Table 28 – Peaks of interest observed in GSH:OxPt:MSA (1:1:1) solution 
Most Abundant Isotope m/z Assignment 
308.17 [GSH + H]+ 
402.08 [(MSA + G) +H] + 
432.08 [MSA + GSH +H] + 
613.33 [(GSH)2 + H] + 
705.17 [OxPt + GSH + H] + 
798.00 [G + OxPt + MSA + H] + 
827.92 [GSH + OxPt + MSA + H] + 
1010.25 [OxPt+ (GSH)2 + H] + 
1196.00 [G + (OxPt)2 + MSA + H] + 
1591.83 [G + (OxPt)3 + MSA + H] + 
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As can be seen in Figure 72 a range of binding occurred between GSH, oxaliplatin and MSA. The 
largest peak observed was that of MSA and glutathione at m/z 402 (having lost the thiol group). 
One noticeable difference in this spectrum is the addition of a peak at m/z 432 which is MSA and 
glutathione without the loss of the thiol which was not seen in previous spectra (Figure 128, 
Appendix C). However, while it appears that the primary binding of glutathione was with MSA, 
binding with oxaliplatin and a combination of oxaliplatin and MSA was present as well, and in fact 
little or no free oxaliplatin remained in solution.  
With MSA, oxaliplatin and glutathione being present in solution at equimolar concentrations it 
was thought that not all MSA and oxaliplatin would be able to bind to the glutathione and thus 
would result in a competitive binding scenario. This however was found not to be the case as 
oxaliplatin dimers and trimers were found to interact with the glutathione and MSA such that 
little or no free oxaliplatin was found in solution. The presence of such oxaliplatin dimers and 
trimers is evidence of the high affinity oxaliplatin has for glutathione, as was previously reported 
by Shoeib et al.134 As well as the variety of different ways oxaliplatin is able to bind with 
glutathione, it is worth noting that this binding is not prevented by the presence of an equimolar 
concentration of MSA.   
However, it is also worth noting that the high levels of oxaliplatin, and MSA, as used in this 
experiment, would not be found in a true biological system, and therefore the results are not 
wholly representative of what would happen in the body. The presence of oxaliplatin dimers is 
unlikely to be seen within the body due to the plethora of binding sites which can be found within 
cells, however in an attempt to force a competitive binding scenario, high concentrations were 
used in this experiment. 
While previously in this chapter it was observed that the amount of Pt in the cytosol did decrease 
slightly when MSA was also used to dose cells (Figure 53), the results from this work are not 
conclusive to say whether this was due to MSA binding preferentially to cytosolic proteins or 
peptides, such as glutathione. Despite the largest peak being observed being glutathione and 
MSA only, due to no peak for unbound oxaliplatin being observed it can be assumed that all 
oxaliplatin was bound to glutathione/glutathione and MSA in various combinations, as discussed 
above. Therefore, the presence of selenium did not conclusively appear to free up binding sites 
that could otherwise be taken up by oxaliplatin.  
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4.4 Conclusions 
This chapter explored the effect of selenium supplementation on oxaliplatin and colorectal cancer 
cells. Firstly, when investigating the cells at a subcellular level, the most notable result was the 
decrease in the level of platinum in the cytosol in the presence of MSA. This was accompanied by 
a slight decrease of platinum within the nuclear fraction, however this change was not significant. 
Furthermore, a slight decrease in the level of Pt-DNA adducts was observed when MSA was 
present; however this was again deemed to not be a significant difference. However, while the 
platinum at the subcellular level was easily determined, selenium was not measured above 
background level.  
Following this, the effect of selenium supplementation of the total cellular uptake of oxaliplatin 
was investigated. In cultured cells it was seen that the presence of selenium, in the form of MSA, 
did reduce the amount of oxaliplatin taken up by the cell. This was seen in analysis of populations 
of cells as well as by single cell analysis. In this work both selenium and platinum were 
successfully measured, suggesting that in the previous selenium was either at too low a 
concentration or being lost in the DNA or cell partitioning methods. While this work showed that 
when dosed with MSA, the cells did not take up the oxaliplatin as readily, this effect was not in a 
linear relationship with the MSA dosage concentration. Furthermore, the level of both oxaliplatin 
and selenium found in the cells had decreased when compared to the one hour recovery time 
point, possibly suggesting a level of repair. The platinum in whole cells was also examined using 
LA-ICP-MS, and while not quantitative, a comparison of the relative signal intensities also showed 
that less Pt was present within cells exposed to MSA than those which were not, thus confirming 
the results from the solution based work. 
When investigating whether MSA and oxaliplatin competitively bound in the presence of 
glutathione, the dominant peak was that of glutathione and MSA potentially suggesting that MSA 
was preferentially bound. However, no free oxaliplatin was observed in the solution, and instead 
it bound in multiple other forms, both with glutathione on its own and in combination with 
glutathione and MSA. And therefore, no evidence was found to suggest that the presence of 
selenium freed up oxaliplatin for binding elsewhere. 
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5. Summary and further work 
This thesis aimed at addressing just a few of the many potential areas of research surrounding the 
use of Pt-based chemotherapy drugs while utilising highly sensitive techniques such as ICP-MS, 
with a primary focus on the measurement of Pt in clinical samples, the effect of selenium 
supplementation on the distribution and adduct formation in in-vitro cell cultures, and the 
binding of platinum to cytosolic proteins. 
Due to the different themes being explored in each experimental chapter the main conclusions 
can be found in the relevant chapters, however a brief summary of each section of work along 
with potential areas of further work is presented below. 
5.1 Pt-DNA adduct comparison in blood and saliva samples from patients 
undergoing Pt-based chemotherapy  
ICP-MS was successfully utilised in the measurement of Pt-DNA adducts in both blood leukocyte 
and saliva samples. This work highlighted some practical issues associated with patient sampling, 
and in particular with the collection of saliva samples. While one of the aims of the work was to 
investigate the feasibility of using a more patient friendly and less invasive sampling technique, 
problems obtaining patient adherence to the sampling protocol were experienced, suggesting 
that while in theory saliva collection is more favourable from the patient’s perspective, from an 
analytical standpoint obtaining a useable sample was difficult. Furthermore, as is often the case 
when working with clinical patients a high dropout rate was experienced. Therefore collecting 
enough samples for a comparison study was challenging. When a comparison of the number of 
adducts in the two sample types was made, a limited correlation was observed in the pre-infusion 
samples, while a lack of correlation in the 1 hour post-infusion samples was found, suggesting 
that saliva is not, as used here, a viable alternative to leukocytes for the determination of Pt-DNA 
adducts. However, as platinum could be measured rapidly in the saliva as well as leukocyte 
samples at the 1 hour post-infusion time point, saliva may still have some potential for use as a 
clinical sample type. 
While the research presented here in this thesis has made some interesting discoveries it has also 
highlighted some areas which would benefit from further research. While the work on saliva as a 
viable alternative source of Pt-DNA adducts to leukocytes proved unsuccessful, if a saliva sample 
could be cell sorted prior to DNA extraction, this could potentially provide a better correlation or 
help to illustrate why a poor correlation was observed in these samples. However, this would 
require a fresh saliva sample and not one stored as was the case in this investigation, thus 
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defeating the objective of having a sampling kit patients could use at home, and which could 
ultimately not provide any benefits over the current leukocyte sampling technique. Nevertheless, 
an extended time study (whether by blood, saliva or another sample type) which would allow the 
accurate tracking of Pt-DNA levels over the hours and days following treatments, and between 
cycles, would allow a more accurate comparison between adduct levels and toxicities 
experienced by patients which could help clinicians increase the quality of patient care and 
potentially aid in the personalisation of doses.  
5.2 Binding of oxaliplatin to cytosolic proteins 
ESI-MS was used in the investigation of the binding of platinum to cytosolic proteins. Platinum 
binding to both nitrogen and sulfur rich peptides was observed immediately after mixing, and 
with the samples being re-analysed after 24 hours no obvious effect of time was observed and 
the complexes observed appeared stable. Although reproducing biological conditions was beyond 
the scope of this experiment, and thus oxaliplatin bound to the peptides as a whole molecule, the 
fact that it bound to both sulfur and nitrogen rich peptides shows potential for these peptides to 
be binding sites within the cells. 
The computational study demonstrated that, as observed from the experimental data, oxaliplatin 
would bind to both sulfur and nitrogen binding sites. The relative free energies of various 
peptide-oxaliplatin binding scenarios were examined and while often the nitrogen sites offered a 
lower relative free energy, the difference between the nitrogen and sulfur values tended to be 
very small, and thus binding to both sulfur and nitrogen would be found in the samples analysed. 
Initially only two peptides where selected for analysis via computational modelling, however this 
work could be extended to include the remaining 8 peptides. 
The work presented here suggests that there is a large excess of potential binding sites for Pt in 
the cellular proteome and that no single species or functionality is likely to dominate. It follows 
that therapeutic intervention would be difficult as there doesn’t appear to be a single therapeutic 
target that could be modified to improve the efficiency of Pt binding to its target, the DNA. 
However, given recent improvement in UHPLC and nano-LC for the analysis of peptides it would 
be appropriate to reinvestigate a direct top-down analysis of the Pt-cytosol-proteome.  
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5.3 Effect of selenium on the cellular distribution and uptake of 
oxaliplatin in cultured cells  
ICP-MS was used in the investigation into the effect of selenium supplementation on platinum-
based chemotherapy in cultured colorectal cancer cells. Firstly attempts were made to determine 
the effect of selenium on the number of Pt-DNA adducts as well as the subcellular distribution of 
platinum, but as the selenium was not successfully measured only the effect of selenium on 
platinum could be determined. The work showed there appeared to be a slight shift of the 
platinum away from the nucleus when selenium was present, as evident by a small reduction in 
Pt-DNA adducts and a lower amount of Pt in the nuclear fraction. When the cells were studied as 
a whole, it was evident that selenium did reduce the overall amount of platinum being taken up 
by the cells. Cells were incubated with selenium for 24 hours prior to being washed and then 
dosed with platinum, thus ensuring that any change in platinum uptake observed was due to the 
selenium and not any Pt-Se interactions. Furthermore an attempt was made to measure the 
selenium and platinum in single cell analysis via LA-ICP-MS, and while this work was not 
quantitative a comparative look at platinated cells with and without selenium supported the 
findings of an overall reduction in the level of platinum per cell when selenium was present. And 
finally, a competitive binding study found that both selenium and platinum bound to glutathione, 
and no preferential binding was observed. While the predominant peak observed was that of 
GSH-MSA, it is worth noting that no free oxaliplatin was observed due to dimeric and trimeric 
binding of oxaliplatin to the peptide which was present. 
The work performed on cell cultures showed a great deal of promise but more work is required.  
Firstly, some of the experiments could be repeated in order to confirm the results observed and 
to obtain better average results. However, the primary interest would be to extend the work and 
look further at dosing levels of both oxaliplatin and MSA, and to attempt to find a DNA extraction 
procedure and subcellular fractionation technique which would allow the measurement of 
selenium as well as the platinum.  
LA-ICP-MS uniquely provided a means of studying platinum distribution at the single cell level. 
Further research is required to establish a robust methodology for selenium so that the effect of 
selenium on platinum could be measured at the single cell level which has never been done 
before. But perhaps the most significant application which LA-ICP-MS could be applied to is its 
use in the measurement of platinum in patient samples, such as leukocytes or tumour cells. 
Gaining clinical patient sample data is always useful due to the natural variability in humans, 
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however to be able to investigate how the platinum-based drugs are taken up by and affect 
individual cells is of prime interest.  
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8. Appendices 
Appendix A – Chapter 2 supplementary information  
 
Table 29 - Patient saliva sample condition details 
Patient 
ID 
Saliva 
Pre 1 hour post 24 hours post 
033 IC   
035    
034    
036  IC IC 
037  X X 
038 IC   
039      
040   X 
041 IC X X 
044 IC  X 
045 *   
042   IC 
043 IC  IC 
047    IC 
046   X 
048    
049    
050    
051    
052 IC   
053    
054    
055    
 
Note:  Patient 045 – Pre sample not taken till end of treatment due. 1 hour sample was done 1 
hour following this. 
Key 
IC Incomplete sample (too little given) 
 Sample given, correct volume 
X Missing sample 
  Complete set of 3 saliva samples 
 Pre and 1 hour set complete 
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Table 30 - Clinical study patient details 
Patient 
ID 
Chemotherapy 
regime 
Cycle 
Number 
Diagnosis Age Sex Best 
response 
Grade 3/4 Toxicities Cycles 
received 
(intended) 
Dose reduction of 
platinum (cycle 
number) 
PFS (days) OS 
(days) 
Additional 
comments 
33 EOX 2 SCC 
Oesophagus 
71 F PR Lethargy cycle 1 6 
(6-8) 
75% 2 
50% 3 onwards 
474 822 (still 
alive) 
 
34 EOX 4 Adeno ca 
oesophagus 
67 M PR  6 
(6-8) 
75 % 3 onwards 161 333  
35 FOLFOX and 
Bev 
10 CRC 65 M PR Diarrhoea cycle 1 12 (12) 75% 2 onwards 398 848  
36 ECF 5 Gastric 70 F PR  8 
(6-8) 
50% cycle 1 onwards 
(poor baseline renal 
function) 
273 279  
37 FOLFOX 4 CRC 29 F NA Thrombocytopenia 
cycle 7 
8 (12) 80% cycle 8 onwards 629 836 (still 
alive) 
Adjuvant -  
post surgical 
resection of 
mets 
38 FOLFOX and 
Bev 
11 CRC 64 M PR Neutropenia cycle2 12 (12) 75% cycle 3 onwards 
50% cycle 10 
onwards 
472 941 (still 
alive) 
Neo-
adjuvant 
39 FOLFOX and 
Bev 
8 CRC 64 M PR Neuropathy cycle 3 12 (12) 70% cycle 4 onwards 
0% cycle 10 onwards 
433 874 (still 
alive) 
 
40 FOLFOX 3 Small bowel 
adeno 
67 F NA Diarrhoea and 
fatigue cycle 5 
6 (12) 80% cycle 6 onwards 277 463  
41 EOX 1 Gastric 69 M PR  8 (6-8)  354 375  
42 FOLFOX and 
Bev 
2 CRC 71 F SD  12 (12)  291 297  
43 XELOX 11 CRC 46 F PR Diarrhoea cycle 2 9 (12) 80% cycle 3 onwards 
70% cycle 5 onwards 
735 (not 
progressed 
yet) 
735 (still 
alive) 
 
44 EOX 1 Gastric 78 M PR Neutropaenia and 
neuropathy cycle 1 
6 (6-8) 80% cycle 2 onwards 389 419  
45 EOX 1 Gastric 62 M CR  6 (6-8)  238 277  
46 ECX 3 GOJ 64 M PR  3 (6-8)  308 609  
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47 FOLFOX 3 CRC 58 F NA  6 (12)  369 481 (still 
alive) 
Adjuvant 
48 FOLFOX 2 CRC 65 F NA Neutropaenia and 
neuropathy cycle 2 
8 (12) 75% cycle 3 onwards 144 261 Adjuvant 
49 FOLFOX and 
Bev 
7 CRC 47 F PR Neuropathy cycle 3 12 (12) 80% cycle 4 onwards 
75% cycle 8 onwards 
Stopped cycle 12 
433 651 (still 
alive) 
Neo-adj 
50 FOLFOX 2 CRC 56 M SD Neuropathy cycle 1 8 (12) 75% cycle 2 onwards 
50% cycle 7 onwards 
0% cycle 8 
102 171 Neo Adj 
51 FOLFOX and 
Bev 
11 CRC 60 F PR  12 (12)  398 665 (still 
alive) 
 
52 FOLFOX 5 CRC 62 M NA  9 (12)  504 (no PD 
yet) 
504 (still 
alive) 
Adjuvant 
53 ECX 2   GOJ 67 M PR  3 (3)  307 445 Neo- Adj 
54 Cis / etop 3 Small cell 
oesophagus 
53 M PR Deterioration in 
hearing cycle 3 
4 (6) 85% cycle 4 350 483 (still 
alive) 
 
55 EOX 2 Gastric 72 M PR Fatigue, diarrhoea, 
neutropenia, 
vomiting, 
neuropathy cycle 1 
7 (6-8) 75% cycle 2 onwards 
50% cycle 4 onwards 
490  (no 
PD yet) 
490 (still 
alive) 
 
 
Table Key and Notes 
SCC = Squamous cell carcinoma 
CRC= colorectal cancer 
GOJ = gastric oesophageal junction adeno ca 
PR= partial response 
SD= stable disease 
PD = progressive disease 
NA = Not assessable Or not assessed 
CR = Complete radiological response 
Adeno ca. SCCs and GOJ could all be lumped as Upper GI 
Dose reduction = % of full dose given – if 100% implies they tolerated it well. The earlier on in the cycle number they had a reduction the more prone they were to toxicities 
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Blood calibration graphs 
Table 31 - Patient blood batch details
Batch Number Patient ID numbers 
1 36, 37, 38, 40 
2 41, 44, 45, 42 
3 43, 46, 47, 52 
4 35, 34, 39, 48, 49 
5 50, 51, 53, 54 
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Figure 73 - Blood batch 1 - P calibration graph 
 
Figure 74 - Blood batch 1 - Pt calibration graph 
 
Figure 75 - Blood batch 2 - P calibration graph Figure 76 - Blood batch 2 - Pt calibration graph 
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 Figure 78  - Blood batch 3 - Pt calibration graph 
 
Figure 80  - Blood batch 4 - Pt calibration graph 
 
Figure 82  - Blood batch 5 - Pt calibration graph 
Figure 77 - Blood batch 3 - P calibration graph 
 Figure 79 - Blood batch 4 - P calibration graph 
Figure 81 - Blood batch 5 - P calibration graph 
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Saliva calibration graphs 
Table 32 - Patient saliva batch details
Batch Number Patient ID numbers 
1 36, 37, 38, 40, 41, 44, 45 
2 42, 43, 46, 47, 52 
3 35, 34, 39, 48, 49 
4 50, 51, 53, 54 
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Figure 84 - Saliva Batch 1 - Pt calibration graph 
Figure 86 - Saliva Batch 2 - Pt calibration graph 
Figure 83 - Saliva Batch 1 - P calibration graph 
Figure 85 - Saliva Batch 2 - P calibration graph 
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Figure 88 - Saliva Batch 3 - Pt calibration graph 
Figure 90 - Saliva batch 4 - Pt calibration graph 
Figure 87 - Saliva Batch 3 - P calibration graph 
Figure 89 - Saliva batch 4 - P calibration graph 
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Table 33 - Blood Pt-DNA adduct replicates 
Patient ID Time point Replicate Number 
P conc 
(ppb) 
Pt conc 
(ppb) 
Number of 
adducts per 
106 
nucleotides 
Average 
adducts 
(per 106 
nucleotides) 
35 
Pre 
1 3306 0.009 0.417 
0.424 2 3764 0.010 0.407 
3 3549 0.010 0.447 
1 hour 
1 3458 0.081 3.695 
3.840 2 3840 0.095 3.931 
3 3082 0.076 3.894 
34 
Pre 
1 3972 0.005 0.197 
0.205 2 4188 0.006 0.212 
3 3643 0.005 0.208 
1 hour 
1 3485 0.113 5.128 
4.098 2 3451 0.080 3.681 
3 4196 0.092 3.485 
24 hour 
1 3660 0.109 4.744 
5.098 2 3378 0.114 5.357 
3 3438 0.113 5.195 
39 
Pre 
1 3326 0.012 0.561 
0.562 2 4098 0.015 0.581 
3 3201 0.011 0.543 
1 hour 
1 3620 0.072 3.157 
3.349 2 3988 0.088 3.500 
3 4145 0.089 3.390 
48 
Pre 
1 3644 0.008 0.328 
0.376 2 3515 0.009 0.399 
3 3510 0.009 0.402 
1 hour 
1 3953 0.131 5.267 
5.317 2 3445 0.116 5.348 
3 3251 0.109 5.337 
49 
Pre 
1 3897 0.016 0.632 
0.651 2 3486 0.015 0.684 
3 3782 0.015 0.638 
1 hour 
1 3050 0.144 7.494 
7.107 2 3306 0.145 6.963 
3 3702 0.160 6.863 
50 
Pre 
1 3536 0.002 0.100 
0.134 2 3641 0.004 0.164 
3 3142 0.003 0.139 
1 hour 
1 3366 0.093 4.376 
4.534 2 3610 0.101 4.429 
3 3153 0.095 4.798 
51 
Pre 
1 4193 0.007 0.263 
0.275 2 3193 0.006 0.293 
3 3487 0.006 0.269 
1 hour 1 4138 0.086 3.304 3.355 2 3212 0.065 3.200 
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3 4024 0.090 3.560 
53 
Pre 
1 3845 0.011 0.444 
0.437 2 3835 0.011 0.453 
3 3057 0.008 0.414 
1 hour 
1 4080 0.086 3.357 
3.347 2 3072 0.066 3.428 
3 3921 0.080 3.256 
54 
Pre 
1 3781 0.007 0.305 
0.274 2 3030 0.005 0.252 
3 3666 0.006 0.264 
1 hour 
1 3518 0.046 2.091 
1.678 2 3278 0.030 1.440 
3 3997 0.038 1.504 
55 
Pre 
1 3068 0.007 0.347 
0.368 2 3989 0.010 0.376 
3 4106 0.010 0.381 
1 hour 
1 3799 0.071 2.961 
2.867 2 3340 0.055 2.608 
3 3226 0.062 3.032 
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Table 34 - Saliva Pt-DNA adduct replicates 
Patient ID Time point Replicate Number 
P conc 
(ppb) 
Pt conc 
(ppb) 
Number of 
adducts per 
106 
nucleotides 
Average 
adducts 
(per 106 
nucleotides) 
35 
Pre 1 17662 0.050 0.446 0.447 2 17044 0.048 0.447 
1 hour 1 15567 0.549 5.600 5.602 2 14560 0.514 5.604 
24 hour 1 10007 0.393 6.235 6.223 2 10322 0.404 6.212 
34 
Pre 1 34011 0.084 0.391 0.395 2 28509 0.072 0.398 
1 hour 1 7833 0.184 3.732 3.741 2 7575 0.179 3.749 
24 hour 1 8567 0.127 2.349 2.360 2 8612 0.129 2.370 
39 
Pre 1 11936 0.044 0.581 0.593 2 12064 0.046 0.605 
1 hour 1 10129 0.285 4.463 4.437 2 11379 0.316 4.411 
24 hour 1 9297 0.084 1.432 1.435 2 11256 0.102 1.437 
48 
Pre 1 11057 0.053 0.759 0.761 2 13213 0.063 0.762 
1 hour 1 9489 0.199 3.329 3.336 2 8976 0.189 3.343 
24 hour 1 15221 0.268 2.792 2.781 2 14709 0.257 2.769 
49 
Pre 1 11547 0.080 1.098 1.170 2 11194 0.088 1.241 
1 hour 1 7327 0.195 4.229 4.240 2 7674 0.206 4.251 
24 hour 1 8914 0.183 3.250 3.244 2 8834 0.180 3.238 
50 
Pre 1 26880 0.048 0.284 0.287 2 24460 0.045 0.290 
1 hour 1 11290 0.284 3.992 4.002 2 11289 0.285 4.012 
24 hour 1 26605 0.263 1.571 1.574 2 27385 0.272 1.576 
51 
Pre 1 139028 0.665 0.759 0.765 2 120872 0.586 0.770 
1 hour 1 60356 1.140 2.997 3.041 2 54505 1.059 3.084 
24 hour 1 11404 0.384 5.339 5.346 2 11398 0.384 5.352 
53 Pre 1 22865 0.087 0.603 0.602 2 24131 0.091 0.601 
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1 hour 1 21177 0.420 3.149 3.165 2 19831 0.397 3.181 
24 hour 1 37837 0.953 3.996 3.990 2 36420 0.914 3.984 
54 
Pre 1 13230 0.057 0.680 0.681 2 13197 0.057 0.682 
1 hour 1 37533 1.375 5.814 5.812 2 37188 1.361 5.810 
24 hour 1 18000 0.733 6.461 6.471 2 17460 0.713 6.480 
55 
Pre 1 20359 0.046 0.362 0.367 2 15585 0.036 0.371 
1 hour 1 16157 0.414 4.069 4.075 2 16578 0.426 4.081 
24 hour 1 10582 0.278 4.169 4.165 2 10846 0.284 4.160 
 
 
  
 
 
161 
 
Table 35- Blood and Saliva adduct values for incomplete patient sets 
Patient ID Time point 
Replicate 
number 
Blood Saliva 
Adducts 
(per 106 
nucleotides) 
Average 
adducts 
(per 106 
nucleotides) 
Adducts 
(per 106 
nucleotides) 
Average 
adducts 
(per 106 
nucleotides) 
33 
Pre 
1 0.348 
0.348 
0.345 
0.356 2 0.344 0.367 
3 0.351 - 
1 hour 
1 2.622 
2.627 
4.542 
4.537 2 2.631 4.531 
3 2.630 - 
24 hour 
1 - 
- 
3.813 
3.803 2 - 3.793 
3 - - 
36 
Pre 
1 0.348 
0.345 
0.413 
0.404 2 0.342 0.394 
3 0.345 - 
1 hour 
1 2.230 
2.233 
1.245 
1.255 2 2.238 1.264 
3 2.230 - 
24 hour 
1 - 
- 
1.467 
1.460 2 - 1.452 
3 - - 
37 
Pre 
1 0.351 
0.344 
0.421 
0.411 2 0.342 0.401 
3 0.339 - 
1 hour 
1 5.012 
5.006 
- 
- 2 4.993 - 
3 5.012 - 
24 hour 
1 - 
- 
- 
- 2 - - 
3 - - 
38 
Pre 
1 0.345 
0.331 
0.437 
0.431 2 0.315 0.425 
3 0.334 - 
1 hour 
1 2.461 
2.454 
4.361 
4.357 2 2.442 4.354 
3 2.458 - 
24 hour 
1 - 
- 
3.710 
3.715 2 - 3.719 
3 - - 
40 
Pre 
1 0.436 
0.438 
0.259 
0.261 2 0.433 0.263 
3 0.443 - 
1 hour 
1 4.964 
5.014 
3.413 
3.414 2 5.012 3.414 
3 5.065 - 
24 hour 1 - - - - 
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2 - - 
3 - - 
41 
Pre 1 0.009 
0.009 
0.008 
0.009  2 0.009 0.009 
 3 0.009 - 
1 hour 1 2.357 
2.361 
- 
-  2 2.364 - 
 3 2.361 - 
24 hour 1 - 
- 
- 
-  2 - - 
 3 - - 
42 
Pre 
1 0.451 
0.455 
0.354 
0.353 2 0.461 0.353 
3 0.454 - 
1 hour 
1 4.325 
4.328 
6.531 
6.513 2 4.322 6.495 
3 4.337 - 
24 hour 
1 - 
- 
4.315 
4.321 2 - 4.326 
3 - - 
43 
Pre 
1 0.485 
0.475 
0.403 
0.399 2 0.462 0.395 
3 0.476 - 
1 hour 
1 3.113 
3.107 
2.465 
2.456 2 3.102 2.447 
3 3.107 - 
24 hour 
1 - 
- 
2.846 
2.858 2 - 2.869 
3 - - 
44 
Pre 
1 0.007 
0.007 
0.010 
0.010 2 0.008 0.010 
3 0.008 - 
1 hour 
1 3.254 
3.256 
4.894 
4.899 2 3.264 4.903 
3 3.251 - 
24 hour 
1 - 
- 
- 
- 2 - - 
3 - - 
45 
Pre 
1 1.023 
1.029 
1.345 
1.353 2 0.997 1.362 
3 1.065 - 
1 hour 
1 4.651 
4.632 
1.846 
1.840 2 4.642 1.834 
3 4.601 - 
24 hour 
1 - 
- 
2.345 
2.351 2 - 2.357 
3 - - 
46 Pre 
1 0.235 
0.227 
0.174 
0.171 2 0.234 0.168 
3 0.213 - 
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1 hour 
1 1.974 
2.983 
3.824 
3.809 2 2.013 3.794 
3 1.961 - 
24 hour 
1 - 
- 
- 
- 2 - - 
3 - - 
47 
Pre 
1 0.321 
0.338 
0.684 
0.678 2 0.358 0.671 
3 0.335 - 
1 hour 
1 4.325 
4.328 
3.154 
3.178 2 4.330 3.201 
3 4.330 - 
24 hour 
1 - 
- 
3.022 
3.008 2 - 2.995 
3 - - 
52 
Pre 
1 0.294 
0.279 
0.354 
0.354 2 0.262 0.354 
3 0.280 - 
1 hour 
1 3.644 
3.634 
4.355 
4.344 2 3.624 4.332 
3 3.634 - 
24 hour 
1 - 
- 
4.684 
4.673 2 - 4.662 
3 - - 
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Appendix B – Chapter 3 supplementary information 
Nitrogen rich peptides 
Peptide 1 – NNIK 
 
Figure 91 – Full mass spectrum for peptide 1 (NNIK) 
Table 36 – Peak assignments for peptide 1 (NNIK) 
Most abundant isotope m/z Assignment 
244.79 [NNIK + 2H]2+ 
301.61 [(NNIK+N) + 2H]2+ 
374.32 [(NNIK – N) + H]+ 
488.25 [NNIK + H]+ 
602.31 [(NNIK+N) + H]+ 
975.06 [(NNIK)2 + H]+ 
 
Pep1_Full_MS #1 RT: 0.00 AV: 1 NL: 8.77E7
T: ITMS + c ESI Full ms [150.00-2000.00]
200 400 600 800 1000 1200 1400 1600 1800 2000
m/z
0
10
20
30
40
50
60
70
80
90
100
R
el
at
iv
e 
A
bu
nd
an
ce
488.31
244.79
602.31301.61 374.32 975.06730.29 1463.151219.54868.27 1706.80 1965.771808.231069.21
 
 
165 
 
 
Figure 92 – Full mass spectrum for peptide 1 (NNIK) and oxaliplatin after 24 hours 
 
Table 37 – Peak assignments for peptide 1 (NNIK) and oxaliplatin after 24 hours incubation 
Most abundant isotope m/z Assignment 
398.17 [OxPt + H]+ 
488.25 [NNIK + H]+ 
602.45 [(NNIK+N) + H]+ 
885.25 [NNIK+ OxPt + H]+ 
1281.08 [NNIK + (OxPt)2 + H]+ 
1371.08 [(NNIK)2 + OxPt + H]+ 
1679.08 [NNIK + (OxPt)3 + H]+ 
1769.33 [(NNIK)2 + (OxPt)2 + H]+ 
  
  
Pep1_24hr_Full_MS_130118132049 #1 RT: 0.00 AV: 1 NL: 1.99E5
T: ITMS + p ESI Full ms [270.00-2000.00]
400 600 800 1000 1200 1400 1600 1800 2000
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Peptide 2 – ENQK 
 
 
Figure 93 – Full mass spectrum for peptide 2 (ENQK) 
 
Table 38 – Peak assignments for peptide 2 (ENQK) 
Most abundant isotope m/z Assignment 
259.67 [ENQK + 2H]2+ 
389.33 [(ENQK-K) + H]+ 
488.33 [(ENQK-CH2NH3) + H]+ 
518.33 [ENQK + H]+ 
632.42 [ENQK + (ENQK-C4H11N) + H]+ 
1035.08 [(ENQK)2 + H]+ 
 
Pep2_Full_MS_wide #1 RT: 0.00 AV: 1 NL: 9.76E6
T: ITMS + p ESI Full ms [130.00-1500.00]
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Figure 94 – Full mass spectrum for peptide 2 (ENQK) and oxaliplatin after 24 hours incubation 
 
Table 39 – Peak assignments for peptide 2 (ENQK) and oxaliplatin after 24 hours incubation 
Most abundant isotope m/z Assignment 
259.67 [ENQK + 2H]2+ 
398.08 [OxPt + H]+ 
488.33 Peptide 1 carryover 
518.25 [ENQK + H]+ 
532.17 [(ENQK – C14H19N6O7) + OxPt + H]+ 
632.33 [ENQK + (ENQK-C4H11N) + H]+ 
795.00 [(OxPt)2 + H]+ 
915.17 [ENQK + OxPt + H]+ 
1035.83 [(ENQK)2 + H]+ 
1311.92 [ENQK + (OxPt)2 + H]+ 
1433.33 [(ENQK)2 + OxPt + H]+ 
1711.17 [ENQK + (OxPt)3 + H]+ 
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Figure 95 - Orbitrap spectrum of peptide 2 (ENQK) and oxaliplatin 
  
2013_1085 #1-77 RT: 0.00-1.02 AV: 77 NL: 2.45E8
T: FTMS {1,1}  + p NSI Full ms [100.00-2000.00]
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Peptide 3 – QHEK 
 
 
Figure 96 – Full mass spectrum for peptide 3 (QHEK) 
 
Table 40 – Peak assignments for peptide 3 (QHEK) 
Most abundant isotope m/z Assignment 
262.67 [QHEK – NH3 + 2H]2+ 
271.17 [QHEK + 2H]2+ 
413.25 [(QHEK-Q) + H]+ 
541.25 [QHEK + H]+ 
1081.17 [(QHEK)2 + H]+ 
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Figure 97 – Full mass spectrum for peptide 3 (QHEK) and oxaliplatin after 24 hours incubation 
 
Table 41 – Peak assignments for peptide 3 (QHEK) and oxaliplatin after 24 hours incubation 
Most abundant isotope m/z Assignment 
397.17 [OxPt + H]+ 
413.33 [(QHEK-Q) + H]+ 
524.25 [(QHEK-NH3) + H]+ 
541.33 [QHEK + H]+ 
793.17 [(OxPt)2 + H]+ 
938.25 [QHEK + OxPt + H]+ 
1082.68 [(QHEK)2 + H]+ 
1335.08 [QHEK + (OxPt)2 + H]+ 
1480.42 [(QHEK)2 + OxPt + H]+ 
1877.08 [(QHEK)2 +(OxPt)2 + H]+ 
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Figure 98 - Orbitrap spectrum of peptide 3 (QHEK) and oxaliplatin 
  
2013_1087 #1-77 RT: 0.00-1.02 AV: 77 NL: 1.65E8
T: FTMS {1,1}  + p NSI Full ms [100.00-2000.00]
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Peptide 4 – YRPR 
 
 
Figure 99 – Full mass spectrum for peptide 4 (YRPR) 
 
Table 42 – Peak assignments for peptide 4 (YRPR) 
Most abundant isotope m/z Assignment 
435.33 [(YRP + H]+ 
541.33 Peptide 3 carry over 
591.42 [YRPR + H]+ 
1181.42 [(YRPR)2 + H]+ 
1771.50 [(YRPR)3 + H]+ 
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Figure 100 – Full mass spectrum for peptide 4 (YRPR) and oxaliplatin after 24 hours incubation 
 
Table 43 – Peak assignments for peptide 4 (YRPR) and oxaliplatin after 24 hours incubation 
Most abundant isotope m/z Assignment 
296.25 [YRPR + 2H]2+ 
398.17 [OxPt + H]+ 
591.33 [YRPR + H]+ 
988.25 [YRPR + OxPt + H]+ 
1386.17 [YRPR + (OxPt)2 + H]+ 
 
  
Pep4_24hr_Full_MS_130118132049 #1 RT: 0.00 AV: 1 NL: 1.62E5
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Sulfur rich peptides 
Peptide 5 – GCMR 
 
 
Figure 101 – Full mass spectrum for peptide 5 (GCMR) 
 
Table 44 – Peak assignments for peptide 5 (GCMR) 
Most abundant isotope m/z Assignment 
175.08 [R + H]+ 
233.08 [GCMR + 2H]2+ 
308.08 [(GCMR-R) + H]+ 
466.25 [GCMR + H]+ 
482.17 [GCMR + NH2 + H]+ 
772.83 [GCMR +GCM + H]+ 
931.00 [(GCMR)2 + H]+ 
1396.08 [(GCMR)3 + H]+ 
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Figure 102 – Full mass spectrum for peptide 5 (GCMR) and oxaliplatin after 24 hours incubation 
 
Table 45 – Peak assignments for peptide 5 (GCMR) and oxaliplatin after 24 hours incubation 
Most abundant isotope m/z Assignment 
233.67 [GCMR + 2H]2+ 
398.08 [OxPt + H]+ 
432.25 [(GCMR-SH) + H]+ 
466.25 [GCMR + H]+ 
482.17 [GCMR + NH2 + H]+ 
633.58 [(GCMR)2 + OxPt + 2H]2+ 
863.08 [GCMR + OxPt + H]+ 
930.92 [(GCMR)2 + H]+ 
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Peptide 6 – AMMK 
 
 
Figure 103 – Full mass spectrum for peptide 6 (AMMK) 
 
Table 46 – Peak assignments for peptide 6 (AMMK) 
Most abundant isotope m/z Assignment 
175.00 [(AMMK- C7H15N2OS) + H]+ 
240.58 [AMMK + 2H]2+ 
278.17 [(AMMK-C8H20N3O2S) + H]+ 
409.33 [(AMMK-A) + H]+ 
480.25 [AMMK + H]+ 
958.75 [(AMMK)2 + H]+ 
1438.58 [(AMMK)3 + H]+ 
1918.33 [(AMMK)4 + H]+ 
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Figure 104 – Full mass spectrum for peptide 6 (AMMK) and oxaliplatin after 24 hours incubation 
 
Table 47 – Peak assignments for peptide 6 (AMMK) and oxaliplatin after 24 hours incubation 
Most abundant isotope m/z Assignment 
240.67 [AMMK + 2H]2+ 
394.25 [(AMMK-A) –H2O + OxPt + 2H]2+ 
438.62 [AMMK + OxPt + 2H]2+ 
480.25 [AMMK + H]+ 
634.25 [AMMK + (OxPt)2 + 2H]2+ 
788.33 [(AMMK-A) –H2O + OxPt + H]+ 
877.25 [AMMK + OxPt + H]+ 
958.75 [(AMMK)2 + H]+ 
1274.17 [AMMK + (OxPt)2 +H]+ 
1356.56 [(AMMK)2 + OxPt + H]+ 
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Peptide 7 – MSMK 
 
 
Figure 105 – Full mass spectrum for peptide 7 (MSMK) 
 
Table 48 – Peak assignments for peptide 7 (MSMK) 
Most abundant isotope m/z Assignment 
248.67 [MSMK + 2H]2+ 
365.25 [(MSMK-M) + H]+ 
496.33 [MSMK + H]+ 
991.00 [(MSMK)2 + H]+ 
1486.58 [(MSMK)3 + H]+ 
1987.42 [(MSMK)4 + H]+ 
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Figure 106 – Full mass spectrum for peptide 7 (MSMK) and oxaliplatin after 24 hours incubation 
 
Table 49 – Peak assignments for peptide 7 (MSMK) and oxaliplatin after 24 hours incubation 
Most abundant isotope m/z Assignment 
147.00 [M + NH2 + H]+ 
248.67 [MSMK + 2H]2+ 
365.25 [(MSMK-M) + H]+ 
398.17 [OxPt + H]+ 
402.25 [MSMK + (OxPt-C2O4) + 2H]2+ 
496.25 [MSMK + H]+ 
803.33 [MSMK + (OxPt-C2O4) + H]+ 
892.92 [MSMK + OxPt + H]+ 
992.08 [(MSMK)2 + H]+ 
1289.00 [MSMK + (OxPt)2 + H]+ 
1388.25 [(MSMK)2 + OxPt + H]+ 
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Peptide 8 – MMTK 
 
 
Figure 107 – Full mass spectrum for peptide 8 (MMTK) 
 
Table 50 – Peak assignments for peptide 8 (MMTK) 
Most abundant isotope m/z Assignment 
231.67 [(MMTK – MM -NH3) + H]+ 
255.75 [MMTK + 2H]2+ 
379.25 [(MMTK-M) + H]+ 
510.25 [MMTK + H]+ 
1019.00 [(MMTK)2 + H]+ 
1528.58 [(MMTK)3 + H]+ 
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Figure 108 – Full mass spectrum for peptide 8 (MMTK) and oxaliplatin after 24 hours incubation 
 
Table 51 – Peak assignments for peptide 8 (MMTK) and oxaliplatin after 24 hours incubation 
Most abundant isotope  m/z Assignment 
255.75 [MMTK + 2H]2+ 
379.33 [(MMTK-M) + H]+ 
398.33 [OxPt + H]+ 
454.17 [MMTK + OxPt + 2H ]2+ 
510.33 [MMTK + H]+ 
907.17 [MMTK + OxPt + H ]+ 
1018.83 [(MMTK)2 + H]+ 
1305.08 [MMTK +(OxPt)2 + H]+ 
1416.50 [(MMTK)2 +OxPt + H]+ 
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Peptide 9 – MCAAR 
 
 
Figure 109 – Full mass spectrum for peptide 9 (MCAAR) 
 
Table 52 – Peak assignments for peptide 9 (MCAAR) 
Most abundant isotope  m/z Assignment 
276.25 [MCAAR + 2H]2+ 
420.33 [(MCAAR)-M + H]+ 
551.33 [MCAAR + H]+ 
567.25 [MCAAR + NH2 + H]+ 
1101.08 [(MCAAR)2 + H]+ 
1652.33 [(MCAAR)3 + H]+ 
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Figure 110 – Full mass spectrum for peptide 9 (MCAAR) and oxaliplatin after 24 hours incubation 
 
Table 53 – Peak assignments for peptide 9 (MCAAR) and oxaliplatin after 24 hours incubation 
Most abundant isotope  m/z Assignment 
252.14 [(MCAAR-C8H17N3O2S2) + H]+ 
276.17 [MCAAR + 2H]2+ 
317.25 [(MCAAR-C8H16N2O2S2) + H]+ 
398.17 [OxPt +H]+ 
420.33 [(MCAAR-M) + H]+ 
551.33 [MCAAR + H]+ 
673.50 [MCAAR + OxPt + 2H]2+ 
948.17 [MCAAR + OxPt + H]+ 
1102.17 [(MCAAR)2 + H]+ 
1347.83 [MCAAR + (OxPt)2 + H]+ 
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Peptide 10 – CVK 
 
 
Figure 111 – Full mass spectrum for peptide 10 (CVK) 
  
Table 54 – Peak assignments for peptide 10 (CVK) 
Most abundant isotope m/z Assignment 
175.17 [CVK + 2H]2+ 
349.25 [CVK + H]+ 
696.92 [(CVK)2 + H]+ 
1044.92 [(CVK)3 + H]+ 
1393.50 [(CVK)4 + H]+ 
1742.25 [(CVK)5 + H]+ 
 
Pep6_FullMS1_130923135159 #1 RT: 0.00 AV: 1 NL: 1.62E6
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Figure 112 – Full mass spectrum for peptide 10 (CVK) and oxaliplatin after 24 hours incubation 
 
Table 55 – Peak assignments for peptide 10 (CVK) and oxaliplatin after 24 hours incubation 
Most abundant isotope m/z Assignment 
175.17 [CVK + 2H]2+ 
349.25 [CVK + H]+ 
398.08 [OxPt + H]+ 
571.67 [CVK + OxPt + 2H]2+ 
697.00 [(CVK)2 + H]+ 
746.17 [CVK + OxPt + H]+ 
1093.25 [(CVK)2 + OxPt + H]+ 
1143.08 [CVK + (OxPt)2 + H]+ 
1540.17 [CVK + (OxPt)3 + H]+ 
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Appendix C – Chapter 4 supplementary information 
Cell culture: Whole cell population analysis 
 
Figure 113 - 82Se calibration graph for determining the level of Se in populations of whole cells 
 
 
Figure 114 - 195Pt calibration graph for determining the level of Pt in populations of whole cells 
 
Figure 115 - 31P calibration graph for determining the level of P in populations of whole cells 
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Table 56 - Replicate and average data for whole cell experiment 
Sample 
code Sample name 
Pt (ppb) per 
million cells Average 
Se (ppb) per 
million cells Average 
C1.1 Control 1 5M 0.056 
0.058 
0.816 
0.865 
C1.2 Control 2 5M 0.049 0.823 
C1.3 Control 3 5M 0.052 0.737 
C1.4 Control 4 10M 0.076 1.085 
M1.1 25uM MSA 1 hr 1 5M 0.148 
0.080 
5.531 
5.966 
M1.2 25uM MSA 1 hr 2 5M 0.048 5.627 
M1.3 25uM MSA 1 hr 3 5M 0.048 6.114 
M1.4 25uM MSA 1 hr 4 10M 0.075 6.592 
M2.1 50uM MSA 1 hr 1 5M 0.048 
0.056 
7.859 
8.132 
M2.2 50uM MSA 1 hr 2 5M 0.049 8.353 
M2.3 50uM MSA 1 hr 3 5M 0.051 7.499 
M2.4 50uM MSA 1 hr 4 10M 0.074 8.816 
M3.1 75uM MSA 1 hr 1 5M 0.047 
0.055 
8.849 
9.269 
M3.2 75uM MSA 1 hr 2 5M 0.050 9.713 
M3.3 75uM MSA 1 hr 3 5M 0.049 9.649 
M3.4 75uM MSA 1 hr 4 10M 0.074 8.865 
P1.1 Pt 1 hr 1 5M 7.014 
6.711 
0.898 
0.866 
P1.2 Pt 1 hr 2 5M 6.931 0.843 
P1.3 Pt 1 hr 3 5M 6.860 0.842 
P1.4 Pt 1 hr 4 10M 6.041 0.882 
MP1.1 25uM MSA Pt 1 hr 1 5M 4.745 
4.777 
6.509 
6.260 MP1.2 25uM MSA Pt 1 hr 2 5M 4.941 6.725 
MP1.3 25uM MSA Pt 1 hr 4 10M 4.645 5.545 
MP2.1 50uM MSA Pt 1 hr 1 5M 5.135 
5.047 
6.995 
7.134 
MP2.2 50uM MSA Pt 1 hr 2 5M 5.146 7.260 
MP2.3 50uM MSA Pt 1 hr 3 5M 5.148 7.341 
MP2.4 50uM MSA Pt 1 hr 4 10M 4.758 6.940 
MP3.1 75uM MSA Pt 1 hr 1 5M 4.704 
4.554 
9.687 
9.606 
MP3.2 75uM MSA Pt 1 hr 2 5M 4.651 9.869 
MP3.3 75uM MSA Pt 1 hr 3 5M 4.674 9.877 
MP3.4 75uM MSA Pt 1 hr 4 10M 4.187 8.992 
M4.1 25uM MSA 24 hr 1 5M 0.048 
0.054 
4.718 
4.871 
M4.2 25uM MSA 24 hr 2 5M 0.048 4.950 
M4.3 25uM MSA 24 hr 3 5M 0.047 4.873 
M4.4 25uM MSA 24 hr 4 10M 0.074 4.943 
M5.1 50uM MSA 24 hr 1 5M 0.047 
0.054 
8.226 
7.686 
M5.2 50uM MSA 24 hr 2 5M 0.047 7.589 
M5.3 50uM MSA 24 hr 3 5M 0.048 7.495 
M5.4 50uM MSA 24 hr 4 10M 0.074 7.433 
M6.1 75uM MSA 24 hr1 5M 0.047 
0.056 
8.500 
8.515 
M6.2 75uM MSA 24 hr 2 5M 0.047 8.819 
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M6.3 75uM MSA 24 hr 4 10M 0.074 8.226 
P2.1 Pt 24 hr 1 5M 5.163 
4.687 
0.853 
0.855 
P2.2 Pt 24 hr 2 5M 4.366 0.869 
P2.3 Pt 24 hr 3 5M 4.324 0.870 
P2.4 Pt 24 hr 4 10M 4.894 0.829 
MP4.1 25uM MSA Pt 24 hr 1 5M 2.805 
2.745 
5.256 
5.226 
MP4.2 25uM MSA Pt 24 hr 2 5M 2.905 5.387 
MP4.3 25uM MSA Pt 24 hr 3 5M 2.917 5.393 
MP4.4 25uM MSA Pt 24 hr 4 10M 2.353 4.865 
MP5.1 50uM MSA Pt 24 hr 1 5M 3.330 
3.401 
6.965 
6.705 
MP5.2 50uM MSA Pt 24 hr 2 5M 3.320 6.864 
MP5.3 50uM MSA Pt 24 hr 3 5M 3.403 6.974 
MP5.4 50uM MSA Pt 24 hr 4 10M 3.550 6.018 
MP6.1 75uM MSA Pt 24 hr 1 5M 3.548 
3.447 
6.756 
6.746 
MP6.2 75uM MSA Pt 24 hr 2 5M 3.562 6.877 
MP6.3 75uM MSA Pt 24 hr 3 5M 3.676 7.012 
MP6.4 75uM MSA Pt 24 hr 4 10M 3.003 6.337 
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Single cell LA-ICP-MS: 
 
Figure 116 - Test ablation of 10 cells measuring 82Se (LR) 
 
Evidence of inconsistent 77Se signals: 
 
Figure 117 - Test ablation of 10 cells measuring 77Se (LR) 
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Figure 118 - Second test ablation of 10 cells measuring 77Se (LR) 
 
 
Figure 119 - Third test ablation of 10 cells measuring 77Se (LR) 
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Slide background: 
 
Figure 120 - 195Pt slide background test ablation of 10 blank areas of slide 
 
Platinum ablation results: 
 
Figure 121 - Ablation of 100 (4 x 25) cells on control slide measuring 195Pt 
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Figure 122 – Intensity of 195Pt in 100 (4 x 25) ablated cells on slide containing cells exposed to 50 µM oxaliplatin with 
1 hour recovery 
 
 
Figure 123 - Intensity of 195Pt in 100 (4 x 25) ablated cells on slide containing cells exposed to 50 µM oxaliplatin and 
75 µM MSA with 1 hour recovery 
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Figure 124 - Intensity of 195Pt in 100 (4 x 25) ablated cells on slide containing cells exposed to 50 µM oxaliplatin with 1 
hour recovery 
 
 
Figure 125 - Intensity of 195Pt in 100 (4 x 25) ablated cells on slide containing cells exposed to 50 µM MSA with 24 
hours recovery 
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Figure 126 - Full mass spectrum for GSH solution 
 
Figure 127 - Full mass spectrum for GSH:OxPt solution 
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Figure 128 - Full mass spectrum for GSH:MSA solution 
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Abstract This note presents a comparison of the use of saliva
versus leukocytes for the determination of Pt-DNA adducts
obtained from patients undergoing platinum-based chemo-
therapy. Samples of both blood and saliva were taken pre-
and post-treatment and were analysed via sector-field induc-
tively coupled plasma mass spectrometry (SF-ICP-MS) to
determine the level of Pt-DNA adducts formed. As expected,
significant inter-patient variability was seen; however, a lack
of correlation between the levels of adducts observed in saliva
and blood samples was also observed (Pearson correlation
coefficient r=−0.2598). A high yield of DNA was obtained
from saliva samples, but significant difficulties were experi-
enced in obtaining patient adherence to the saliva sampling
procedure. In both leukocyte and saliva samples, not only was
Pt from previous chemotherapy cycles detected, but the rapid
appearance of Pt in the DNAwas noted in both sample types
1 h after treatment.
Keywords ICP-MS . Oxaliplatin . Cisplatin . Clinical
samples . Blood . Saliva . Pt-DNA adducts
Introduction
Since the first report of the chemotherapeutic action of
cispatin (diamminedichloroplatinum(II)) in the late 1960s by
Rosenberg, several new platinum-based drugs have come into
use for the treatment of cancer, including oxaliplatin and
carboplatin. Cisplatin and oxaliplatin form platinated intra-
strand cross-links, primarily between two adjacent guanine
bases or guanine-adenine bases, distorting the DNA structure
and resulting in cell apoptosis if the damage is too great for
repair [1].
The formation of these Pt-DNA adducts has been the focus
of several studies. For example, Zayed et al. investigated the
level of adducts in leukocyte samples, pre- and post-treatment
at 1- and 4-h time points, in patients receiving platinum-based
chemotherapy and also observed a level of carry-over of plat-
inum between treatment cycles [2]. For such investigations, an
alternative sampling method would be desirable as blood sam-
pling requires trained personnel to obtain the sample as well as
the need for rapid extraction of the leukocytes, so it is an
unsuitable method for frequent sampling of patients unless they
are hospitalised. The use of saliva would be advantageous as it
is a non-invasive and more patient-friendly sampling technique
and does not require trained personnel to obtain the sample.
Furthermore, commercially available kits allow saliva sampling
in the privacy of a patient’s home and keep the sample stable for
at least 5 years before the DNA needs to be extracted [3]. This
study sets out to investigate the feasibility of using saliva as a
viable alternative to blood sampling for quantitative investiga-
tion of the formation of platinum-associated DNA, “Pt-DNA
adducts”, in patients undergoing platinum-based chemothera-
py. The data set presented is not designed to be statistically
powered for clinical purposes, but rather to investigate the
feasibility of using saliva samples.
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Experimental
Materials
All chemicals and reagents used were purchased from Sigma
(Poole, UK), unless otherwise stated. HNO3 (70 %) was
purchased from Romil Ltd. (Cambridge, UK). OG-500 saliva
collection kits and PrepIT.L2P DNA extraction reagents were
purchased from Oragene (Ontario, Canada), QIAGEN
QiaAmp DNA Blood Mini Kit was purchased from Qiagen
(Crawley, UK) and Ficoll-Paque PLUS from GE Healthcare
(Chalfont, UK).
Collection of blood and saliva samples from patients
Informed consent was obtained from patients fulfilling the
criteria stated on the ethical approval which was granted by
the Leicestershire and Rutland Research Ethics Committee
(no. 6106). Approximately 15 mL of blood and 2 mL saliva
were collected from 10 patients undergoing platinum-based
chemotherapy immediately prior to treatment and 1 h post
treatment, with a further 24-h time point for saliva. The
sampling time points were chosen for patient convenience,
and therefore, a 24-h blood sampling time point was not
possible (with the exception of patient number 34) and only
saliva samples, which could be collected by the patient at
home, were obtained. Samples were taken from patients on
different cycles and on different combination treatment re-
gimes, including epirubicin, oxaliplatin and capecitabine
(EOX); 5-fluorouracil, folinic acid and oxaliplatin
(FOLFOX); FOLFOX and bevacizumab (Bev); epirubicin,
cisplatin and capecitabine (ECX); and cisplatin and etopside
(Cis/etop).
Leukocyte isolation and DNA extraction
Blood samples were stored at room temperature in vials
containing potassium EDTA (SARSTEDT, Germany),
giving a concentration of 1.2–2 mg EDTA/mL of blood.
The leukocytes from the blood samples were isolated as
quickly as possible, typically within 2 h of the sample
being taken. Leukocytes were extracted from the blood
samples using Ficoll-Paque PLUS following the manu-
facturer’s guidelines, before cell counting and separation
into aliquots of 4–5 million cells/mL which were frozen
at −80 °C in RPMI 1640 media containing 20 % FCS
and 10 % DMSO. The QiaAmp DNA Blood Mini Kit
was used in conjunction with an automated system for
the DNA extraction, QIAcube (Qiagen, Crawley, UK).
The manufacturer’s guidelines were followed, and the
extracted DNA was dissolved in water.
DNA extraction from saliva
Patients were asked to abstain from food, drink, chewing
gum and smoking for 1 h prior to donating 2 mL of
saliva. Patients were encouraged to allow the saliva to
form naturally and to pool at the front of the mouth and
then to deposit the sample as opposed to forcing the
saliva production. A stabilising solution, provided as part
of the kit, was added to the saliva and mixed thoroughly
with the sample to give a final volume of 4 mL before a
leak-free secure lid sealed the container. This allowed the
final 24-h sample to be collected by the patient at home
and posted securely back to the laboratory. Samples were
stored upright at room temperature until the DNA extrac-
tion was performed as per the manufacturer’s protocol.
The extracted DNA was dissolved in water, and both
saliva and leukocyte DNA were quantified using UV
absorbance at 260 nm before being stored at −20 °C for
analysis via sector-field inductively coupled plasma mass
spectrometry (SF-ICP-MS).
Sample preparation, instrumentation and statistical analysis
A digestion method originally described by Yamada
et al. and modified by Kerr was used on the extracted
DNA samples for both blood and saliva [4, 5]. Briefly,
0.8 volume of 70 % nitric acid was added to 1 volume
of sample and heated at 70 °C for 1 h; 0.8 volume of
30 % hydrogen peroxide was then added to each sample
and heated at 70 °C for a further 4 h. The digested
samples were evaporated to dryness while being heated
at 70 °C under a gentle stream of oxygen-free nitrogen
gas before being reconstituted in 350 μL of 2 % nitric
acid with 0.5 ppb Eu internal standard [2]. Replicate
analyses of blood and saliva samples were performed as
follows: DNA extracted from three individual leukocyte
aliquots were analysed, while, as only one saliva sample
was obtained at each time point, the extracted DNA was
divided into two equal aliquots before analysis.
The digested DNA clinical samples were analysed
using SF-ICP-MS (Thermo Scientific, Element 2 XR,
Bremen, Germany). The instrument was operated with
a sample uptake rate of approximately 80 μL/min using
a PFA nebuliser (PFA-ST Elemental Scientific, Omaha,
USA) fitted to a cyclonic spray chamber (Glass Expan-
sion, Victoria, Australia). Three elements, Eu, Pt and P,
were determined in each sample by monitoring the
singly charged isotopes 153Eu+, 195Pt+ (in low resolu-
tion) and 31P+ (in medium resolution). The data obtain-
ed via SF-ICP-MS was used to calculate the level of Pt
associated with DNA (Pt-DNA adducts per 106 nucleo-
tides). Statistical analysis of the data was performed
using the statistical package R (version 3.0.2).
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Results
Figures 1 and 2 show the levels of Pt-DNA adducts measured
in each sample at the different sampling time points for blood
and saliva samples respectively for all 10 patients on the
various platinum-based chemotherapies. Furthermore, the fig-
ures highlight the good reproducibility observed from the
replicate samples. Figure 3 depicts the data for both sample
types for easier comparison at each time point. A large amount
of variability in adduct formation was observed between
patients which can, at least in part, be attributed to the different
combination treatments, doses and types of cancer of the
patients in this study. Variability in adduct formation is well
known, reflecting the fact that patient-specific factors are
involved in determining how a patient reacts to chemotherapy
treatment [2, 6].
A low number of Pt-DNA adducts were observed in each
pre-drug infusion sample; however, this was expected as none
of the patients were on their first cycle of chemotherapy and a
carry-over effect between cycles has been seen before, indi-
cating that a low level of platinum persists in the patients’
DNA between cycles, which are typically between 2 and
3 weeks apart [2]. The level of Pt-DNA adducts increases
rapidly after drug infusion, not only in leukocyte samples but
also in the DNA derived from saliva. Figure 2 also shows that
in some cases, the number of adducts at the 24-h time point
had increased, when compared to the 1-h sample; in other
patients, this level had decreased, potentially due to
depurination, or an indication of adduct repair and/or en-
hanced drug clearance, an effect previously observed in leu-
kocyte samples [1, 2, 7].
While it is clear from Figs. 1 and 2 that it was possible to
measure Pt-DNA adducts in clinical blood and saliva samples,
the number of adducts recorded for saliva and blood did not
correlate. The pre- and 1-h post-infusion time points were
directly compared, and the Pearson correlation coefficients
were calculated as 0.6143 and −0.2598, respectively. While
there was some positive correlation between the pre-infusion
samples for the blood and saliva samples, there was a lack of
correlation between the number of adducts per 106 nucleotides
recorded in the 1-h post-infusion blood and saliva samples.
However, with the exception of patient 54, the range of
adducts per 106 nucleotides recorded was within a factor of
2 at the 1-h time point. Furthermore, a paired t test was
performed on the two data sets, and the results were not found
to be significantly different (t=0.32, tcrit=2.26, P=0.05). This
suggests that any correlation in the data should have been
evident, but the differences are distributed about the mean and
show no obvious trend.
Previous work has shown that saliva DNA does not come
exclusively from buccal epithelial cells, but rather is a mixture
of a range of cells depending on the condition of the mouth.
One study found that the number of leukocyte cells in saliva
varied greatly from 2 to 136,000 cells/mL up to 1.1×106 cells/
mL where a patient had an inflamed oral cavity [8]. Oral
mucositis, a common side effect of chemotherapy experienced
by some chemotherapy patients, can result in sores and ulcers,
leading to an increased level of blood in the mouth. While the
extent of oral mucositis is not fully known for the patient group
in this investigation, it is feasible that a potential reason for the
poor correlation observed in this study is due to an unknown
and variable level of leukocyte contamination in each saliva
sample, and potentially that the mechanism of the uptake of
platinum by buccal cells is different to that of blood cells.
Only 10 patients were chosen for this investigation as this
was an initial feasibility study to investigate whether saliva
was a viable alternative to leukocyte sampling. The study was
not extended to a larger patient cohort for two reasons: the lack
of correlation with leukocyte data and poor patient compliance
with the sampling protocol. While in theory the saliva kits
were easy to use and could be used at home, frequently
samples were returned incomplete (either too little saliva or
stabilising solution not used) and, thus, could not be used as
part of this study. Had the collection of samples met with
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greater patient acceptance, replicate samples would have been
included in this study. A further difficulty is that samples
should be from ‘drool’ and not ‘forced’ saliva, and so repli-
cates at a single time point were not practical. Best results
were obtained under supervision in the clinic but here blood
sampling is a viable alternative.
For saliva to be considered as an alternative to leukocytes
for the measurement of Pt-DNA adducts, it is clear that a cell-
sorting step prior to the DNA extraction would be required;
however, this would likely have to be done on a fresh saliva
sample (i.e. not lysed and stabilised in a kit such as was the
case in this experiment), and thus it is impractical for the
collection of clinical samples at regular intervals outside the
hospital environment. Ultimately, it may not have significant
advantages over blood sampling.
Conclusion
This investigation has shown that it is possible to determine
the level of Pt-DNA adducts in DNA extracted from both
white blood cells and saliva clinical samples using SF-ICP-
MS; significant inter-patient variability was observed in both
data sets. Platinum from previous chemotherapy cycles was
readily observed in both sample types. To the best of our
knowledge, this was the first time that Pt-DNA adducts ob-
tained from both saliva and leukocyte samples from the same
patients have been successfully recorded by ICP-MS.
The purpose of this investigation was to determine whether
saliva could be used as a less invasive and more patient-
friendly sampling technique for the measurement of Pt-DNA
adducts. DNA adducts were quantified, but the correlation
found between sample types was poor. A surprising finding
was the practical problems encountered in obtaining patient
compliance with the saliva sampling protocol. More work is
required before saliva can be validated as an alternative sam-
ple for the measurement of Pt-DNA adducts in cancer
patients.
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